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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that accounts for 60-80%
of dementia cases, especially in people over 65 years. More than 36 million people
had AD or related dementias in 2010, and more than ⇠ 116 million will be diag-
nosed by 2050. Over the last 30 years, our group has studied the largest multigener-
ational extended pedigree from the Paisa genetic isolate in which the p.Glu280Ala
(E280A) fully penetrant mutation in the Presenilin-1 (PSEN1) gene causes early-onset
familial AD ( fAD). One of the most intriguing aspects of this pedigree is the broad
spectrum of the AD age of onset (ADAOO) that ranges from the earliest 30s to the
80s, and has an average of 48 years. It is hypothesised that genetic variants of major
effect (i.e., mutations) modify ADAOO in individuals from this pedigree suffering
from early-onset fAD or sporadic AD (sAD).
In this thesis, the problem of the ADAOO high variability in this pedigree is
tackled by scrutinising functional variants distributed through the whole exomes
of individuals with fAD and sAD. Individuals with these forms of AD are de-
scendants from the original founder of the Paisa pedigree and exhibit an extreme
phenotype based on the ADAOO for this population. Quality control, filtering, and
functional annotation were applied prior to performing association analysis using
the multi-locus linear mixed-effects model and collapsing methods to identify com-
ix
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mon and rare ADAOO modifiers, respectively. Using data mining and predictive
modelling tools, a clinical diagnostic tool with potential applications in the clinical
setting is developed to predict disease status (early-onset versus late-onset) based
on demographic and genetic information. The set of genes harbouring the identified
ADAOO modifier variants are involved in physiopathology of AD including neu-
ron apoptosis and apoptotic processes, neurogenesis, dopamine receptor signalling,
Wnt protein secretion, the inflammatory processes linked to AD, the negative reg-
ulation of glutamergic synaptic transmission, the positive regulation of apoptosis,
memory processes, and could be pivotal for prediction, follow-up and eventually
as therapeutical targets of AD.
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Chapter1
Introduction
“If we can delay the onset [of Alzheimer’s disease], any delay would be a success.
One year, two years, five years . . . There are some studies that predict that if we
could delay the onset of the disease for five years the prevalence of Alzheimer’s in
the world would drop 50%.”
Dr. Francisco Lopera, Filling the Blank, CNN Documentary, 2011.
1.1 Alzheimer’s disease: a 100 years search
More than 100 years have passed since Alois Alzheimer, a German psychiatrist, first
diagnosed a fifty-one year old woman with what is known today as Alzheimer’s
disease (AD) [1]. In the 1906 original report, Alzheimer correlated the woman’s
cognitive and behavioural features with the formation of senile plaques and neu-
rofibrillary tangles (NFT) found in the histopathological studies of the cerebral cor-
tex following her death at age 55. Today, AD accounts for ⇠ 60  80% of dementia
cases in people over 65 years old, and is clinically characterised by learning dis-
abilities, cognitive decline and memory loss that are sufficient to interfere with the
everyday activities and performance of individuals [2, 3, 4]. Although much has
been learned since the first diagnosis of this neurodegenerative disorder, its symp-
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toms, causes, risk factors and potential treatments have only been dissected and
understood over the last three decades [5].
1.1.1 Clinical and genetic features of AD
From the clinical point of view, familial AD ( fAD) and sporadic AD (sAD) are the
two recognised forms of the disease, the former accounting for ⇠ 1% of all cases
[5]. Several studies support the clinical and neuropsychological similarities between
these two forms of the disease. In fact, no difference has been found in global
clinical severity of dementia, the duration of disease, rigidity, hypokinesia, tremor,
myoclonus, hallucinations, delusions, or epileptic seizures, memory, language, or
visuospatial, executive and praxic functions profiles [6]. In contrast to comparable
MRI and PET features, in sAD the percentage of women affected is higher than in
fAD [7].
Neuropathology studies suggest that neurons of patients with sAD exhibit a
similar phenotype to that observed in fAD, but with higher levels of amyloid-b1 40
and phospho-tau (Thr-231) [8]. Furthermore, analyses of brain regions from post-
mortem brains have shown that patients with sAD present less striatal tau pathol-
ogy and a disproportionate accumulation amyloid-b1 42 (Ab) in cortical areas of
the brain (which may be mediated by synaptic processes) compared to fAD [9].
Despite decreasing amounts of grey matter between sAD and fAD compared to
healthy controls, particularly in areas involving the temporal lobe, cingulate gyrus,
caudate, putamen, thalamus and precuneus, voxel-based morphometry analysis
provided no evidence of distinct atrophy patterns of grey matter between fAD and
early-onset sAD [10]. Furthermore, brain tissue from patients with sAD is indistin-
guishable from that of patients with autosomal dominant forms of AD [11].
Research over the last three decades have revealed that genetic factors are im-
plicated in these clinical forms of AD [12]. In fAD, single-gene mutations in the
2
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This ﬁnding is likely the result of the methods by which the
genes were identiﬁed, in studies testing for association with AD
case-control status (3–7,13). Using alternative AD phenotypes
may reveal additional genes that modify particular aspects of
the disease. Use of biomarkers as quantitative endophenotypes
has led to the identiﬁcation of additional genes that modify tau
and Aβ metabolism in cerebrospinal ﬂuid and neuroimaging
phenotypes (14–21). Using biomarkers as quantitative endo-
phenotypes in populations that are tracked over the course of
disease can give us more information regarding genes that
inﬂuence disease onset and progression (14). Additional risk
alleles may modify tau metabolism and have an impact on AD
progression; however, these studies are still ongoing.
APP, PSEN1, and PSEN2
Dominantly inherited mutations in β-amyloid precursor protein
(APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) cause
early-onset AD (2,22). Sequential cleavage of APP, a trans-
membrane neuronal protein, by β-secretase and then by
γ-secretase produces Aβ (23). PSEN1 and PSEN2 are critical
components of the γ-secretase complex. The amyloid cas-
cade hypothesis posits that changes in APP or Aβ homeo-
stasis, or both, lead to the aggregation of Aβ and deposition in
plaques and that these events are sufﬁcient to initiate the
cascade of pathologic abnormalities associated with AD (1).
Proteolysis of APP by α-secretase results in cleavage within
the Aβ domain generating nonamyloidogenic fragments that
are reported to possess neurotrophic and neuroprotective
properties (24,25).
Increasing evidence suggests that there are additional
variants in APP and APP-modifying genes that alter AD risk
in LOAD cases. Novel, rare variants in APP, PSEN1, PSEN2,
and ADAM10 have been identiﬁed in large LOAD families
(26–28). Segregation data and bioinformatic analysis suggest
that these rare variants in APP may increase (e.g., APP
N660Y), decrease (e.g., APP A673T), or have no effect on
AD risk (e.g., APP E599K) (26,29). A polymorphism in PSEN1,
PSEN1 E318G, is associated with a 10-fold increase in LOAD
risk in APOEε4 carriers (27). Additionally, rare coding variants
in ADAM10, the major α-secretase involved in shedding of the
APP ectodomain (30), cosegregate in seven LOAD families
(8,31). ADAM10 risk variants Q170H and R181G increase Aβ
levels in vitro (8). In Tg2576 AD mice, ADAM10 Q170H and
R181G disrupt α-secretase activity and shift APP processing
toward amyloidogenic cleavage, yielding increased plaque
load (31). Together, these ﬁndings illustrate that variants
in APP and APP-modifying genes (e.g., PSEN1, PSEN2,
ADAM10) can cause early-onset AD or alter risk for LOAD.
CHOLESTEROL METABOLISM
APOE genotype is the strongest risk factor for LOAD. Its
central role in cholesterol metabolism implicates this pathway
in AD pathogenesis. In LOAD GWAS, variants in several genes
were identiﬁed that are involved in cholesterol metabolism,
including CLU, ABCA7, and SORL1 (3–6,13).
ApoE
Apolipoprotein E (APOE) is the strongest risk factor for LOAD.
APOE is located on chromosome 19q13.2. APOE encodes
three common alleles (ε2, ε3, ε4). APOEε4 is associated with
increased AD risk (32,33): one APOEε4 allele increases AD risk
3-fold, and two APOEε4 alleles increase AD risk by 12-fold.
APOEε4 is also associated with a dose-dependent decrease
in age at onset. Conversely, APOEε2 is associated with
decreased risk for AD and later age at onset (32,33).
APOE is a regulator of lipoprotein metabolism (34). APOE
plays several important roles in the central nervous system,
such as cholesterol transport, neuroplasticity, and inﬂamma-
tion (35). APOE binds to Aβ and inﬂuences the clearance of
soluble Aβ and the Aβ aggregation (35,36). APOE also
regulates Aβ metabolism indirectly by interacting with recep-
tors such as LRP1 (37). In APP transgenic mice, APOE
inﬂuences the amount and structure of intraparenchymal Aβ
deposits in an isoform-speciﬁc manner (38–41). Neuropatho-
logic and neuroimaging studies demonstrate that APOEε4
carriers exhibit accelerated and more abundant Aβ deposition
than APOEε4-negative individuals (42–44). APOE genotype is
Figure 1. Rare and common variants contribute to
Alzheimer’s disease risk. GWAS, genome-wide asso-
ciated studies. (Updated and modiﬁed with permis-
sion from Guerreiro et al. [149].)
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Figure 1.1: Genetic factors in fAD and sAD. Observe that single-gene mutations in the APP, PSEN1
and PSEN2, though rare in the population, cause AD. In contrast, several genetic variants in diff rent
gene increase the risk of developing sAD (i. ., confer susceptibility) but do not cau e AD. Modified
fro Karch an Goate [12].
Amyloid precursor protein (APP), Presenilin-1 (PSEN1), and Presenilin-2 (PSEN2) genes
cause AD, a d account for < 5% of the fAD cases [13, 14, 15, 16]. Conversely in
sAD, genes do not directly cause the disease but confer susceptibility (i.e., genes are
risk factors) [5, 17, 18]. Discovered in 1993 [19], the Apolipoprotein E (APOE) gene
is estimated to account for up to 20-25% of sAD cases [5]. Other loci conferring
susceptibility, but of minor effect, include the PLD3, TREM2, ADAM10 and CLU
genes (Figure 1.1) [20, 21, 12].
In terms of the AD age of onset (ADAOO), that is, the age at which signs and/or
symptoms of a disease appear for the first time in an individual, AD cases are often
referred to as early-onset AD (EOAD) or late-onset AD (LOAD). Although most
cases of fAD have an age of onset (AOO) before 60 years [5], the AOO of dementia
symptoms can range from the early 30s to the late 70s [22]. Conversely, the vast
majority of cases in sAD have an AOO > 60 years, with most of them occurring
between 70 and 80 years and diagnosed at the final stages of the illness [5, 23].
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1.1.2 An epidemiological view of AD
Today, AD is considered a modern pandemic. As of 2010, more than 36 million
people had AD or a related dementia worldwide [5]. Without new medicines to
prevent, delay or stop the disease, this figure is projected to dramatically increase
to ⇠ 66 million dementia cases by 2030 and ⇠ 116 million by 2050 [24]. In per-
spective, ⇠ 2 million new dementia cases will be diagnosed per year for the next
40 years, a number equivalent to the 2014 population of Perth, WA, Australia [25].
By 2050, ⇠ 2.5 times the actual population of Colombia [26] will be diagnosed with
dementia. In terms of monetary costs, the financial burden associated with the dis-
ease is estimated to be $605 billion worldwide [5], between $157  $215 billion in
the United States (i.e., ⇠ $42, 000  $56, 000 per person) in 2010 [27], and more than
A$4.9 billion in Australia in 2009  2010 [28].
Unfortunately, AD is spread all over the world. The estimated number of demen-
tia cases roughly doubles every 20 years, and some continents/regions are prone to
experience dramatic changes in those estimates (Figure 1.2). For instance, Europe
will go from having the second highest number of dementia cases worldwide in
2010 to be the fifth highest by 2050 (only comparable with all Asia, East and South
Asia, and the Americas), whilst the Americas (South, Centre and North America)
will go from being third in 2010 to second in 2050. In addition, the total number of
dementia cases in Asia will go from slightly more than 15 million in 2010 to > 60
million cases in 2050. Overall, the fastest growth in the population with dementia
is observed in both Asia and western Pacific neighbours.
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1.1.3 Causes of AD
Genetic, environmental and lifestyle factors have been implicated in the aetiology
of AD, but exactly what causes the condition has not yet been fully understood
[5]. In a recent review, Armstrong [29] discusses and provides evidence supporting
the following eight theories: (i) ageing; (ii) degeneration of anatomical pathways;
(iii) environmental factors including exposure to aluminium, head injury, diet and
malnutrition; (iv) genetic factors such as mutations in the APP, PSEN1 and PSEN2
genes, and allelic variations in APOE; (v) a metabolic disorder resulting from mito-
chondrial dysfunction; (vi) vascular factors including the dysfunction of the blood
brain barrier (BBB); (vii) an immune system dysfunction; and (viii) infectious agents
suggesting that either a virus could cause Ab deposition through the activation of
microglia and pericytes, or that the herpes simplex virus (HSV) could result in paired
helical filaments (PHF) and NHT.
Armstrong [29] also proposes that brain-related anatomical systems and path-
ways break as a consequence of ageing, which subsequently results in the loss of
synapses. The fact that this age-related degeneration is highly influenced by mu-
tations in PSEN1, PSEN2 or APP, supports the theory that this ‘age-effect’ begins
early in life and worsens depending on the stress levels leading to hypertension,
cardiovascular diseases, diabetes and immunological problems. In other words,
AD can be seen as a multifactorial disorder in which genetic and environmental
risk factors interact to increase the rate of normal ageing, and that AOO modi-
fier genes (discussed in Section 1.2) or those modifying Ab deposition may also be
involved [30, 31]. The ‘multifactorial’ gene hypothesis may explain why AD devel-
ops in some individuals and not in others, whilst the ‘modifier genes’ may answer
why some members of the same family (possibly with the same genetic mutation)
present AD-related signs and symptoms at an earlier than others.
6
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1.1.4 Phenotypes in AD
Most of the genetic studies in AD have been focused on the determination of loci
conferring susceptibility to this devastating condition. In other words, the pheno-
type of interest has been the presence or absence of AD symptoms in a group of
individuals. Only recently have genetic studies on AD started using (continuous)
measurable characteristics either at a single point in time [31, 32, 33] or over time
(e.g., Ab deposition as in recently illustrated by Villemagne et al. [34] and Rembach
et al. [35]). The use of quantitative phenotypes may lead to the identification of loci
responsible for the wide spectrum in the ADAOO, and could be important alterna-
tives for early interventions in AD [31, 32, 33, 36].
-3 -2 -1 0 1 2 3
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Figure 1.3: Qualitative and qualitative phenotypes in genetic research of AD. In the first case, the
abscence or presence of the disease is asessed in a population, such as individuals with the condition
are identified. When the phenotypes is quantitative (i.e., AOO), individuals developing signs and
symptoms extremely early or extremely late compared to the AOO of the population they belong
to, are selected for genetic studies.
Broadly speaking, a phenotype is an observable characteristic in individuals from
a population. Some examples include ADAOO, height, blood pressure, weight,
body mass index (BMI), the presence of a disease or the time taken to complete a
particular task (i.e., reaction time). In genetic research, the definition of a phenotype
7
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is crucial. Provided that genetic markers are available for a population, without an
observable characteristic in that population the association of these genetic markers
cannot be assessed.
Two main distinctions can be made depending upon the nature of the pheno-
type of interest (Figure 2.1). Whilst qualitative phenotypes refer to those in which
an attribute is expressed by an individual (i.e., sex, presence or absence of a dis-
ease), quantitative phenotypes are those in which the characteristic of interest is a
measurable quantity (i.e., ADAOO). Quite often, association analyses with quali-
tative phenotypes are referred to as case/control, and those involving quantitative
phenotypes as quantitative trait loci (QTL). When a continuous phenotype is avail-
able, another alternative is to categorise the measures and perform genetic studies
comparing individuals at the extremes of the phenotype distribution. In AD, this
categorisation could be performed based on how early or late the first signs and
symptoms of AD appear (Figure 2.1, right). The main idea behind these analyses
is to map genes conferring susceptibility to or being associated with the disease,
respectively.
1.1.5 Why AOO as a phenotype in AD?
The AOO, one of the least commonly phenotypes studied in epidemiology [37], has
been catalogued as essential in AD for the definition of risk factors [36] and/or for
the identification of genes that modify the appearance of AD signs and symptoms
in a specific population [31, 32, 33]. For instance, Lopera et al. [38] first suggested
to study AOO in extended multigenerational pedigrees from the Paisa genetic iso-
late in Antioquia, Colombia (Figure 1.4) [39] to identify genetic and environmental
modifiers in this type of dementia. The work by Lendon et al. [40] was the first to
follow this suggestion.
Despite how difficult it is to define what the AOO is in patients with AD, using
8
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tales como succión, prensión y pérdida del 
control de esfínteres. Algunos pacientes pue-
den presentar ocasionalmente mioclonias. 
Existen múltiples hipótesis sobre la etiolo-
gía de la enfermedad (alteración en la función 
de neurotransmisores, neurotoxinas, viral, 
genética, senil) (3, 7). En estudio realizado 
por Paul Brown y col. (8) inoculando en pri-
mates tejido cerebral de 57 pacientes con 
enfermedad de Alzheimer, encontraron que 
en 55 no se desarrolló enfermedad neurológica 
y en dos primates se presentó una encefalopa-
tía esponjiforme que fue clínica y anatomopa-
tológicamente característica de Jakob Creutz-
feldt. Diversos estudios genéticos han demos-
trado un patrón autosómico dominante de 
transmisión de la enfermedad (9). 
El objetivo principal de este trabajo es dar 
a conocer una familia con un cuadro clínico 
de demencia tipo Alzheimer, en varios miem-
bros, en distintas generaciones y revisar consi-
deraciones acerca de su etiología. 
MATERIAL Y METODOS 
El caso índice fue detectado a través de la 
consulta externa de neurología del Hospital 
Universitario San Vicente de Paúl y procedía 
de área rural de Belmira (Antioquia). 
Caso número uno: Se trata de un hombre 
de 49 años, agricultor, con escolaridad de 
segundo de primaria y cuadro clínico de 
cuatro años de evolución, iniciado por pér-
dida progresiva de la memoria reciente; dos 
años después pérdida del reconocimiento de 
vínculos familiares y trastornos de orientación 
global, finalmente descuido en su arreglo per-
sonal, labilidad emocional,. incoherencias, 
ideación delirante persecutoria, alucinaciones 
visuales y auditivas. Su personalidad previa 
fue descrita como: inteligente, sociable, alegre, 
buen trabajador, responsable, sin antecedentes 
de ingestión de alcohol o drogas. Anteceden-
tes familiares: ver genograma (Figura 1). 
Examen físico: Alopecia frontal. El examen 
neurológico fue normal. 
La evaluación neuropsicológica mostró los 
siguientes hallazgos: 
Atención-conciencia-orientación: Conscien-
te, alerta, desorientado en persona; da su 
nombre, pero no su edad. Desorientado en 
lugar y tiempo. Puede prestar atención por 
períodos no mayores de diez minutos. Severa 
dificultad de concentración. 
—Memoria: Severa alteración de la memoria 
retrógrada. No recuerda la fecha de nacimien-
to. No recuerda nombre, ni número de hijos. 
Retiene solo dos dígitos en progresión. Retiene 
parcialmente una frase. Con dos frases presenta 
fenómenos de confabulación y contaminación. 
No es posible realizar una curva de memoria 
verbal. Severa amnesia anterógrada global 
inespecífica, alteraciones de la memoria inme-
diata. 
-Lenguaje: La expresión verbal se limita a 
frases cortas, estereotipadas. No posee comu-
nicación verbal funcional. La comprensión es 
muy deficiente. Tiene dificultades para seña-
lar partes del cuerpo y objetos externos. En 
Arcos-Burgos and Muenke
casian and 15% Amerindian (92). No significant
African component could be identifi d in the
above study. In this context, it was possible to dis-
criminate this community from the others inhabit-
ing Colombia, whose principal gen tic compo-
nents are African or Amerindian, (88). Secondly,
another study (94) found strong admixture distor-
tions in the gender vectors. More tha 96% of Y-
chromosomes are Caucasian and most of the mito-
chondrial component is Amerindian. Thirdly,
str ng founder effects for some deleterious muta-
tions resulting in neurodegenerative diseases, such
as early onset Alzheimer disease (PS-1 E280A) and
Parkinson disease, have been detected in this com-
munity (95–97). Thus far, the Paisa community
represents one of the more important populations
in apping genes. The advantages of this com-
munity include the large size of their genealogies
(including in some cases up to five generations and
sibships with more than 10 children) (98–104), and
the availability of the community. F inally, records
indicate that the Paisas arose from multiple foun-
der families 20 generations ago, which is likely to
increase linkage disequilibrium of adjacent loci. In
Fig. 3. State of Antioquia in Colombia, South America. In the map of South America (Fig. 3a), Colombia is located in north-
western region of the continent (F ig. 3b). Approximately 50% of the Paisa community inhabit the State of Antioquia (Fig. 3c). The
other 50% are distributed in the States of Caldas, Risaralda and Quindio.
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fact, the occurrence of linkage disequilibrium
could be caused by the following: recent mutation,
founder effect, the recent racial admixture of diver-
gent populations and epistatic selection (105).
Linkage isequilibrium will decrease in a few gen-
erations because of the genetic recombination ex-
cept for closely linked loci (105–107). It appears
contradictory that two evolutionary forces, i.e. ad-
mixture and isolation, lead to the perpetuation of
linkage disequilibrium. Because of the importance
of this ph nomenon and because of the existence
of some genetic isolates resulting from this phe-
nomenon, a potentially powerful tool in gene map-
ping exists. In fact, the Finnish and Paisa com-
munities resulted from a multifounder effect, and
therefore, the levels of linkage disequilibrium could
be larger than the ones present in those genetic iso-
lates arising as the result of a unique founder effect
(53, 91, 94). In theory, linkage disequilibrium be-
tween two genes spaced 10–20cM apart remains in
populations with a recent history of genetic admix-
ture between diff rent racial gr ups. Mapping by
admixture disequilibrium contrasts differential ga-
metic disequilibrium among linked and non-linked
a 
b 
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Parkinson disease, have been detected in this com-
munity (95–97). Thus far, the Paisa community
represents one of the more important populations
in apping genes. The advantages of this com-
munity include the large size of their genealogies
(including in some cases up to five generations and
sibships with more than 10 children) (98–104), and
the availability of the community. F inally, records
indicate that the Paisas arose from multiple foun-
der families 20 generations ago, which is likely to
increase linkage disequilibrium of adjacent loci. In
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could be caused by the following: recent mutati ,
founder effect, the recent racial admixture of diver-
gent populations and epistatic selection (105).
Linkage i equilibrium will decrease in a few gen-
erations because of the genetic recombination ex-
cept for closely linked loci (105–107). It appears
contradictory that two evolutionary forces, i.e. ad-
mixture and isolation, lead to the perpetuation of
linkage disequilibrium. Because of the importance
of this ph nomenon and because of th existence
of some genetic isolates resulting from this phe-
nomenon, a potentially powerful tool in gene map-
ping exists. In fact, the Finnish and Paisa com-
munities resulted from a multifounder effect, and
therefore, the levels of linkage disequilibrium could
be larger than the ones present in those genetic iso-
lates arising as the result of a unique founder effect
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admixture disequilibrium contrasts differential ga-
metic disequilibrium among linked and non-linked
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Figure 1.4: (a) Location of the state of Antioquia in Colombia, South America where most of the
individuals with PSEN1 E280A AD are located (red circle). Colombia is located in the northwest
region of South America (left). Approximately 50% of the Paisa community inhabit in Antioquia,
and the other 50% are distributed in the States of Caldas, Risaralda and Quindio [39]. (b) First
family identified with Alzheimer-related presenilin dementia in the Paisa genetic isolate. Proband
is highlighted in red. Numbers correspond to age (in years) at assessment.
it as a phenotype has important implications for preventive interventions [37]. By
using the presence or absence of AD as a phenotype instead of AOO, it would be
almost impossible to determine the appropriate age range for interventions [37],
to assess how the disease evolves depending on the starting clinical stage [22], or
to identify modifier genes (i.e., the purpose of this thesis). Thus, using AOO as
phenotype in AD could lead to the identification of new genes and therapeutic
venues focused on prevention and/or intervention at the early stages of the illness.
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1.2 Modifier genes
Modifier genes (MGs) are believed to be responsible for the change in the onset of
AD, especially in populations, such as the Paisa genetic isolate, where single-gene
mutations cause the disease. The identification and further study of MGs in AD
is of relevant importance because they may (i) provide an insight into genes that
underlie many biological processes; (ii) have an impact on diagnosis, treatment,
prevention and genetic counseling; (iii) lead to the discovery of novel drug targets;
and (iv) allow a better understanding of cell-cell and protein-protein interactions
and their role in the pathogenesis of disease [41, 42, 43, 44, 45, 46]. There is no doubt
that individuals suffering from fAD or sAD would greatly benefit from genetic
studies aimed at the identification and further comprehensive study of MGs that
may potentially lead to treatments of some sort that delay the AOO.
1.2.1 What, how and why?
The concept of modifier genes (MGs) was initially introduced by Haldane [41]
based on the wide spread nature of the AOO observed in Huntington’s chorea,
Friedreich’s ataxia, Spastic ataxia and Spastic paraplegia, all of which are caused
by single-gene mutations. These AOO changes have recently been supported by
studies confirming the role of MGs in producing ‘normal’, novel, less extreme or
more extreme phenotypes [47].
MGs affect the phenotypic expression of another gene [48], may be responsible
for changes in AOO and the rate of disease progression [42], and are known to
affect penetrance (the probability that, given a single-gene mutation, the phenotype
is present), dominance (how an allele is expressed over a second one), expressivity
(how much the phenotype is affected by a particular genotype) and pleiotropy (the
presence of diverse qualitative phenotypes given a single-gene mutation) [43], and
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to explain a large amount of the phenotypic variation in Mendelian disorders and
how they are transmitted [44]. Since their introduction, the identification of MGs
and the quantification of their role in the genetic of diseases has been of particular
interest [42, 43, 45, 47].
The process of identifying possible MGs by statistical methods starts with the
definition of a phenotype, followed by segregation, linkage and association genetic
analyses [45]. To illustrate this process, let us start with the following example from
Genin et al. [45] about coat colour in mice:
“. . . colour is controlled by gene B but its intensity (full or diluted) depends on
gene D. If the phenotype is defined in three classes, as white, grey, and black, it
can be explained by a digenic inheritance model. If instead we consider that the
primary phenotype is white or black (unaffected/affected), we find differences in
intensity among the mice with the black phenotype (full black or grey) and gene
D, which controls intensity, is a modifier gene.”
Despite how simple this example may seem, this example highlights the im-
portance of a well-defined phenotype when searching for MGs. This subtle but
critical distinction has important implications on which phenotype and strategies
should be used when gene(s) responsible for disease and/or MGs are searched for.
In the first case, a dichotomous (affected/unaffected) phenotype is used, whilst a
measure (or a proxy) of clinical variability must be used when searching for mod-
ifiers. Segregation and linkage analysis, followed by association studies constitute
the suggested workflow in the difficult endeavour of searching for MGs [45].
For AD in particular, especially in situations in which a single-gene mutation is
known to cause the disease but individuals start showing AD-related symptoms at
different points in time, AOO constitutes a suitable measure of clinical variability.
Furthermore, by clinically and genetically evaluating individuals living in similar
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environmental conditions, the effect of MGs is likely to be better differentiated from
other sources of phenotypic variation [43, 45]. In that sense, as discussed in Subsec-
tion 1.2.2, genetic isolates [39] such as the Paisa community in Antioquia, Colombia
constitute a powerful tool for dissecting the contribution of MGs to produce a less
or more extreme AD phenotype (i.e., early-onset vs. late-onset). Importantly, a MG
could have two distinct modifier variants, one of which increases the AOO, and one
of which decreases it. Most, but not all of the statistical analyses in this thesis are
searching for modifier variants.
1.2.2 The E280A pedigree
The story of this extended multigenerational pedigree began more than 25 years
ago in Belmira, one of the 125 municipalities of the state of Antioquia in Colom-
bia, South America (Figure 1.4a). Known as ‘la bobera’ (the silliness) in one single
individual, this condition was further characterised in a three-generation family as
the first identified case of Alzheimer-type dementia in Colombia (Figure 1.4b). To-
day, this ‘single family’ is comprised by more than 6,000 individuals, and is known
to suffer from one of the most severe forms of early-onset fAD in which a fully
penetrant mutation in the PSEN1 gene causes EOAD [49].
Here, the importance of the E280Amultigenerational extended pedigree from the
Paisa genetic isolate is highlighted in the context of clinical and genetic research,
as well by how the combination of clinically well-characterised individuals and a
sequential methodological approach has successfully led to important discoveries
in AD. The developments from when the first individual with AD was indentified
in this community, until a recently-launched clinical trial focused on the prevention
of AD, show how clinical and genetic studies performed on the E280A pedigree
may ultimately lead to early interventions in AD, or to the prediction of AD onset
based on clinical and genetic information (as discussed in Chapter 3).
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1. Discovery and clinical characterisation of the first family with AD-related dementia.
The first individual with Alzheimer-related presenilin dementia in the Paisa genetic
isolate (Figure 1.4a) was identified 27 years ago [50]. The proband, a 49 year-old
farmer that completed only second year at primary school, had clinical dementia-
related symptoms for four years at the time of diagnosis. These symptoms initiated
with progressive memory loss and the no recognition of family members two years
later, finally followed by carelessness for personal appearance, incoherences as well
as visual and auditive hallucinations. Exploration of the family history revealed
that nine family members across four generations showed an AOO of ⇠ 48 years, a
high degree of consanguinity and a dominant pattern of inheritance (Figure 1.4b).
After identifying three patients with AD, Lopera et al. [51] reconstructed the cor-
responding genealogies and found that the average ADAOO was ⇠ 47 years with a
duration of disease of ⇠ 8 years. A total of 1,093 individuals in 53 nuclear families
comprised these pedigrees. Observation of the reconstructed pedigrees pointed out
that there were high proportions of individuals having any one of four surnames
suggesting that they possibly belonged to the same family (i.e., a founder effect).
Later on it was found that the most common of these surnames could be traced to
1783 when it was registered for the first time in Yarumal, Antioquia (founded in
1780) [38]. Nineteen years later, Lalli et al. [52] traced the most common ancestor
back to 10 generations (i.e., a single founder during the 16th century when Spanish
Conquistadors began colonising Colombia).
2. Genetic mapping of the locus causing early-onset fAD.
Complex segregation analysis revealed the existence of a dominant major gene that
defines the AD phenotype in high proportion, and small multifactorial contribu-
tions that define the AD phenotype in its entirety. Gene frequency estimations
showed that ⇠ 2% of individuals inhabiting this region are carriers of the gene
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causing AD [51].
Clark et al. [53] performed linkage analysis on seven families exhibiting early-
onset fAD (ADAOO < 60 years) from this genetic isolate. This analysis lead to
the identification of the E280A mutation within the PSEN1 gene. The logarithm
(base 10) of odds (LOD) score, a measure of how likely it is that within a family
the disease and the genetic marker are cosegregating due to the existence of linkage
(with a given linkage value) compared to chance, was > 3 for the E280A mutation
[53]. This figure indicates a 1000 to 1 odds that the disease and marker loci are
close to one another and that this closeness does not occur by chance. This mu-
tation (rs63750231, GAA ! GCA), produces an E (Glutamic acid) by A (Alanine)
substitution at codon 280, and was shown to be fully penetrant [53]. This implies
that having one or two copies of the PSEN1 E280A mutation results in early-onset
fAD. The common ancestor of the E280A mutation was traced to 10 generations
ago [52].
3. Clinical profile, and disease progression stages in E280A mutation carriers.
Following the identification of the PSEN1 E280A mutation, Lopera et al. [38] sur-
veyed and clinically characterised the AD phenotype in ⇠ 3, 000 individuals from
five extended multigenerational pedigrees from the Paisa genetic isolate. A total of
128 individuals with AD were identified (six had EOAD, 93 had probable EOAD
and 29 had possible EOAD). The average ADAOO was ⇠ 47 years, and the average
interval until death was ⇠ 8 years. Memory loss and progressive loss of language
ability were the most common clinical features among patients. Another important
finding of this study is that the clinical phenotype in patients with early-onset fAD
is indistinguishable from sAD. Interestingly, based on the clinical characterisation
of the AOO in these individuals, the authors suggested for the first time that the
characteristics of this family (i.e., extended multigenerational pedigrees) provide a
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these participants were classed as healthy carriers. Seven 
participants died of causes other than AD: one died in a car 
accident before reaching any disease stage, three died 
before the MCI stage (one patient had symptomatic pre-
MCI; no data were available for the other two patients) of 
causes not registered in their records, one participant with 
MCI died of myocardial infarction, and two participants in 
initial stages of dementia died of causes not related to 
dementia complications (myocardial infarction and 
cancer). These participants were analysed as right censored, 
and outcome values were set as they were at the last 
assessment. 34 participants received treatment during 
their clinical progression, 31 during dementia and three 
during MCI. Administered drugs were cholinesterase 
inhibitors or memantine, which did not modify the disease 
progression (data not shown). None of the participants 
identifi ed as non-carriers developed dementia during the 
study. We did not assess whether any non-carriers 
developed MCI or pre-MCI. However, two non-carriers 
were detected by the MCI criteria. One was identifi ed after 
being diagnosed with cranioencephalic trauma and one 
after bipolar aﬀ ective disorder. After genotyping, these 
participants were excluded from all analyses.
We diﬀ erentiated fi ve clinical stages with a non-
overlapping progression in the PSEN1 E280A carriers 
(fi gure 2). The median time to progression from 
asymptomatic to symptomatic pre-MCI was 4 years 
(95% CI 2–8), from symptomatic pre-MCI to MCI was 
6 years (4–7), from MCI to dementia was 5 years (4–6), and 
from dementia to death was 10 years (9–12). Median age of 
onset was 35 years (95% CI 30–36) for asymptomatic pre-
MCI, 38 years (37–40) for symptomatic pre-MCI, 44 years 
(43–45) for MCI, and 49 years (49–50) for dementia. 
Carriers died at a median age of 59 years (58–61; fi gure 3). 
About 50% of carriers had asymptomatic pre-MCI by age 
35 years, and there was an interval of about 25 years 
between onset of asymptomatic pre-MCI and death.
Neuropsychological assessments of diﬀ erent cognitive 
domains in participants for whom exact age at onset was 
known for each stage (table 4) were classifi ed into four 
diﬀ erent subtypes, according to whether the amnestic 
domain, multiple amnestic domains, a single non-
memory domain, or multiple non-memory domains 
were most severely aﬀ ected (webappendix pp 6–8 and 10). 
Several cognitive domains were aﬀ ected in participants 
with asymptomatic pre-MCI, including memory (table 4). 
Participants with symptomatic pre-MCI and those with 
MCI presented mainly with memory impairment, with 
or without involvement of other cognitive domains. 
No participants were identifi ed with non-memory 
impairment in multiple domains at any stage. 
21 participants with pre-MCI or MCI had a single non-
memory domain aﬀ ected. The main aﬀ ected domains in 
these patients were attention, executive function, 
constructional praxis, and calculation.
162 PSEN1 E280A carriers who did not have any cognitive 
defi cit or subjective complaint in the fi rst assessment were 
classed as healthy and were compared with the other 
groups. There was a statistically signifi cant decline in 
memory (p=0·001), language (p=0·002), praxis (p=0·015), 
and abstract reasoning (p=0·009) in participants with 
asymptomatic pre-MCI compared with healthy carriers 
(webappendix p 10), which seemed to recover in 
symptomatic pre-MCI (fi gure 4). From this stage onwards, 
the Z score in these cognitive domains decreased 
progressively in a statistically signifi cant manner (fi gure 4 
Figure 2: Survival analysis of disease progression in PSEN1 E280A carriers
MCI=mild cognitive impairment.
Figure 3: Progression of disease in PSEN1 E280A carriers
MCI=mild cognitive impairment. 95% CI=bootstrap 95% CI. *Age by which half the participants had reached 
each stage. 
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Table 4: Cognitive impairment subtypes in participants for whom an exact age at onset was available
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identifi ed as non-carriers developed dementia during the 
study. We did not assess whether any non-carriers 
developed MCI or pre-MCI. However, two non-carriers 
were detected by the MCI criteria. One was identifi ed after 
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asymptomatic to symptomatic pre-MCI was 4 years 
(95% CI 2–8), from symptomatic pre-MCI to MCI was 
6 years (4–7), from MCI to dementia was 5 years (4–6), and 
from dementia to death was 10 years (9–12). Median age of 
onset was 35 years (95% CI 30–36) for asymptomatic pre-
MCI, 38 years (37–40) for symptomatic pre-MCI, 44 years 
(43–45) for MCI, and 49 years (49–50) for dementia. 
Carriers died at a median age of 59 years (58–61; fi gure 3). 
About 50% of carriers had asymptomatic pre-MCI by age 
35 years, and there was an interval of about 25 years 
between onset of asymptomatic pre-MCI and death.
Neuropsychological assessments of diﬀ erent cognitive 
domains in participants for whom exact age at onset was 
known for each stage (table 4) were classifi ed into four 
diﬀ erent subtypes, according to whether the amnestic 
domain, multiple amnestic domains, a single non-
memory domain, or multiple non-memory domains 
were most severely aﬀ ected (webappendix pp 6–8 and 10). 
Several cognitive domains were aﬀ ected in participants 
with asymptomatic pre-MCI, including memory (table 4). 
Participants with symptomatic pre-MCI and those with 
MCI presented mainly with memory impairment, with 
or without involvement of other cognitive domains. 
No participants were i entifi ed with non-memory 
impairment in multiple domains at any stage. 
21 participants with pre-MCI or MCI had a single non-
memory domain aﬀ ected. The main aﬀ ected domains in 
these patients were attention, executive function, 
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162 PSEN1 E280A carriers who did not have any cognitive 
defi cit or subjective complaint in the fi rst assessment were 
classed as healthy and were compared with the other 
groups. There was a statistically signifi cant decline in 
memory (p=0·001), language (p=0·002), praxis (p=0·015), 
and abstract reasoning (p=0·009) in participants with 
asymptomatic pre-MCI compared with healthy carriers 
(weba pendix p 10), which seemed to recover in 
symptomatic pre-MCI (fi gure 4). From this stage onwards, 
the Z score in these cognitive domains decreased 
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Figure 3: Progression of disease in PSEN1 E280A carriers
MCI=mild cognitive impairment. 95% CI=bootstrap 95% CI. *Age by which half the participants had reached 
each stage. 
100
80
60
40
20
0
0 20 40
Age of onset (years)
Fr
ee
-s
ta
ge
 P
SE
N1
 E
28
0A
 ca
rri
er
s (
%
)
60 80
Asymptomatic pre-MCI
Symptomatic pre-MCI
MCI
Dementia
Death
5
35
(30–36)
38
(37–40)
44
(43–45)
49
(49–50)
59
(58–61)
10 15 20
Median age*
(95% CI)
Years of follow-up
Progression 4 years
(95% CI 2–8) 
6 years
(4–7) 
5 years
(4–6) 
10 years
(9–12) 
Asymptomatic
pre-MCI
Symptomatic
pre-MCI
MCI Dementia
Amnestic* Amnestic* 
multiple domains
Single non-
memory† domain
Non-memory† 
multiple domains
Asymptomatic pre-MCI (n=17) 5 (29%) 8 (47%) 4 (24%) 0 (0%)
Symptomatic pre-MCI (n=102) 59 (58%) 30 (29%) 13 (13%) 0 (0%)
MCI (n=117) 45 (38%) 68 (58%) 4 (3%) 0 (0%)
Dementia (n=173) 0 (0%) 173 (100%) 0 (0%) 0 (0%)
Data are number (%). Totals do not always add to 100% because of rounding. MCI=mild cognitive impairment. 
*Memory. †Attention, language, constructional praxis, abstract reasoning, calculation, and executive function.
Table 4: Cognitive impairment subtypes in participants for whom an exact age at onset was available
a 
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Figure 1.5: (a) Survival analysis of disease progression and (b) progression of disease in PSEN1
E280A mutation carriers. Modified with permission from Acosta-Baena et al. [22].
unique opportunity to search for genetic and environmental modifiers in AD [38].
Acosta-Baena et al. [22] identified five clinical stages of non-overlapping pro-
gression to AD after following 449 PSEN1 E280A mutat on carriers from the Paisa
genetic isolate for ⇠ 15 years: asym tomatic pre-MCI, symptomatic pre-MCI, MCI,
dementia and death (Figure 1.5a). The me ian ADAOO was 35 years (95%CI 30-36)
for asymptomatic pre- MCI, 38 years (95%CI 37-40) for symptomatic pre-MCI, 44
years (95%CI 43-45) for MCI, and 49 years 95%CI 49-50) for dementia (Figure 1.5b).
In terms of median time to progression, E280A mutation carriers last and average
of 4 years (95%CI 2-8) to progress from symptomatic to sympto atic pr -MCI, 6
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years (95%CI 4-7) from symptomatic pre-MCI to MCI, 5 years (95% CI 4-6) from
MCI to dementia, and 10 years (95%CI 9-12) from dementia to death. The median
age at death was 59 years (95%CI 58-61) (Figure 1.5b).
4. First studies identifying AOO modifiers, and noninvasive biomarkers.
The first study assessing AOO differences in the E280A pedigree was performed by
Lendon et al. [40] who studied the effect of the APOE e4 allele on the AOO in seven
kindreds, and found no difference between 4 carriers (n = 12) and non-carriers
(n = 16). A few years later, Pastor et al. [54] genotyped coding and promoter
polymorphisms of the APOE gene in 109 carriers of the E280A mutation. Survival
analysis showed that carries of the APOE e4 allele were more likely to develop AD
at an earlier age than those without the allele, and that, although not statistically
significant, the APOE e2 allele may have a modest protective effect on the ADAOO.
These results suggest a potential interaction between PSEN1 and APOE to modify
the AOO in individuals from this population (see also Chapter 3).
The literature on genome wide association studies (GWAS) suggests that large
sample sizes may be required to detect significant associations of genomic regions
for complex disorders when comparing the allele frequency of thousands of ge-
netic markers between cases and controls [55, 56]. Because of the challenges of
obtaining such large cohorts, Ve´lez et al. [31] developed and empirically applied
a novel sequential strategy, namely pooling-based/bootstrap GWAS (prGWAS), to
a sample of 102 E280A mutation carriers. prGWAS, specifically designed to iden-
tify disease-associated SNPs using DNA from small samples of cases and controls
from exquisitely well-defined homogenous cohorts, combines DNA pooling [57]
and resampling methods [58] to significantly increase the statistical power and ex-
ponentially reduce costs [31].
Individuals with MCI symptoms before 48 years of age were classified as EOAD
16
CHAPTER 1. INTRODUCTION
(cases), and those with MCI symptoms appearing after 50 years of age as LOAD
(controls). This cutoff value was selected based on the 40th and 60th percentile of
the survival curve presented in Acosta-Baena et al. [22] for the MCI clinical stage
(Figure 1.5a). It is noteworthy that this categorisation of the AOO resembles the
strategy presented in Figure 2.1 in which individuals at the extremes of a quanti-
tative trait are studied. By comparing the allele frequencies of genetic markers in
these individuals, ADAOO modifiers in PSEN1 E280A AD were identified for the
first time [31]. Interestingly, the Nephronophthisis 1 (juvenile) (NPHP1) gene, which
was one of the ADAOO modifier genes identified in the E280A pedigree, was also
found to modify ADAOO in a family from Dominican Republic carrying the G206A
mutation in the PSEN1 gene [59].
Reiman et al. [60] performed a case/control study in which brain imaging and
fluid biomarker analysis on 44 cognitively normal individuals (20 PSEN1 E280A
mutation carriers and 24 non-carriers, 18-26 years of age) revealed that carriers of
the E280A mutation presented greater right hippocampal and parahippocampal ac-
tivation, less precuneus and posterior cingulate deactivation, less grey matter in
several parietal regions, and higher cerebral spinal fluid (CSF) and plasma Ab1 42
concentrations than non-carriers. These findings suggest that functional and struc-
tural MRI changes, as well as CSF and plasma biomarker findings are detectable
⇠ 20 years before AD symptoms and Ab deposition begin in PSEN1 E280A muta-
tion carriers. In other words, that brain changes precede Ab plaque deposition, and
that these changes begin before onset of AD in this pedigree.
Londono et al. [61] studied 75 individuals, 44 of whom were E280A mutation
carriers (17 with either MCI or EOAD) and 31 unaffected non-carriers. The au-
thors identified noninvasive biomarkers accessible to the clinical setting that might
have important implications in the identification of E280A carriers, the detection of
disease progression and monitoring of treatment response.
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5. Identification and clinical characterisation of patients with sAD.
An ongoing study from the Neuroscience Research Group at the University of An-
tioquia, Colombia has identified individuals with sAD from the Paisa genetic iso-
late. To date, ⇠ 500 individuals are enrolled. Although these patients inhabit in
the Metropolitan Area of Medellin in Antioquia, Colombia, and share the same ge-
netic background with the PSEN1 E280A pedigree [39, 62], mutations in the PSEN1
or other known AD-related genes have been discarded. Clinical assessment in-
cludes ADAOO as well as other relevant outcomes such as the Mini-mental state
(MMSE) [63], Functional Assessment Staging Test (FAST) [64], Subjective Memory
Complaints (SMC) for Patients (SMCP) [65], and SMC for Family members (SMCF)
[66]. As detailed in Chapter 5, some of these patients with sAD have been followed
for up to ⇠ 13 years.
This cohort of patients with sAD is important for three reasons. Firstly, like the
E280A pedigree, it comes from a genetic isolate. This reduces the role of environ-
mental factors in shaping the natural history of the disease. Second, the clinical
characterisation of these individuals, which include AOO, provides a unique re-
source to identify genetic modifiers of the AOO. Given that individuals are followed
over time and a clinical outcome is measured, it would be possible to establish pat-
terns of cognitive decline and further establish clinical diagnostic tools to monitor
these patients. Thirdly, identifying genes that increase or decrease cognitive decline
in sAD might lead to early therapeutic interventions.
6. Clinical trial.
In 2012, the National Institutes of Health (NIH) funded the first phase 2 clinical
trial to study the effect of crenezumab, which stimulates amyloid phagocytosis, on
the formation of amyloid plaques in the brain [67]. The importance of this trial, and
in particular the importance of the E280A pedigree in the search for a therapeutic
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interventions for AD has been highlighted by several Editorial and first-page articles
in the New York Times [68, 69, 70].
The trial is lead by the Banner Alzheimer’s Institute in Phoenix, AZ, USA and
will cost more than $130 million [69]. A total of 100 PSEN1 E280A mutation carri-
ers in a preclinical phase of AD (not meeting the MCI criteria or dementia due to
AD), and a cohort of 100 non-carriers will be followed for 260 weeks. During this
time, PSEN1 E280A mutation carriers will receive either the drug or placebo subcu-
taneously every 2 weeks, and non-carriers will receive placebo only. The primary
outcome at the end of the observation period is the change on Alzheimer’s Pre-
vention Initiative (API) composite cognitive test total score [71]. Other secondary
outcomes include time to progression from MCI to AD, and changes in episodic
memory, the average cerebral fibrillar amyloid accumulation, and a tau-based cere-
bral spinal fluid biomarker [67].
1.3 Scope of the present study
The main topic of this thesis is the development of a framework combining statisti-
cal (linear mixed-effect models), genetic (genetic isolates and extreme phenotypes),
bioinformatic (functional prediction and pathway analysis) and data mining tools
to identify modifier variants (and/or genes) in complex human diseases. As a test
case of this model, AOO modifier variants/genes are identified in AD.
The proposed framework is described in detail in Chapter 2. Furthermore, sev-
eral key genetic concepts, statistical and bioinformatic tools used in this thesis such
as GWAS, genetic isolates, extreme phenotypes and their role in genetic research, as
well as parameters such as minor allele frequency (MAF), Hardy-Weinberg Equilib-
rium, and genotype call rate (CR) are discussed. Emphasis is put on the definition
of well-characterised cohorts, and the use of analytical tools to control for popu-
lation structure when performing genetic association analyses. Furthermore, the
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multiple testing problem is briefly introduced and available solutions are outlined.
In Chapter 3, I performed whole-exome association analysis in patients with
PSEN1 E280A AD from the Paisa genetic isolate. Instead of selecting exonic vari-
ants harboured in genes reported by Ve´lez et al. [31], here the full exonic content
of the Illumina’s HumanExome BeadChip-12v1 A was submitted to quality control,
filtering and annotation. Genetic association analyses were performed using those
CEFVs passing quality control and the ADAOO as phenotype. In addition to an im-
portant decelerator effect on the ADAOO of the e2 allele of the APOE gene (Figure
3.4), other relevant ADAOO modifier mutations were identified (Table 3.1).
Looking for replication of the association findings in an independent sample,
a collection of patients with sporadic AD (sAD) from the same genetic isolate
was whole-exome genotyped using the HumanExome BeadChip-12v1 A chip. I
extracted only variants harboured in those ADAOO modifier genes identified in
individuals with E280A AD, and performed genetic association analyses. A muta-
tion in the G protein-coupled receptor 20 (GPR20) gene was found to delay ADAOO
in individuals with E280A AD, but accelerate it in individuals with sAD (i.e., AD
symptoms start appearing earlier).
Later in Chapter 3, a clinical/genetic-based framework to predict whether an
individual carrying the E280A would develop EOAD or LOAD (i.e., before or af-
ter 48 years of age) was constructed using demographic and genetic information
(Figure 3.3). A battery of performance measures (e.g., area under the curve, sensi-
tivity, specificity, and precision, among others) applied to this framework indicated
an extraordinary predictive power to discriminate patients with EOAD and LOAD,
making it a potential tool for AD diagnosis, prediction, and follow-up.
Subsequently, in Chapter 4 I focused on determining whether mutations har-
boured in ADAOO modifier genes reported by the pooling/bootstrap GWAS
(prGWAS) method presented in Ve´lez et al. [31], also modify ADAOO. Specifically, I
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performed targeted genetic association analysis on a cohort of n = 60 patients with
AD from the E280A extended multigenerational pedigree [38, 39, 22], and with an
ADAOO at the extremes of the ADAOO distribution specific to this population.
The common exonic functional variants (CEFVs) tested in this analysis, 71 in total,
resulted after the application of quality control measures and functional filtering
and annotation (described in detail in Chapter 2) on the Illumina’s HumanExome
BeadChip-12v1 A. A mutation in the D-amino acid oxidase activator (DAOA) gene
was associated as an ADAOO modifier in this sample. This finding suggests not
only that prGWAS is a feasible method for detecting ADAOO modifiers or variants
conferring susceptibility to disease (as in the Welcome Trust Cases/Control Con-
sortium [WTCCC] data – see below), but also points to the location and further
discovery of genetic variants of major effect (i.e., mutations) on the phenotype of
interest.
In the next chapter of this thesis, Chapter 5, I applied statistical, genetic and
bioinformatic tools to identify ADAOO modifier genes in patients with sAD. Al-
though some relevant molecular and biological mechanisms of these genes have
already been described in AD, here I show for the first time that mutations har-
boured in those genes are observed, modify ADAOO and are involved in the phys-
iopathology of the disease. Furthermore, pathway and enrichment analyses pro-
vided additional evidence supporting the role of these genes in AD, and highlight
their importance for prediction, and as potential therapeutic targets. Like patients
with the PSEN1 E280A mutation, sAD patients included in this research are from
the Paisa genetic isolate exhibiting an ADAOO at the extremes of the ADAOO dis-
tribution.
Despite the advantages of the prGWAS methodology (see Subsection 1.2.2), lit-
tle had yet been done to validate it using a different sample. In Chapter 6 of this
thesis, I validate prGWAS using seven independent case/control samples from the
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WTCCC study comprising a total of ⇠ 17, 000 individuals [72]. I conceived, de-
signed, developed and implemented all in silico experiments, as well as an strategy
to compare prGWAS and the traditional GWAS using the WTCCC data. I found that
prGWAS identifies up to 98% of the previously reported signals showing strong or
moderate association overall [73]. Furthermore, unlike the WTCCC study in which
thousands of DNA samples were genotyped, at least 80 DNA pools (up to 10 DNA
pools per disease + 10 DNA pool from the controls) would have been needed using
prGWAS [73]. This highlights the feasibility of prGWAS as an important alternative
in applications such as whole-exome and whole-genome sequencing for cases and
controls, or GWAS where the genotyping/sequencing cost is prohibitive.
Chapter 7 discusses the role of extreme phenotypes, genetic isolates and mod-
ifier genes in genetic research with emphasis in complex human diseases. I will
also present my research work in Alzheimer’s disease as a successful test case and
provide a brief summary of the key findings and their implications in the under-
standing of the natural history of this devastating neurodegenerative condition.
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Chapter2
A general framework for detecting
modifier genes and its application to
Alzheimer’s disease
Abstract
Identifying modifier genes (MGs) is of great interest in genetic research
of complex traits, and Alzheimer’s disease (AD) is no exception. In this
chapter, a framework that combines genetic, statistical and bioinformatic
tools used in this thesis is proposed and described in detail. Key concepts
such as extreme phenotypes (EPs), genetic isolates and control for popu-
lation stratification in genetic analysis, as well as correction for multiple
testing and in silico strategies for evaluating the potential functional impli-
cations of genes and their genetic variants on the aetiology of AD are the
core component of this framework. Finally, some data mining tools with
potential application in the clinical setting for predicting disease status
based on genetic and clinical information are presented.
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A well-defined phenotype is the first step towards the identification of genetic
variants conferring susceptibility to disease or modifying some measure of clinical
variability (see Subsection 1.1.4). Once the phenotype has been clearly defined,
DNA from individuals is extracted, genetic markers are further genotyped and
genetic analysis is performed.
Here the clinical tests used to diagnose AD are briefly described, along with the
definition of an extreme phenotype (EP) and its implications in the genetic research
of AD and other clinical conditions. In addition, genome-wide association studies
(GWASs) and methods to perform quality control and to control for population
stratification (i.e., the presence of subpopulation within samples) are described.
Methods for testing the association of genetic variants in GWAS are also discussed,
and insight into the multiple testing problem as well as several solutions is given.
In the absence of fast and easy-to-conduct biological experiments to determine
the role of genetic variants found in GWASs, bioinformatic tools (used throughout
this thesis and described in detail further below) have increasingly been used to de-
termine, in silico, whether these variants affect the structure of the protein encoded
by genes harbouring them. I utilised algorithms (described in Subsection 2.2.4) for
predicting the potential function of these changes, and publicly available databases
and genome browsers such as Ensembl (www.ensembl.org) and UCSC Genome
Browser (genome.ucsc.edu) to determine (i) whether genetic variants have any be-
nign or pathological functional role at the protein level; (ii) whether genes harbour-
ing these variants are implicated in the aetiology of disease or could be potential
therapeutical targets; or (iii) whether these genes are closely biologically related to
other genes previously reported. Although these in silico analyses do not replace
by any means the actual experiments (often conducted with animal models), they
give some insight into the functional relevance and potential deleterious nature of
genetic variants.
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Once the functional role of genetic variants is determined, researchers could use
this information in combination with the phenotype and demographic variables
(i.e., as sex, years of education) to establish a diagnostic tool applicable in the clinical
setting (i.e., genomic and predictive medicine). In other words, it could be possible
to correlate the phenotype with the pathogenicity of these variants to diagnose,
based on a blood sample, whether individuals with a specific genetic profile have
(or will develop) the disease (and when). Some statistical and data mining methods
for predicting disease status (early-onset vs. late-onset) in AD based on genetic and
clinical data are described.
2.1 Clinical diagnosis and extreme phenotypes in AD
As previously discussed in Section 1.2, the identification of MGs heavily depends
on a well-defined measure of clinical variability. In this thesis, the age of onset
(AOO) is used as such a measure for the reasons mentioned in Subsection 1.1.5.
Patients included for analysis in this study were recruited and clinically, neu-
rologically and neuropsychologically assessed at the Group of Neurosciences AD
Clinic, University of Antioquia in Medellı´n, Colombia using a Spanish version of
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) evalua-
tion battery [1] adapted for the cultural and linguistic characteristics specific to this
population [2, 3, 4, 5]. Carriers and non-carriers of the PSEN1 E280A mutation (see
Subsection 1.2.2 for more details) were clinically assessed. The modified CERAD
battery used in this case includes the following measures:
(i) Semantic Fluency (Animal Naming). Individuals are requested to name as many
animals as they can in 1 min. The dependent variable is the number of non-
repeated animals named.
(ii) Modified Boston Naming Test. Consists in asking individuals to identify 15 line
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drawings of increasing complexity (high, medium and low frequency) with a
maximum of 10 seconds for each drawing. One point is awarded for each cor-
rect response. The dependent variable is the total number of correct namings.
(iii) Mini-mental State Exam (MMSE). A modified version of the MMSE [6] was used.
The spelling backward subtest was excluded because the spelling ability in-
volved in this task is not a common skill for Spanish-speaking people. Instead,
we replaced it with subtraction by threes, which is more appropriate for this
population. The total score of this test was 30 points. The dependent variable
was the total number of correct points.
(iv) Word List Memory (WLM). This test assesses the ability to recall newly learned
information. Individuals are presented 10 printed words on a card at the rate
of one every 2 seconds. They are immediately asked to recall as many words
as possible from the list. This procedure is repeated in three consecutive trials.
The maximum number of correct words is 30 for the three trials. The number
of correct words identified serves as the dependent variable.
(v) Constructional Praxis. Individuals are presented with four line drawings of
figures of increasing complexity (circle, rhombus, pentagon and cube), one at a
time, and asked to copy them. Maximum time allowed for copying each figure
is 2 min. Reproductions are scored according to predetermined criteria and the
dependent measure is the total score for the four drawings.
(vi) Word List Recall. This test assesses delayed memory by requesting individuals
to recall the list of ten words presented in the WLM task. The maximum time
allowed for this recall is 90 seconds. One point is awarded for each word
recalled correctly with maximum of 10 points if all the words are recalled.
(vii) Word List Recognition. This test consists of recognition of the 10 words from the
WLM task, presented in a list of 20 words (including 10 additional distractor
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words). A forced-choice paradigm is used so that subjects must respond with
YES to the words they consider correct (i.e., in the list of words previously
read), and NO to the words that were not on that list. One point is awarded
for each word correctly recognised. To adjust by chance, the subject’s score is
calculated as the total number of correct answers minus 10; if the result is less
than 0, a score of 0 is given.
(viii) Line-Drawing Recall. Individuals are asked to recall the drawings they copied
previously and draw them from free recall on a blank sheet of paper. This tests
serves to assess visual memory.
Patients were defined as affected by mild cognitive impairment (MCI) based on
Petersen’s criteria [7], and by AD if they met DSM-IV criteria [8]. Along the MCI
and AD diagnosis, the AOO of both was registered.
2.1.1 Extreme phenotypes from a genetic isolate
An extreme phenotype (EP) can be seen as that departing from the disease’s natural
history. Recent in silico studies have shown that the use of EPs could assist geneti-
cists in the discovery and replication of common and rare variants for the following
reasons [9, 10, 11]:
(i) EPs facilitate the identification of common and/or rare genetic variants. This
is based on the assumption that the frequencies of those alleles contributing to
the trait are more likely to differ between individuals placed at the extremes of
the phenotype distribution [12] (illustrated in Figure 2.1). As described further
below, common and rare genetic variants are defined based on the minor allele
frequency (MAF), that is, on the frequency of the less common of all alleles.
(ii) The use of EPs may require smaller sample sizes to identify genetic variants
compared to GWAS, whole-exome or whole-genome sequencing studies (see
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[12], [13], [14] and [15] for successful studies in cystic fibrosis, morbid obe-
sity, autoimmunity and AD, respectively, in which less than 100 individuals
were included). As a consequence of this, the genotyping/sequencing costs
are considerably reduced.
(iii) EPs may empower the identification of MGs as illustrated by Emond et al. [12]
and Ve´lez et al. [15].
Despite much controversy on what the cutoff should be for the MAF for defining
common and rare variants [16], is now widely accepted that variants with a MAF
of > 1% are considered common and rare otherwise [17, 18]. This subtle distinc-
tion has important implications when elucidating the genetic basis of complex traits
such as AD. As discussed by Iyengar and Elston [19], the reasons behind are related
with how the genetic variance (GV) of the disease (i.e., the proportion of the pheno-
type due to the genetic background) is explained. When variants are common, the
GV can be explained by some genetic variants (often of small effect), whilst DNA
sequence variations (i.e., mutations) found rarely in the population are assumed
to account for most of the GV when variants are rare. Other arguments in favour
and against the analysis of common and rare variants are discussed extensively by
Gibson [20].
Not many studies have used EPs in AD to identify either MGs or genetic variants
conferring susceptibility to AD. Based on Alzheimer’s disease AOO (ADAOO), an
EP can be derived by selecting individuals with AD that have an AOO much earlier,
or later than the ‘average’ AOO observed in the population. A recent example of
this strategy is given by Ve´lez et al. [15], who, based on the AOO, categorised AD
status as early-onset (AOO < 48 years) or late-onset (AOO > 50 years). Interest-
ingly, the authors identified, using a small sample size, genes previously reported
as conferring susceptibility to AD, as well as new AOO MGs in individuals from
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the Paisa genetic isolate affected by AD and carrying the PSEN1 E280A mutation.
Similar strategies involving EPs that led to the identification of genetic variants in
other conditions were utilised by Emond et al. [12], Paz-Filho et al. [13] and Johar
et al. [14].
The common denominator of genetic studies making use of EPs can be sum-
marised as (i) clinically assessing patients and studying the distribution of a mea-
sure of clinical variability; (ii) classification of patients into categories such as ‘low’,
‘normal’ and ‘high’ to define some degree of severity; (iii) genotyping of patients
with the more ‘severe’ (or extreme) phenotypes; and (iv) performing genetic and
statistical analysis. In this thesis, the AOO was used as a measure of clinical vari-
ability, with an extreme AOO indicating that the individual developed AD signs
and symptoms much earlier (or much later) than other individuals in the Paisa
genetic isolate [21]. Being from a genetic isolate make these individuals unique.
However, the fact that some of them either developed AD as a consequence of a
fully penetrant mutation in the PSEN1 gene that causes early-onset familial AD
(see Subsection 1.2.2 for more details) make their phenotype even more extreme.
Thus, the possibility of studying such EP in AD in this sample gives a great oppor-
tunity to elucidate the genetic causes responsible for the wide spread of the AOO in
this community, and may give some clues as to how these mechanisms shape other
forms of the disease (i.e., sporadic AD as shown in Chapter 5). Lastly, DNA was
extracted from individuals with an AOO at the extremes of the AOO distribution
for this population and further genotyped using high-throughput genotyping tech-
nologies such as whole-exome genotyping (WEG) or whole-exome capture (WEC).
These technologies are briefly described further below.
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2.2 Genome-wide association studies
The National Human Genome Research Institute (NHGRI) defines a GWAS as [22]
“. . . an approach that involves rapidly scanning markers across the complete sets
of DNA, or genomes, of many people to find genetic variations associated with a
particular disease . . . ”
From this definition, it is clear that GWASs constitute a feasible alternative to
determine the genetic causes of human complex diseases. As mentioned in Sub-
section 1.1.4, how to determine whether genetic markers have an effect on the phe-
notype actually depends on the nature of the phenotype. When the phenotype
corresponds to the presence or absence of the disease, a group of cases (individ-
uals with the disease) and a group of controls (individuals without the disease)
are assessed and m genetic markers are genotyped. This is usually known as a
case/control study. In its simplest form, case/control studies test whether the dis-
ease is caused by genetic and environmental factors, the former quantified by m
genetic markers assumed to have each a small effect (i.e., its presence alone does
not cause the disease), by comparing the allele frequency of each genetic marker
between cases and controls [23]. On the other hand, when the phenotype is contin-
uous (i.e, AOO in AD), the strategy is to compare not the allele frequencies between
cases and controls, but the average AOO either between alleles or between geno-
types. This comparison is performed using statistical methods such as analysis
of variance (ANOVA), generalised linear models (GLMs) and linear mixed-effects
models (LMEMs) after controlling for confounding variables [24]. ANOVA usually
compares the average phenotype across all genotypes (or alleles) with the global
average after controlling for confounding variables. The drawback of this approach
is that it does not allow one to control for population stratification. GLMs on the
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other hand, constitute a more flexible approach as different theoretical distributions
for the outcome (i.e., the phenotype), and link functions relating the phenotype and
the predictors can be used. However, GLMs also lack the possibility of efficiently
controlling for population structure. LMEMs will be discussed later in this chapter.
As discussed further below, an inherent complication of GWASs is that m is
usually large, often of the order of hundred of thousands and some times up to
millions (i.e., m ! •) [23]. From the statistical point of view, this is known as
a ‘multiple testing problem’ [25] as m statistical tests are performed. When unat-
tended, this leads to innacurate findings, by falsely stating that a given genetic
variant is associated with increased risk or decreased risk for a particular disease
(i.e., false positives). Other complications in GWASs are the effects of population
structure (i.e., subpopulation within a sample of individuals) and genetic microd-
ifferentiation (i.e., genetic divergence between individuals within a sample) [23].
Some alternatives used to overcome these complications are discussed in Subsec-
tion 2.2.5.
2.2.1 Types of GWAS
GWASs can be performed using different designs, each of which has strengths and
weakness [23, 24, 26, 27]. Usually, case/control and cohort studies are the most
commonly used designs, but other designs may also be used. Cohort studies in-
volve the following-up of individuals without the disease and registering who gets
the disease during that time. Regardless of the design, DNA from the individuals
under study is extracted and further genotyped or sequenced. When genotyped, it
is common to use high-throughput single nucleotide polymorphisms (SNPs) arrays
that allow assessing the genotypes of m SNPs across the genome for all individuals.
SNPs are DNA sequence variations in which a single-nucleotide (Adenine [A], Cy-
tosine [C], Guanine [G] or Thymine [T]) in the genome differs. Whole-exome and
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whole-genome genotyping constitute other high-throughput genotyping technolo-
gies; the former refers to interrogate the single-nucleotide changes within exomes
(i.e., protein-coding part of the gene) and the latter to interrogate those changes
across the genome. In addition to these genotyping technologies, genetic stud-
ies can also be performed by using sequencing technologies. Unlike SNP geno-
typing where single-nucleotide changes are registered, sequencing assesses all nu-
cleotides within a specific region of the genome (i.e., targeting sequencing), within
exomes (i.e., whole-exome sequencing [WES] also referred to as whole-exome cap-
ture [WEC]) or across the genome (whole-genome sequencing [WGS]).
2.2.2 Whole-exome genotyping and sequencing
In the journey of identifying AOO modifier genes in AD, DNA samples from these
individuals from the Paisa genetic isolate with and without the PSEN1 E280A muta-
tion were whole-genome amplified, fragmented, hybridized, fluorescently tagged,
and scanned using the Infinium assay [28] by the Australian Genome Facility (AGF;
Melbourne, VIC, Australia), an Illumina Certified Service Provider for the Infinium
Genotyping Service. For assessing the genetic content in these individuals, in
particular single-nucleotide changes that are functionally relevant (i.e., produce
changes at the protein level), whole-exome genotyping (WEG) and WES high-
throughput technologies were used; WEG was used to generate the genetic data
used for analysis in all chapters of this thesis, and WES was used for a similar
purpose in Chapter 3 only.
The Illumina’s HumanExome 12v1 A BeadChip (Illumina Inc., San Diego, CA,
USA) was used to conduct WEG. This chip covers regions with putative functional
exonic variants selected from exome- and whole-genome sequences of > 12, 000
individuals. The exonic content consists of > 250, 000 markers representing diverse
populations (including European, African, Chinese, and Hispanic individuals) in
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addition to common conditions including type 2 diabetes, cancer, and metabolic
and psychiatric disorders. The quality and reliability of the genotyping system was
tested by replicating one individual and comparing the results obtained in each
run. DNA samples with calls below Illumina’s expected 99% SNP call rates were
excluded as part of the initial quality control suggested by Illumina. Furthermore,
the identity by descent (IBD) matrix between all pairs of individuals, estimated
from genotype data [29], was used for quality control and for subsequent analy-
ses concerning the LMEM as described in subsubsection 2.2.5.1 below. Entries of
the IBD matrix correspond to a measure of how many alleles at any marker came
from the same ancestral chromosome [29, 30]. It is worth mentioning that apply-
ing an exome array that was developed using primarily European cohorts to ethnic
and family-based samples may introduce some bias, so caution is needed during
performing genetic analysis and interpreting results.
On the other hand, WEC was performed exclusively on individuals with AD car-
rying the PSEN1 E280A mutation. DNA was extracted from peripheral blood from
all patients and processed by AGF using the Infinium assay previously described.
DNA libraries were constructed from 1 µg of genomic DNA using an Illumina
TruSeq genomic DNA library kit (Illumina Inc., San Diego, CA, USA), and mul-
tiplexed with six samples pooled together (500 ng of each). Exons were enriched
from 3 µg of pooled library DNA using an Illumina TruSeq Exome enrichment kit
(Illumina Inc., San Diego, CA, USA), and ran on a 100-base-pair paired-end run on
an Illumina HiSeq 2000 sequencer (Illumina Inc., San Diego, CA, USA). A total of
201,071 genomic regions (sampled at ⇠ 50X coverage) were surveyed using the ex-
ome capture platform. The coverage is defined as the number of reads, on average,
representing a given nucleotide in the reconstructed sequence.
An additional step to get the WES in all individuals consisted of the processing
of sequencing image data. This was done in real time using Illumina’s Real Time
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Analysis software and converted to fastq files using the CASAVA pipeline (Illu-
mina Inc., San Diego, CA, USA). This pipeline processes sequencing reads and au-
tomatically generates a range of statistics, such as mean depth and percentage chro-
mosome coverage, to enable comparison with previous builds or other samples. The
entire workflow of data curation and analysis for variant-calling was developed by
the Genome Discovery Unit (GDU) at The Australian National University (ANU),
and consists of the following key components: (i) quality assessment; (ii) read align-
ment; (iii) local realignment around the known and novel insertion/deletion (indel)
regions to refine indel boundaries; (iv) recalibration of base qualities; (v) variant
calling; and (vi) assigning quality scores to variants.
The resulting fastq files from this workflow, each of which contain the sequence
of nucleotides per individual in addition to some quality scores, were further pro-
cessed for genetic analysis using Golden Helix’s SNP variation suite (SVS) version
8.3.0 (Golden Helix, Inc. Bozeman, MT, USA). Golden Helix’s SVS is an integrated
collection of analytic tools for managing, analysing, and visualising multifaceted
genomic and phenotypic data.
2.2.3 Quality control in GWAS
Making sure that the genetic data generated by high-throughput genotyping or
sequencing technologies is of decent quality constitutes a crucial step in the process
of identifying genetic variants modifying AOO in AD. Before performing any type
of statistical analysis to determine the existence of such variants, genotype and
sequence data are passed through quality control (QC). Although it is possible to
perform three different types of QC in GWAS (see Figure 2.1), only sample and
marker quality were used in this thesis.
Sample quality refers to analyses of all genotypes from each individual and de-
termining whether they agree with his/her characteristics (i.e., sex check), related-
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Figure 1.19.1 A flowchart overview of the entire GWAS QC process. Each topic is discussed in detail in the corresponding
section in the text. Squares represent steps, ovals represent input or output data, and trapezoids represent filtering of
data.
GWAS DATA FORMAT
Regardless of the underlying study design
(such as family-based or population-based),
the most commonly used format for genetic
data is the linkage, or pedigree file format
(pedfile). This file contains one individual per
row, where the first six columns are identifying
information (family ID, individual ID, father
ID, mother ID, sex, phenotype), and the re-
maining columns are genotypes (two columns
per genotype; one for each allele). The geno-
type column pairs correspond to an ordered set
of SNP markers present in an associated file
(.map or .bim). Additional phenotypes can
also be stored in separate files consisting of
family ID, individual ID, then extra columns
representing additional phenotypes. There are
several variations on pedfile format, includ-
ing transposed (long) formats (tped), and com-
pressed (binary) formats. Descriptions of these
file formats can be found on the PLINK home-
page (Table 1.19.1). PLINK is a freely avail-
able, open-source, cross-platform application
for QC and analysis of GWAS data (Purcell
et al., 2007). We used PLINK for imple-
menting most of the eMERGE network’s QC
pipeline.
An important issue when creating a pedfile
for QC analysis is the choice of strand ori-
entation to use for allele calls (i.e., forward
or reverse complement). While forward strand
is a commonly used allele-coding scheme, Il-
lumina has developed a consistent and sim-
ple method to ensure uniformity in genotype
call reporting that uses the polymorphism it-
self and the contextual surrounding sequence
(“TOP/BOT” strand and “A/B” allele cod-
ing; Illumina Technical Note; see Internet
Figur 2.1: QC types in GWAS. Modified from [31]
ness between samples, presence or ab ence of genetic stratification, or if the geno-
type call rate (GCR) meets certain standards. The relationship between samples was
established based on th IBD matrix calculated using all markers in the Illumina’s
HumanExome 12v1 A BeadChip.
Genetic stratification is t prese ce of dif erences in allele frequencies between
subpopulations within a population, possibly due to differences in ancestry [32].
When not co trolled, spurious results may be g n rated (i.e., false positives) from
the genetic analysis mainly because of type I error probability inflation. Although
several methods have been proposed to control for genetic stratification including
Principal Component Analysis (PCA) [33] and LMEMs. Because PCA does not
account for family structure [32], the LMEM method developed by Segura et al.
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[34] was used in this thesis to study and further define AOO modifiers in AD.
The LMEMs, implemented in Golden Helix SVS 8.3.0, are briefly described further
below.
GCR is the proportion of markers per sample with genotype information. For
the ith individual, the GCR can be calculated as GCRi = xi/m, where xi is the
number of markers with non-missing genotypes (i = 1, 2, . . . , n), m is the number of
markers (or positions in the genome) genotyped, and n is the number of individuals
included in the study. At least stated otherwise, a GCR > 0.9 was used for QC
purposes to be consistent with previous research from our group despite the fact
that this threshold may introduce questionable calls.
Provided that genotypes for m markers in n individuals are available, marker
quality refers to the application of different QC measures upon these markers. In
general, these measures are given by [31]:
(i) Marker call rate. This is a QC measure similar to GCR but applied to each
marker. The same threshold used for GCR quality control was set in this case.
(ii) Minor allele frequency (MAF). Given a bi-allelic marker (with alleles a and A),
the MAF measures the proportion of the less common allele. For the jth
marker genotyped in n individuals, this QC measure is calculated as MAFj =
min{ fˆa, fˆA} where fˆa = na/(2n), fˆA = nA/(2n), and na and nA are, respec-
tively, the number of a and A alleles in the sample (j = 1, 2, . . . ,m).
(iii) Hardy-Weinberg Equilibrium (HWE). In its simplest case (i.e., two alleles), HWE
allows the estimation of the genotype frequencies fAA, fAa and faa for one
specific marker from the allele frequencies (AFs) as fˆAA = fˆ 2A, fˆAa = 2 fˆA fˆa, and
fˆaa = fˆ 2a . To test whether the jth marker is in HWE, a test statistic comparing
the observed genotype frequencies in the sample with those expected under
HWE is used. Departure from HWE may indicate potential genotyping errors,
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population stratification or evolution occurring this population [35].
Suppose that out of n individuals, the observed genotype frequencies are nAA,
nAa and naa. Then, the expected genotype frequencies are eAA = n fˆAA, eAa =
n fˆAa and eaa = n fˆaa and the test statistic is given by
c2HWE =
(nAA   eAA)2
eAA
+
(nAa   eAa)2
eAa
+
(naa   eaa)2
eaa
· (2.1)
A marker is not in HWE when the probability of finding a theoretical value of
the test statistic larger than c2HWE is less than a 2 (0, 1). The value a is usually
referred to as the type I error probability of the test, that is, the probability that
the observed departure from HWE is in fact false. Formally, this is equivalent
to calculating the p-value of the test. For one marker, the p-value is calculated
as p = P(cHWE > c22), where c
2
2 is the value of a c
2 probability distribution
with two degrees of freedom. Further, p is compared to a to make a decision
about the departure of HWE for the markers being tested. However, when m
markers are tested, the value compared with p is not longer a but a function
of it. This is explained in detail in Section 2.3.
2.2.4 Functional filtering and annotation
After performing QC on the whole set of genetic variants in the Illumina’s Hu-
manExome 12v1 A BeadChip, the next step is to determine the potential functional
role at the protein level of the remaining variants. This is done using the func-
tional prediction information available in the dbNSFP NS Functional Predictions
GRCh 37 annotation track in Golden Helix SVS 8.3.0. This track is an integrated
database of functional annotations from multiple sources for the collection of hu-
man non-synonymous SNPs (NSs) [36, 37]. Its current version includes a total of
87,347,043 NSs and 2,270,742 splice site variants, and compiles prediction scores
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from different algorithms including Sorting Intolerant From Tolerant (SIFT) [38],
Polymorphism Phenotyping v2 (Polyphen-2) [39, 40], MutationTaster [41], Gerp++
and Phylop [42]. SIFT uses the degree of conservation of amino acid residues in
aligned sequences derived from closely related species to predict whether amino
acid substitutions affect protein function [38], Polyphen-2 predicts the potential im-
pact of these amino acid substitutions on the protein structure and function by
using a Bayesian approach utilising physical and comparative considerations [39,
40], and MutationTaster (http://www.mutationtaster.org/) evaluates the disease-
causing potential of DNA sequence alterations by evaluating conservation, splice-
site changes, loss of protein features and changes that may potentially affect the
amount of micro RNA (mRNA) using information from different biomedical data
bases [41]. Lastly, Gerp++ and Phylop use comparative genomics techniques to
study the similarity of multiple sequence alignments from different species to accu-
rately identify potential functional sequences in the human genome [42].
The dbNSFP NS Functional Predictions GRCh 37 annotation track and the sub-
sequent filters based on prediction algorithms are fully implemented in the Golden
Helix SVS 8.3.0 Variant Classification module. This module was also used to ex-
amine the interactions between variants and gene transcripts to classify variants
based on their potential effect on genes, and according to their position in a gene
transcript. In addition, variants in coding exons were further classified according to
their effect on the gene’s protein sequence. Only variants predicted to be pathogenic
by the functionality filter were kept for assessing their role as AOOmodifiers in AD.
2.2.5 Testing for association of genetic variants
After getting the genotype information for the participants in this research and per-
forming QC followed by functional filtering and annotation of functional variants
as previously described, the next step is to perform association analysis to deter-
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Common exonic 
functional variants 
(CEFVs) 
Filter 1 
Filter 2 
Filter 3 
Illumina’s Human 
Exome-12v1_A BeadChip 
Variants with 
MAF > 1% and 
GCR > 90% 
~250,000 genetic 
variants 
Common 
variants in HWE 
Figure 2.2: Filtering process to obtain CEFVs potentially modifying ADAOO. Filter 1 selects common
variants in the Illumina’s Human Exome-12V1 A BeadChip, Filter 2 those in HWE and with a GCR >
90%, and Filter 3 selects only those with predicted functional implications. The resulting CEFVs
constitute the input of model (2.2).
mine which functional genetic variants modify AOO. As mentioned in Section 2.1,
variants with a MAF > 1% are common and rare otherwise. Resulting functional
variants will be referred to from now on as common exonic functional variants
(CEFVs) in the first case, and rare exonic functional variants (REFVs) in the latter.
The entire workflow to get CEFVs is summarised in Figure 2.2. In what follows,
methods to assess the modifier effect on ADAOO of CEFVs and REFVs are de-
scribed.
2.2.5.1 Association of common variants to ADAOO
Segura et al. [34] proposed the use of single- and multi-locus LMEMs to assess
whether genetic variants are associated with a particular phenotype. This family of
models allows handling of confounding effects and account for loci of small- and
large-effect in structured populations with a small computational burden, and has
shown to be more powerful than existing methods such as ANOVA, linear regres-
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sion models, and GLMs as they allow the inclusion of fixed (i.e., sex and years of
education) and random effects, the later to account for kinship effects (i.e., popu-
lation stratification) by including the IBD matrix [32, 34]. Although all individuals
included in this study are from the Paisa genetic isolate and most of them carry
the PSEN1 E280A mutation (which originates as a consequence of a founder effect
and has been shown to be fully penetrant [43, 44]), controlling for genetic stratifica-
tion is critical. In particular, after many generations, it is possible that descendants
of the E280A pedigree are the result of random mating between individuals from
the pedigree and individuals from other geographical areas, which may potentially
lead to stratification.
The single-locus LMEM assumes that all loci have a small effect on the trait,
whilst the multi-locus LMEM assumes that several loci have a large effect on it.
In a single-locus model, the association between the variant of interest and the
disease trait is tested after covariates and genetic stratification are controlled for.
Conversely, in a multi-locus model the association is tested after covariates, genetic
stratification and the effect of the remaining m  1 genetic variants are controlled
for. In the single-locus LMEM, the general structure is given by [34]:
yi = µ+
m
Â
j=1
b j xij + ei (2.2)
where yi is the phenotype or trait (i.e., ADAOO), µ is the global effect, m is the
total number of causal loci, xij is the numerically-coded genotype of the ith indi-
vidual at the jth locus, b j is the effect size of the jth locus and ei is the error term
(i = 1, 2, . . . , n; j = 1, 2, . . .m). Equation (2.2) can be written as y = Xb + g + e,
where X is a matrix of fixed effects (i.e., years of education, gender, socio economi-
cal strata and genetic markers), b = (b1, b2, . . . , bm) is a vector of effect sizes, g is a
vector of random polygenic effects and e is a vector of random independent effects.
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It is assumed that g follows a N(0, s2gK⇤), with K⇤ the adjusted kinship matrix, and
e follows a N(0, s2e ), with N(a, b) indicating a normal distribution with mean a and
variance b. For m >> n, usually the case in genetic studies, K⇤ is a consistent
estimator of K, that is, K⇤ ! K as m >> n. In the studies of AOO modifiers in
AD conducted in this thesis, K⇤ was estimated using a fraction of common markers
in the Illumina’s HumanExome 12v1 A BeadChip that was obtained after pruning
by linkage disequilibrium (LD). In the above notation, the mathematical form of
the multi-locus LMEM is similar to (2.2), but how the parameters in this model are
estimated differs considerably from the single-locus version. Segura et al. [34] in-
troduced a forward-backward stepwise estimation procedure to estimate s2g as sˆ2g ,
and s2e as sˆ2e . In this procedure, the most significantly associated marker (i.e., that
with the highest effect on the ADAOO) is added to model (2.2) as a cofactor for the
next step, and the p-values for all cofactors (i.e., genetic variants) are re-estimated
along with the variance components. The authors suggest stoping the forward re-
gression procedure when sˆ2g/s2y ! 0 or when the maximum number of forward
step is reached; this number is set before hand by the user. The sˆ2g/s2y ! 0 criterion
indicates that most of the total phenotypic variance s2y can be explained by the m ge-
netic variants included in the model. When the forward stepwise regression stops, a
backward stepwise regression step drops the least significant cofactor in model (2.2)
at each step. Further, all p-values and variance components are re-estimated [34].
The multi-locus LMEM was fitted using the implementation provided in Golden
Helix SVS 8.3.0.
Model selection in single- or multi-locus LMEM
Estimating the variance components and the effect of genetic variants in LMEMs
is just one step towards the definition of AOO modifiers in AD. The next step is
to determine how good the fitted model is based on different performance criteria.
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This process is called “model selection”. Usually, several candidate models are
fitted to the data and one of them is selected based on a comprehensive exploration
of the following multiple criteria [45]:
(i) Bayesian Information Criterion (BIC). This criterion is calculated as
BIC =  2 lF + p log(n), (2.3)
where lF is the logarithm of the full likelihood function, p is the number of
parameters in the model and n is the number of individuals.
(ii) Extended Bayesian Information Criterion (eBIC). Recommended by Segura et al.
[34], this is a penalised version of the BIC. This criterion is calculated as
eBIC = BIC+ 2 log
⇢✓
n
p  q
◆ 
(2.4)
where q is the initial number of parameters and
✓
n
p  q
◆
=
n!
(n  p+ q)! (p  q)!
is the total number of models. Here, x! denotes the factorial of x.
(iii) Modified BIC (mBIC). This criterion is calculated as
mBIC = BIC+ 2p log
⇣ n
2.2
  1
⌘
, (2.5)
where n is the number of genetic variants being tested in the current steps.
(iv) Multiple Posterior Probability of Association (mPPA). This criterion selects the
model with the most covariate marker loci all of which have a PPA > 1/2.
The PPA is calculated as PPA = p0(1+ p0) 1, where p0 = BF(m  1) 1 and BF
is the Bayes factor for the jth genetic variant (j = 1, 2, . . . ,m).
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(v) Multiple Bonferroni criterion (mBonf). Proposed by Segura et al. [34], this cri-
terion selects the model with more covariate marker loci all of which have
individual p-values below 0.05/n, being n the total number of markers tested
in the current step.
To assess the modifier effect on ADAOO of common genetic variants, several
models M1,M2,M3, . . . ,MC are generally fitted to the data, and the aforementioned
criteria are subsequently calculated for each of them. Based on the BIC (or any vari-
ation of it), the selected model would be that for which the BIC is minimum. In
terms of the mPPA and mBonf criteria, the model with the highest value is pre-
ferred. These decision rules are particularly useful, especially when additive, dom-
inant and recessive models with or without correction for confounding variables is
performed, and only one of them is to be selected. In an additive model, it is as-
sumed that there is an ‘additive’ effect of the genetic variants on the ADAOO, that
is, having 0, 1 or 2 copies of the allele will result in a linear effect on the ADAOO.
In the dominant model, the effect of having versus not having the dominant allele
(that with the highest allele frequency) on the ADAOO is measured. Finally, in
a recessive model, the effect of having versus not having the rarest allele (i.e., the
recessive allele) is measured on the ADAOO. The additive, dominant, and reces-
sive models in combination with LMEMs were used in Chapter 4, Chapter 3 and
Chapter 5 to successfully identify genetic variants modifying AOO in AD.
2.2.5.2 Association of rare variants to ADAOO
As previously discussed, genetic variants with a MAF < 1% are rare. To assess the
association of rare variants with the phenotype of interest, single-marker, multiple-
marker and collapsing methods can be used [16, 18, 20]. In this thesis, only col-
lapsing methods were utilised to identify rare genetic variants modifying AOO
in patients with AD as they are more powerful than single- and multiple-marker
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methods [18]. In particular, the modifier effect of rare variants on the ADAOO was
interrogated in Chapter 3 using the regression- and permutation-based variations
of the kernel-based adaptive cluster (KBAC) method developed by Liu and Leal
[46]. These methods are fully implemented in Golden Helix SVS 8.3.0 and R [47].
The KBAC method catalogues rare variant data within each of a number of chro-
mosomic regions into multi-marker genotypes. Since variants are rare, only a rela-
tively few different multi-marker genotypes are found in any given region. A spe-
cial test is subsequently applied to determine their association with the (case/control)
phenotype, weighting each multi-marker genotype by how often it was expected to
occur according to both the data and the null hypothesis of no association between
the genotypic and case/control status of the sample [46]. Thus, genotypes with
high sample risks will be given higher weights that can potentially separate causal
from non-causal genotypes. Further, a one-sided test is applied and the p-values
are estimated using B = 10, 000 permutations. As the KBAC implementation in
Golden Helix SVS 8.3.0 only allows the analysis of case/control data, individuals
with an AOO   50 years (late onset) were ad hoc classified as cases and as controls
otherwise when assessing the modifier effect of rare variants on the ADAOO. This
cut-off value was selected based on previous studies of the ADAOO in the E280A
pedigree [2, 15].
2.3 The multiple testing problem
After fitting model (2.2) to identify CEFVs modifying ADAOO, it is of interest to
determine whether the effect size of the jth variant, denoted as b j, is statistically
significant or not (i.e., whether the jth CEFV modifies ADAOO or not). Formally,
this is equivalent to test
H0,j : b j = 0 vs. H1,j : b j 6= 0 j = 1, 2, . . . ,m, (2.6)
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with m! • the total number CEFVs.
As a byproduct of model (2.2), the p-value for each coefficient b j is calculated
based on the asymptotic properties of the maximum likelihood estimators and the
normal distribution [34]. The jth p-value, pj, reflects the probability that the esti-
mated effect bˆ j would have been obtained purely by chance. After testing m ! •
genetic variants, the p-values p1, p2, . . . , pm are obtained. As m independent hy-
pothesis of the form (2.6) are tested, a multiple testing problem arises [25]. The
main issue with rejecting H0,j when pj < a with a 2 (0, 1) being the type I error of
one single test, is that the actual type I error probability of all m! • tests (i.e., the
family-wise error rate [FWER]) being performed is
am = 1  (1  a)m (2.7)
instead of a [25, 48]. In other words, the probability of obtaining at least one CEFV
modifying ADAOO is am and not a as initially set. Given that am ! 1 as m !
•, the number of CEFVs found to modify ADAOO when this is actually not the
case, dramatically increases. Thus, controlling for multiple testing is imperative
[25, 48, 49]. In this thesis, the Bonferroni [50], false discovery rate (FDR) [48] and
a method based on extreme-values theory [49] were used to correct for multiple
testing. These methods are briefly described below.
2.3.1 Bonferroni correction
The main idea behind this method is to test each of the m hypothesis at level aB =
a/m instead of a so the resulting type I error of the family of m tests is  a [50].
Thus, the jth CEFVs is said to be an ADAOO modifier if pj < aB, j = 1, 2, . . . ,m.
However, Bonferroni’s correction has been highly criticised for its low statistical
power and conservativeness [51]. In this study, this criterion was only used when
testing departure from HWE in the QC process (see Subsection 2.2.3).
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2.3.2 False discovery rate
A less stringent and more powerful method than Bonferroni’s is the false discovery
rate (FDR) by Benjamini and Hochberg [48]. FDR is a relatively new approach
suitable for exploratory analysis [52]. When m independent hypotheses as in (2.6)
are tested, the possible results are presented in Table 2.1.
Table 2.1: Possible results when testing m hypothesis. Here, m is the number of hypothesis, m0 is the
number of true null hypothesis, V is the number of false positives, S is the number of true positives,
T is the number of false negatives, U is the number of true negatives and R is the number of rejected
null hypothesis (i.e., ‘discoveries’). Modified from Benjamini and Hochberg [48].
H0 is true H1 is true Total
H0 is false V S R
H0 is true U T m  R
Total m0 D m
The FDR is formally defined as FDR = E
h
V
R
i
, where E(·) is the expected value
operator. Based on the p-values p1, p2, . . . , pm, to control for multiple testing us-
ing FDR it is enough to reject H0,1,H0,2, . . . ,H0,kˆ when kˆ exists, and no hypothesis
otherwise, with kˆ calculated as
kˆ = max
⇢
i : p(i)  im a
 
, (2.8)
where p(1) < p(2) < · · · < p(m) are the ordered p-values. Unless otherwise stated,
the FDR implemented in Golden Helix SVS 8.3.0 and R [47] was used to correct for
multiple testing in this thesis.
2.3.3 An approach based on extreme values
As a complementary approach to FDR, the method by Ve´lez et al. [49] was also
used to correct for multiple testing. This method, based on extreme-values theory,
is particularly useful when m! • (usually the case in GWAS). Starting with the p-
values p1, p2, . . . , pm, the statistic t⇤j =   log(  log(1  pj)) is calculated and CEFVs
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for which t⇤j >   log(  log(1  a)) + log(m) are considered statistically significant
at level a (j = 1, 2, . . . ,m).
2.4 In silico analyses of AOO modifier genes
As previously mentioned, in silico or computer-based analyses have become a fea-
sible alternative to biological experiments to elucidate the functional role of single-
genes in complex diseases. In what follows, the two in silico approaches used in this
thesis are described.
2.4.1 Network and pathway enrichment analyses
Network and pathway enrichment analyses were performed in order to identify key
physiological pathways and networks harbouring the candidate genes considered
as ADAOO modifiers. The identification of these networks allows the acquisition
of rich ontologies for biological processes at the protein and molecular level with
potential importance in AD. Genes with potential functional effect were examined
with the ‘Analyse Network’, ‘Process Networks’, ‘Shortest Paths’ and ‘Direct Inter-
actions’ algorithms implemented in MetaCore version 6.20 build 66481 (Thomson
Reuters, New York, USA). These algorithms provide a heuristic interpretation of
maps and networks and rich ontologies for biological processes based on the phys-
iological role of candidate genes.
To minimise artefacts in the statistical analysis (which can arise from genes in
the database that may be in the same network but have no functional connection
or interaction with any gene from our filtered list) only nodes with direct physical
interactions between the encoded proteins in the database (known as the high trust
set) were included. In the ‘Analyse Network’ algorithm, a subset of the candidate
gene list is input into a single ‘global’ network, which is subsequently divided in lo-
cal networks. These local networks are prioritised on significance (p-values) based
51
CHAPTER 2. A GENERAL FRAMEWORK FOR DETECTING MODIFIER GENES
on the size of their interaction between the input gene list and all the nodes in the
MetaCore database. The probability that a particular number of genes are prevalent
within a local network given an input gene list of size x is represented by a hyper-
geometric distribution, and calculated accordingly. This calculation also applies to
both the ‘Process Network’ and ‘Analyse Network’ algorithms. Subsets of the in-
terconnected nodes within each subnetwork may have a functional association with
a gene ontology (GO) process within the system database. Once again, these pro-
cesses have assigned p-values in order to determine the probability that the nodes
containing a subset of the candidate genes found to modify AOO in AD would be
associated with any particular biological process (from the entire list of ontological
descriptions) by chance alone. These ontological descriptions, along with the calcu-
lated p-values, can be used as unique identifiers for genes with important biological
roles in AD and the way in which they can potentially cause disease.
2.4.2 Biological distance
The Human Gene Connectome (HGC) database [53] was used to quantify the
biological relatedness between ADAOO modifier genes identified in this study
and those previously reported to confer susceptibility in AD. Similar to Meta-
Core, the rationale of implementing the HGC is to prioritise candidate genes on
the basis of their functional relevance to the AD phenotype. Thus, biological
distances [53] were calculated between candidate genes identified in the associa-
tion analysis and those previously reported. The list of genes with known func-
tional/physiological relevance and/or association to AD was obtained from the
Gene Prospector database [54]. To evaluate the significance of these distances, p-
values were estimated via random permutation of pairwise gene interactions in
the HGC database (http://hgc.rockefeller.edu/), and subsequently corrected for
multiple testing using FDR.
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Chapter3
Age of onset modifier genes in PSEN1
E280A Alzheimer’s disease
Abstract
In this chapter, the presence of pathogenic coding genetic variants with
major effect modifying the Alzheimer’s disease (AD) age of onset (ADAOO)
is scrutinised in individuals from the world’s largest pedigree segregating
AD. These individuals belong to the Paisa community, a genetic isolate,
and segregate one of the most severe forms of early onset AD caused
by the E280A mutation in the PSEN1 gene. A total of 57 DNA samples
from carriers of this mutation, all of them at the extremes of the ADAOO
distribution and with exhaustive clinical and neuropsychological analy-
sis, were subject to whole-exome genotyping (WEG) of ⇠ 250, 000 single-
nucleotide variants. An additional set of 14 carriers of the E280A mutation
from the same pedigree underwent whole-exome capture (WEC) to eval-
uate the resolution of the functional chip. Quality control, filtering, and
functional annotation were applied. The multi-locus linear mixed-effects
model and collapsing methods were used to identify common and rare
ADAOO modifiers, respectively. For replication purposes, variants modi-
fying the ADAOO in E280A carriers were tested in 54 patients with spo-
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radic AD (sAD) with an extreme ADAOO and ascertained from the same
genetic isolate. A total of nine functional genetic variants harboured in the
APOE (rs7412, PFDR = 2.13⇥ 10 30), GPR20 (rs36092215, PFDR = 6.58⇥
10 22), TRIM22 (rs12364019, PFDR = 1.15 ⇥ 10 14), FCRL5 (rs16838748,
PFDR = 8.61⇥ 10 10), AOAH (rs12701506, PFDR = 5.69⇥ 10 8), PINLYP
(rs2682585, PFDR = 1.67⇥ 10 6), IFI16 (rs62621173, PFDR = 8.63⇥ 10 6),
RC3H1 (rs10798302, PFDR = 1.86⇥ 10 4) and DFNA5 (rs754554, PFDR =
3.62⇥ 10 2) genes were identified as ADAOO modifiers in PSEN1 E280A
AD. A variant in the GPR20 (rs34591516, P = 2.34⇥ 10 3) was replicated
in the sAD sample. The pathway and network enrichment analysis dis-
closed significant overrepresentation of some of these genes in processes
such as apoptosis and immune response. A subset of the genes disclosed
exceptional power to discriminate early- and late-onset AD in a predictive
tree, resulting in an area under the curve (AUC) of 0.924 and 0.835 for the
learning and test samples, respectively. Overall, major functional variants
that modify ADAOO are defined here. Also, their role in shaping the nat-
ural history of AD as well as AD prediction, follow-up, and eventually
their potential as therapeutical targets is highlighted.
3.1 Introduction
During the last three decades, our group has studied the world’s largest pedi-
gree in which a Presenilin-1 (PSEN1) mutation (p.Glu280Ala, E280A) dominantly
co-segregates with early onset of Alzheimer’s disease (EOAD). This mutation orig-
inated as a consequence of a founder effect that dates from the Spanish Conquista-
dors colonizing Colombia during the early 16th century [1, 2, 3, 4]. To date, more
than 5,000 individuals are descendants of the original founder, of whom 1,784 are
enrolled to participate in a comprehensive ongoing clinical monitoring. Of 1,181
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genotyped participants, 459 are mutation carriers and 722 are non-carriers of the
mutation [4].
The importance of this pedigree has recently been highlighted by the decision
of the National Institutes of Health (NIH) to launch the first-ever prevention trial
for AD, for which one of the main focus is this extended pedigree (see also Subsec-
tion 1.2.2 for more information about the E280A pedigree). Along with the presence
of exhaustive and detailed medical records of thousand of individuals, the fact that
this pedigree originated as a consequences of a founder effect makes it a valuable
resource for genetic research [1, 5], and the development of biomarkers for predict-
ing and following-up AD [6].
Even though the median ADAOO in patients with the E280A Paisa mutation is 49
years, one of the most intriguing aspects is the broad spectrum of the ADAOO that
ranges from the earliest 30s to the 80s [4]. Thus far, ADAOO might be considered
as an extreme phenotype (discussed in Subsection 2.1.1) [7, 8, 9] with a variance
due to the effect of major modifiers. Because members of this pedigree share a
homogeneous environmental and culture, it is hypothesised the existence ADAOO
modifier genes shaping the natural history of AD.
In the present study, the problem of the high variability of ADAOO in this pedi-
gree is tackled by scrutinising functional variants distributed through the whole-
exomes of 71 carriers of the PSEN1 E280A mutation, all of them descendants from
the original founder of the Paisa pedigree. Several genome-wide significant major
effect exonic mutations harboured in conspicuous loci were identified. These vari-
ants, defined as ADAOO decelerators/accelerators in this pedigree, consequently
modify the natural history of cognitive decline in E280A mutation carriers. These
mutations are harboured in APOE, a gene known to be implicated in the suscepti-
bility and modification of AD risk, and in the GPR20, TRIM22, FCRL5, AOAH, PIN-
LYP, IFI16, RC3H1, and DFNA5 genes. This oligogenic model, combined with data
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mining and predictive modelling tools, exhibits an extraordinary sensitivity and
specificity to predict the ADAOO in the clinical setting. Specifically, this predictive
framework using demographic data and genetic variants modifying ADAOO in this
study to predict whether individuals will develop early-onset (AOO  48 years) or
late-onset (AOO > 50 years) AD.
3.2 Patients and Methods
3.2.1 Patients
3.2.1.1 Individuals from the E280A pedigree
Detailed clinical assessment and ascertainment procedures of this pedigree have
been presented elsewhere [4, 2, 10, 11, 12]. Data collected from all participants
included clinical evaluations, family history, comprehensive neurological and neu-
ropsychological examinations, functional MRI during face-name associative mem-
ory encoding and novel viewing and control tasks, and structural MRI. Clinical,
neurological and neuropsychological assessments were performed at the Group of
Neurosciences AD Clinic using a Spanish version of The Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) evaluation battery [13] described in
detail in Chapter 2.
Seventy-one patients carrying the E280Amutation at the extremes of the ADAOO
distribution were ascertained (44 women [62%] and 27 men [38%]). The aver-
age ADAOO was 47.8 ± 5.8 years in these patients (Figure 3.1a). No difference
in the average ADAOO found by gender (Female: 47.6 ± 6.1; Male: 48.4 ± 5.5,
P = 0.554)(Figure 3.1b). A total of 43 patients (26 women [60%] and 17 men [40%])
had an ADAOO below 48 years [4, 14]. The average ADAOO was significantly dif-
ferent between patients with AOO > 48 and  48 years (44.2± 2.48 vs. 53.5± 5.13,
P = 1.49⇥ 10 10). In those individuals with available information (n = 57), the
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Figure 3.1: (a) Histogram and probability density plots for the ADAOO in 71 patients with PSEN1 E280A AD.
Analysis of the ADAOO distribution disclosed the presence of two hidden groups with an average ADAOO of
⇠ 45 and ⇠ 57 years old, respectively. Box- and violin-plots for the ADAOO by (b) gender and (c) education
group. No difference in the average ADAOO was found in either case. (d) ADAOO as a function of the years
of education. ADAOO. AD = Alzheimer’s disease; ADAOO = Alzheimer’s disease age of onset.
years of education ranged from 0-19 years: four patients (7%) never attended school,
28 (49%) finished primary school (grades 1 to 5), 21 (37%) finished high school
(grades 6 to 11, inclusive) and only 4 (7%) had tertiary education. No difference
was found in the ADAOO across education groups (F3,53 = 2.721, P = 0.053) (Fig-
ure 3.1c). Although not statistically significant, ADAOO seems to increase slightly
for individuals with < 3 years of education (Figure 3.1d).
3.2.1.2 Cohort of patients with sAD
An independent sample of 128 individuals with sAD was recruited from the metro-
politan area of Medellı´n, Antioquia, Colombia, to assess whether variants modify-
ing ADAOO in the E280A pedigree were also ADAOO modifiers in sAD. Several
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population genetic analyses have shown that the community inhabiting this area
has not been subject to micro-differentiation and shares the same genetic back-
ground of the genealogy with the E280A mutation [1, 3]. As in the E280A pedigree,
neurological and neuropsychological assessments of these patients with sAD were
conducted at the Group of Neurosciences AD Clinic using the modified CERAD
evaluation battery.
Fifty-four patients placed at the extremes of the ADAOO distribution (43 women
[80%] and 11 men [20%]) were selected for this study from the collection of 128
patients with sAD. The average ADAOO was 63.26± 6.94 years (as shown in Figure
5.1a) in the selected patients (n = 54), and no statistically significant differences in
ADAOO were found by gender (Females: 63.83 ± 6.29; Males: 62.4 ± 6.06, P =
0.517)(see Figure 5.1b) or education group when including individuals with at least
one year of education (F2,46 = 2.613, P = 0.0842) (see Figure 5.1c). The number
of years of education ranged from 0-18 years: one patient had no information, one
(2%, n = 53) never attended school, 22 (42%) completed primary school, 23 (43%)
completed high school, and seven (13%) attended tertiary education. Although not
statistically significant, individuals with < 3 and > 13 years of education seem to
have a lower ADAOO (Figure 5.1d).
3.2.2 Genotyping
3.2.2.1 Whole-exome genotyping
One hundred eleven individuals (57 with AD from the E280A pedigree and 54
individuals with sAD) were whole-exome genotyped using Illumina HumanExome
BeadChip-12v1 A as described in Chapter 2.
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3.2.2.2 Whole-exome capture
WEC was performed on 14 individuals with AD from the E280A pedigree as pre-
viously described in Chapter 2 after genomic DNA was extracted from peripheral
blood from all patients and processed by the Australian Genome Facility (Mel-
bourne, VIC, Australia).
3.2.3 Genetic, Statistical and Bioinformatics Analysis
3.2.3.1 Quality control, filtering and classification of functional variants
After importing the genetic data to Golden Helix’s SVS 8.3.0, a single genetic data
file was constructed by merging common and not common exonic variants from
both the WEG and WEC platforms. Quality control was subsequently performed
using the following criteria: (i) deviations from the Hardy-Weinberg equilibrium
with P-values < 0.05/m (where m is the number of markers included for analysis);
(ii) a minimum genotype call rate of 90%; (iii) the presence of more than two alleles;
and (iv) monoallelic markers. Markers meeting any of these criteria were excluded
from analyses. Genotype and allelic frequencies were estimated by maximum like-
lihood. Following previous recommendations [15], variants were classified as com-
mon if MAF < 0.01 and as rare otherwise.
Exonic variants with potential functional effect were determined using the func-
tional prediction information available in the dbNSFP NS Functional Predictions
GRCh 37 annotation track [15], which uses SIFT, PolyPhen-2, Mutation Taster,
Gerp++ and PhyloP [16, 17, 18] to predict the potential damaging/benign effect
of single-nucleotide genetic variants. Information on the functional filters and the
implementation in filters and their implementation in Golden Helix’s SVS 8.3.0 is
presented in Chapter 2.
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3.2.3.2 GWAS analysis of common and rare variants
The role of CEFVs as ADAOO modifiers was studied using single- and multi-
locus additive, dominant and recessive linear mixed-effect models (LMEMs) [19]
with up to 10 steps in the backward/forward optimisation algorithm. The op-
timal model was selected using a comprehensive exploration of multiple criteria
including the Extended Bayes Information Criteria (eBIC), the Modified Bayes In-
formation Criteria (mBIC), and the Multiple Posterior Probability of Association
(mPPA). For the analysis of rare exonic functional variants (REFVs), the regression-
and permutation-based Kernel-based Adaptive Cluster (KBAC) methods were used
[20, 21]. LMEMs, model selection criteria, and KBAC have previously been de-
scribed in Chapter 2. Correction for multiple testing was performed using the false
discovery rate (FDR)[22] and a method based on extreme-values theory [23].
3.2.3.3 Predictive framework using an Advanced Recursive Partitioning Approach (ARPA)
ARPA offers fast solutions to reveal hidden complex substructures and provides
truly non-biased statistically significant analyses of high dimension seemingly un-
related data, and is widely used in predictive analyses as it accounts for non-linear
hidden interactions better than alternative methods and is independent of the type
of data and of the data distribution type [24]. ARPA was used to construct a predic-
tive decision tree-model of ADAOO in our patients with PSEN1 E280A AD using
functional genetic variants and other clinical factors [6, 25, 26]. Gender, years of
education, and functional variants identified as ADAOO modifiers were used as
predictors. The outcome variable was AD status defined as early-onset AD (EOAD,
AOO  48 years) or late-onset AD (LOAD, AOO > 48 years).
ARPAwas applied using the Classification and Regression Tree (CART), Random
Forest (RF) and TreeNet modules implemented in the Salford Predictive Modeller
software suite (Salford Systems, San Diego, CA, USA). To derive honest assessments
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of these models and have a better view of their performance on future unseen data,
cross-validation was performed by training the classifier with all data and then
testing it with all the data randomly divided into 10 separate partitions (folds).
This strategy allows to review the stability of results across multiple replications
[27].
CART is a non-parametric approach whereby a series of recursive subdivisions
separate the data by dichotomization [27]. The aim is to identify, at each partition
step, the best predictive variable and its best corresponding splitting value while
optimizing a splitting criterion. As a result, the data set is successfully split into
increasingly homogeneous subgroups [27]. We used a battery of different statis-
tical criteria as splitting rules (including the Gini index, Entropy, and Twoing) to
determine the splitting rule mostly decreasing the relative cost of the tree while in-
creasing the prediction accuracy of target variable categories. The best split at each
dichotomous node was chosen by either a measure of between-node dissimilarity
or an iterative hypothesis testing of all possible splits to find the most homoge-
neous split (lowest impurity) [27]. Similarly, we used a wide range of empirical
prior probabilities to model numerous scenarios recreating the distribution of the
targeted variable categories in the population [27]. Subsequently, each terminal
node was assigned to a class outcome. To avoid over fitting in the CART predic-
tive model, and to ensure that the final splits were well substantiated, tree pruning
was applied. During this procedure, predictor variables that were close competi-
tors (surrogate predictors with comparable overall classification error to the optimal
predictors) were pruned to eliminate redundant commonalities among variables, so
the most parsimonious tree had the lowest misclassification rate for an individual
not included in the original data [27].
Random Forest was conjointly applied with a bagging strategy to identify exactly
the most important set of variables predicting AD status [28]. Unlike CART, RF
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uses a limited number of variables to derive each node while creating hundreds to
thousands of trees, and has proven to be immune to over fitting [28]. In the RF
strategy, variables that appeared repeatedly in trees as predictors were identified,
and the misclassification rate was recorded.
Finally, TreeNet was used as complement to CART and RF strategies because it
reaches levels of accuracy that are usually not attainable by either of the other two
[29]. This algorithm generates thousands of small decision trees built in a sequential
error-correcting process that converge to an accurate model [29]. Cross–validation
training with all data and then indirectly testing with all the data was performed
to derive honest assessments of the derived models and have a better view of their
performance on future unseen data (i.e., review the stability of results across multi-
ple replications) [27]. To do so, the data were randomly divided, with replacement,
into 10 separate partitions (folds).
3.3 Results
3.3.1 CEFVs modifying ADAOO
After quality control, assembling and filtering process, a total of 39,649 variants
with functional effects remained for genetic analyses (Figure 3.2a). For common
variants, a multi-locus LMEM with nine steps in the backward/forward optimi-
sation algorithm was selected as the optimal model maximising the mPPA crite-
rion and best explaining the ADAOO variance (Figure 3.2b). Nine mutations har-
boured in APOE (rs7412, P = 5.44⇥ 10 35), GPR20 (rs36092215, P = 3.36⇥ 10 26),
TRIM22 (rs12364019, P = 8.78 ⇥ 10 19), FCRL5 (rs16838748, P = 8.79 ⇥ 10 14),
AOAH (rs12701506, P = 7.26⇥ 10 12), PINLYP (rs2682585, P = 2.55⇥ 10 10), IFI16
(rs62621173, P = 1.54⇥ 10 9), RC3H1 (rs10798302, P = 3.80⇥ 10 8) and DFNA5
(rs754554, P = 8.32⇥ 10 6) were found to be significantly associated as ADAOO
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modifiers (Table 3.1a and Figure 3.2). The effect of these non-synonymous changes
at the protein level is presented in Table 3.1a.
3.3.2 Exploratory analysis in a cohort of patients with sAD
From the 247,874 exonic variants available for genetic analysis in the sAD cohort,
we found 17 variants were located within the genes significantly associated with
ADAOO in the E280A cohort. A multi-locus LMEM model minimizing the mBIC
and eBIC criteria, and maximising the mPPA criterion was selected. A CEFV har-
boured in GPR20 (rs34591516, P = 2.34⇥ 10 3) was found to modify ADAOO in
our cohort of patients with sAD (Table 3.1b). This CEFV is not in linkage disequi-
librium with variant rs36092215 found to modify ADAOO in fAD (Table 3.1a).
3.3.3 Rare functional exonic variants modifying ADAOO
A total of 9,434 functional rare variants were available after quality control, assem-
bly, and functional filtering process. Regression-based KBAC analysis disclosed
nominal associations between transcripts in the PDZD2 (P = 1.80⇥ 10 2) and ATM
(P = 2.4⇥ 10 2) genes, as well as a borderline nominal association with transcripts
in C10orf12 (P = 5.0⇥ 10 2) (Table 3.2a). Permutation-based KBAC confirmed the
associations in PDZD2 (P = 1.40⇥ 10 2) and ATM (P = 1.40⇥ 10 2), and revealed
a borderline nominal association between ADAOO and rare variants within the
SDK2 gene (P = 5.29⇥ 10 2) (Table 3.2b).
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Table 3.2: Results for the association analysis of rare variants using (a) regression- and (b)
permutation-based KBAC.
(a)
Chr Start Stop Gene m G T P
5 31,799,031 32,111,038 PDZD2 7 8 3.395 1.80⇥ 10 2
11 108,093,559 108,239,826 ATM 4 5 2.423 2.40⇥ 10 2
10 98,741,041 98,745,585 C10orf12 3 4 1.817 5.00⇥ 10 2
(b)
Chr Start Stop Gene m G T P
5 31,799,031 32,111,038 PDZD2 7 8 0.2 1.40⇥ 10 2
11 108,093,559 108,239,826 ATM 4 5 0.143 2.13⇥ 10 2
17 71,330,523 71,640,227 SDK2 3 4 0.107 5.29⇥ 10 2
Chr: Chromosome; m: number of markers; G: number of multi-marker genotypes; T: one-side KBAC test
statistic; P: one-sided P-value; KBAC: Kernel-based adaptative cluster.
3.3.4 Clinical/genetic predictive framework with ARPA
A three-level tree with six terminal nodes was derived by CART to identify pa-
tients with late ADAOO (  48 years) and early ADAOO (< 48 years). Splitting
nodes involved years of education and variants rs2682585 (PINLYP), rs7412 (APOE),
rs16838748 (FCRL5) and rs62621173 (IFI16) (see also Figure 3.3a).
The presence of two copies of the A allele in rs2682585 identifies 50% of the
E280A carriers with late ADAOO (node 4, n = 24). In the second split, E280A
carriers with the A/A genotype in rs2682585 and six or fewer years of education
were mostly identified as having late ADAOO (node 5, n = 20, 64.5%), whilst
attending six or more years of education classified them as having early ADAOO
(node 6, n = 13, 76.5%). On the other hand, the presence of the C/C genotype
in rs62621173 classified most of the E280A carriers with late ADAOO (terminal
node 5, n = 20, 74.1%). Subsequently, individuals having one or two copies of
the G allele in rs2682585 were mostly identified as having early ADAOO (node
2, n = 23, 82.6%) (Figure 3.3a, left). In split 4, these number of copies of the G
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allele in rs2682585 and the C/C genotype in rs7412 (APOE) correctly classified all
E280A carriers with early ADAOO (node 3, n = 20), whilst the T/C genotype
discriminated 75% of those individuals with late ADAOO, suggesting a potential
gene×gene interactions between PINLYP and APOE to modify the delaying effect of
the APOE⇤e2 allele on the ADAOO in PSEN1 E280Amutation carriers (Figure 3.2d).
Finally, split 5 identified the remaining individual with late ADAOO based on the
G/T genotype in rs16838748 (FCRL5) (Figure 3.3a, bottom). Thus, an individual
with a combination of genotypes such as G/A or G/G in rs2682585 (PINLYP), C/C
in rs7412 (APOE) and G/G in rs16838748 (FCRL5) will definitely be classified as
LOAD by the predicting framework.
The variable importance score1 and Receiver Operating Characteristic (ROC)
curves for the CART, RF and TreeNet strategies are shown in Figure 3.3b. Although
similar results were obtained with all strategies, CART included fewer variables
than RF and TreeNet. Overall, these results show that (i) the top 5 variables in-
cluded in the final model are comparable among strategies; and (ii) the years of
education and the genotype in rs2682585 (PINLYP) and rs7412 (APOE) provide the
most consistent set of variables for differentiating patients based on the ADAOO.
The values for the sensitivity, specificity and precision performance measures
for the testing and learning data sets are presented in Figure 3.3c. These measures,
calculated as shown in Table 3.3, indicate how good the ARPA-based model is to
discriminate patients with EOAD from those with LOAD. The AUC, on the other
hand, is calculated as
AUC = (G1 + 1)/2, (3.1)
1This score measures a variable’s ability to perform, in a specific tree of a specific size, either as a primary splitter or as a
surrogate splitter. However, it says nothing about the value of the variable in the construction of other trees.
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where
G1 = 1 
K
Â
i=1
(Xi   Xi 1)(Yi  Yi 1) (3.2)
is the Gini coefficient [30], and the pair (Xi,Yi) represents the false and true posi-
tives at the ith point of the ROC curve (i = 1, 2, . . . ,K).
For the learning data set, CART estimated an AUC of 84.9 (95%CI=75.7 92.6), a
classification rate of 84.5 (95%CI=76.1 91.5), a sensitivity of 85.8 (95%CI=71.4 96.8),
a specificity of 83.8 (95%CI=72.1 93.9) and a precision of 90.1 (95%CI=80.0 97.7),
with overlapping 95%CI for the learning data set based on 10-fold cross-validation
(Figure 3.3c). The TreeNet corroborated these results in both the learning and test
data sets with slightly higher performance measures than those produced by CART.
On the other hand, RF in the testing data set produced similar point estimates for
the sensitivity and precision, and overlapping confidence intervals to those in CART
and TreeNet for other performance measures. Altogether, these measures indicate
an extraordinary predictive power of these genetic variants and schooling to iden-
tify individuals with LOAD and EOAD.
Table 3.3: (a) Possible results when the real and predicted early- and late-onset AD status are compared.
Here, a is the number of individuals with EOAD that are correctly classified, b is the number of EOAD in-
dividuals classified as LOAD, c corresponds to the number of LOAD cases classified as EOAD, and d to the
number of LOAD cases correctly classified. (b) Expressions for calculating the performance measures used to
quantitatively compare the CART, RF and TreeNet strategies.
(a)
Predicted AD status Real AD statusEOAD LOAD
EOAD a b
LOAD c d
(b)
Measure Expression
Sensitivity a/(a+ c)
Specificity d/(c+ d)
Precision d/(b+ d)
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3.3.5 Effect of APOE e2/e4 on ADAOO
Given that the rs7412 (APOE) marker is an ADAOO modifier in our PSEN1 E280A
AD patients, the rs429358 (APOE) marker was genotyped to subsequently deter-
mine the effect of the variants in the APOE haplotype, defined by the e1, e2, e3 and
e4 alleles, on ADAOO. Each of these APOE alleles is defined by the combination
of the above markers (see Figure 3.4a). In particular, individuals with the C/C
genotype in rs7412 and rs429358 markers have the e4/e4 haplotype in the APOE
gene, and those heterozygous for both markers have the e2/e4 or e1/e3 genotype
in APOE (Figure 3.4a). We found that individuals with the PSEN1 E280A mutation
and the e2/e4 genotype in APOE have an ADAOO that is ⇠ 10 (95%CI=1.86-18.14)
years later than that observed in individuals with the E280A mutation alone (Figure
3.4b).
3.4 Discussion
Given the modest outcomes of the common disease-common allele hypothesis [31],
new genomic approaches are needed in complex genetic disorders. Recently, a
comprehensive alternative approach has emerged, which assesses genetic risk with
nonlinear interactions of genetic variants of major effect (i.e., functional mutations)
[25, 32, 33, 34, 35, 36]. For this approach, it is recommendable the identification of
extreme phenotypes in patients ascertained either from extended and multigenera-
tional pedigrees or homogeneous cohorts from genetic isolates [1, 14, 37, 38, 39].
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In this chapter, the effectiveness of this strategy (described in detail in in Chap-
ter 2) is demonstrated by identifying an oligogenic model constituted by functional
variants of major effect harbored in the APOE, GPR20, TRIM5, FCRL5, AOAH, PIN-
LYP, IFI16, RC3H1, and DFNA5 genes. The predictive efficiency of this model to
delineate the ADAOO in E280A mutation carriers is enriched by the inclusion of
clinical and demographic data as demonstrated by the specificity and sensitivity
performance measures of an ARPA-based classification tree.
The characterization of APOE variants as one of the main drivers of the ADAOO
model deserves a comprehensive discussion. Indeed, preliminary analyses of this
cohort are apparently conflicting with those reported here. The first study using
data from 31 PSEN1 E280A mutation carriers of the Paisa pedigree found non-
significant effect of APOE variants on the ADAOO [40]. The second study expanded
the number of patients with the E280A mutation to 52 and defined that carriers of
the APOE e4 allele were more likely to develop AD at an earlier age than non-
carriers (hazard ratio = 2.07; 95%CI = 1.07  3.99; P < 0.03), and that the APOE e2
allele had a modest non-statistically ADAOO decelerator effect [41]. By increasing
the sample size to 71 patients with AD carrying the E280A mutation, here we show
that individuals carrying the APOE e4 allele develop AD at an earlier age, whilst
those carrying the APOE e2 do so at a later age.
The extraordinary performance of the classificatory tree in terms of sensitivity,
specificity, and precision, strongly suggests that this predictive framework can be
used not only for predicting the ADAOO in the E280A pedigree, but also for the
follow-up of individuals in eventual clinical trials. Having previously shown that
the use of image tools as 1HMRI could predict the onset of symptoms in the same
pedigree [6], the next step would be to combine genomic, image, and clinical data
in a similar predictive framework.
In summary, major mutations modifying ADAOO in members of a multigen-
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erational extended family carrying the PSEN1 E280A mutation have been defined
using the general framework presented in Chapter 2. One of the modifier genes
reported herein was also associated with the ADAOO in sporadic cases from the
general population, suggesting that the ADAOO modifier effect is not unique to
the Paisa pedigree but that it might as well be a general finding applicable to
other forms of AD. Of mayor importance is the outlining of the APOE e2 allele
as an ADAOO decelerator. This finding is consistent with recent research [42], and
suggests a potential interaction between PSEN1 and APOE to modify ADAOO in
these patients. Furthermore, with a subset of these variants, an accurate predictive
framework to characterize AD patients as of early or late onset was constructed; this
framework can be used as a diagnostic tool during the clinical assessment of these
patients. Finally, the pathway enrichment analysis indicates that cell proliferation,
protein degradation, and dysregulation of immune processes are overrepresented.
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Chapter4
A mutation in DAOA modifies Age of
Onset in PSEN1 Alzheimer’s disease
Abstract
In this chapter, the results of a targeted analysis of functional exonic vari-
ants harboured in previously reported age of onset (AOO) modifier genes
in Alzheimer’s disease (AD) are presented. These AOO modifier genes
were previously identified in the world’s largest pedigree segregating
one of the most severe forms of early-onset AD (EOAD) caused by the
p.Glu280Ala (E280A) mutation in the PSEN1 gene. Sixty patients with
AD carrying the E280 mutation underwent exhaustive clinical and neu-
ropsychological evaluations. Individuals were whole-exome genotyped
for ⇠ 250, 000 variants. Standard quality control, filtering and annota-
tion for functional variants were applied, and common functional variant
located in previously reported loci modifying the AOOwere selected. Lin-
ear mixed-effects multi-loci models were used to test the association be-
tween these variants and Alzheimer’s disease AOO (ADAOO). A common
functional exonic variant in the G72 (DAOA) gene (rs2391191, P = 1.94⇥
10 4, PFDR = 9.34⇥ 10 3) was significantly associated as a ADAOO mod-
ifier in carriers of the E280A mutation. Nominal associations to ADAOO
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of missense mutations in the CLUAP1 (rs9790, P = 7.63⇥ 10 3, PFDR =
0.1832) and EXOC2 (rs17136239, P = 0.0325, PFDR = 0.391) genes were
also found. Previous studies have linked polymorphisms in the DAOA
gene with the occurrence of neuropsychiatric symptoms such as depres-
sion, apathy, aggression, delusions, hallucinations and psychosis in AD.
These findings strongly suggest that this new conspicuous functional vari-
ant associated withe modification of the ADAOO, harboured in the G72
(DAOA) gene, could be a pivotal for understanding the genetic basis of
AD.
4.1 Introduction
Alzheimer’s disease (AD, OMIM 104300), the most common type of dementia, is
a neurodegenerative disorder characterized by learning disabilities, cognitive de-
cline, aggression as well as short- and long-term memory loss [1]. Mutations in the
Presenilin-1 (PSEN1) [2], Presenilin-2 (PSEN2) [3] and Amyloid precursor protein (APP)
[4] genes cause EOAD. A rare mutation (with a minimum allele frequency [MAF] of
< 1%) in APP had a protective effect against AD in Icelanders [5], whilst a rare mu-
tation in the Phospholipase D family member 3 (PLD3) gene segregates in two families
with late-onset AD (LOAD) and doubles the risk of AD in European and African
American cases/control samples [6]. Likewise, a mutation (rs75932628 causing a
R47H substitution) in the Triggering receptor expressed on myeloid cells 2 (TREM2)
gene was found to double the risk of AD in two independent case/control samples
[7], and associated with AD in a family with frontotemporal lobar degeneration [8].
Over the last 30 years, the Neuroscience Research Group in Antioquia, Colombia
and our group at ANU have studied the world’s largest multigenerational pedigree
in which the PSEN1 p.Glu280Ala E280A mutation (often referred to as the Paisa
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mutation) co-segregates with EOAD. Mutations in the PSEN1 gene have previously
been shown to cause EOAD [2, 9]. This pedigree originated as consequence of a
founder effect [10] initially traced to 1783 [11], and localizes in a homogeneous
environment [11, 12]. These two factors, along with the presence of exhaustive and
detailed medical records of several hundred of individuals, make this pedigree a
powerful tool in genetic research [13, 14]. Genome sequencing analysis successfully
traced the most common ancestor and the first mutation event for the E280 mutation
to 10 and 15 generations ago, respectively [15].
To date, more than 5,000 individuals are descendants of the original founder,
1,784 of whom were enrolled to participate in comprehensive ongoing clinical mon-
itoring. Of those, 459 mutation carriers and 722 non-carriers were genotyped. Al-
though the median ADAOO is ⇠ 49 years (95% CI 49 50), the broad spectrum of
the AOO of dementia symptoms can range from ⇠ 30  80 years [12].
A previous study by Ve´lez et al. [16] identified both known and novel loci
genome-wide significantly associated as AOO modifiers in AD, including DAOA
(rs778296, P = 1.58⇥ 10 12), CD44 (rs187116, P = 1.29⇥ 10 12), GREM2 (rs12129547,
P = 1.69 ⇥ 10 13), NPHP1 (rs10173717, P = 1.74 ⇥ 10 12), CADPS2 (rs3757536,
P = 1.54⇥ 10 10), CLUAP1 (rs1134597, P = 1.12⇥ 10 8) and EXOC2 (rs2804737,
P = 3.28⇥ 10 6). However, replication and functional assessment of these variants
was yet to be performed.
Here, the targeted analysis of common exonic functional variants (CEFVs) har-
boured in those genes reported by Ve´lez et al. [16] is presented. It is found that
a CEFV in the D-Amino Acid Oxidase Activator (DAOA, rs2391191, AGG!AAG,
P = 1.94⇥ 10 4, PFDR = 9.34⇥ 10 3) gene modifies the AOO in AD. Furthermore,
nominal associations in the Clusterin-associated protein 1 (CLUAP1, rs9790, CGG!
TGG, P = 7.63⇥ 10 3, PFDR = 0.1832) and Exocyst complex component 2 (EXOC2,
rs17136239, CAA!CGA, P = 0.0325, PFDR = 0.391) were also found. Clinical, bi-
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ological and mouse models evidence suggest that these functional coding variants
are important players in shaping the susceptibility to AD, opening new windows
towards outlining the genetic basis of this devastating neurodegenerative disease.
4.2 Patients and Methods
4.2.1 Subjects
Sixty patients with AD carrying the Paisa mutation were selected for whole exome
genotyping (36 women [60%] and 24 men [40%]) [12]. The average ADAOO was
47.8± 6.4 years. No difference in the average ADAOO was found by gender (Fe-
male: 48.0 ± 7.02; Male: 47.4 ± 5.52, P = 0.702)(Figure 4.1a, top). A total of 49
patients (28 women [57%] and 21 men [43%]) had an ADAOO below 48 years and
ad hoc classified as EOAD, whilst the remaining 11 (AOO > 48 years) were ad hoc
classified as LOAD [16]. The average ADAOO was significantly different between
EOAD and LOAD patients (EOAD: 45.1± 2.22, LOAD: 59.4± 6.15, P < 1.41⇥ 10 5)
(Figure4.1a, middle). Years of education ranged from 0-19 years. Four patients
(7%) never attended school, 30 (50%) completed primary school (grades 1 to 5), 22
(37%) completed high school (grades 6 to 11, inclusive) and only 4 (6%) had ter-
tiary education. No difference was found in AOO of AD across education groups
(F3,56 = 1.487, P = 0.228) (Figure 4.1a, bottom).
4.2.2 Whole-exome Genotyping
Genomic DNA from 60 participants and whole-exome genotyped by the Australian
Genome Facility (Melbourne, VIC, Australia) as described in Chapter 2 using Illu-
mina’s HumanExome 12v1 A BeadChip.
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4.2.3 Genetic/Statistical Analysis
4.2.3.1 Quality Control
Genotypes were extracted using the Genotyping module of Illumina’s GenomeS-
tudio v2010.3 (with the default settings) and the Illumina HumanExome 12v1 A
manifest cluster file. Samples with calls below Illumina’s expected 99% single nu-
cleotide polymorphisms (SNPs) call rates were excluded.
For replication purposes, only variants located in the top 30 chromosomal re-
gions reported by Ve´lez et al. [16] were included for subsequent analysis. Marker
exclusion criteria included (i) deviations from the Hardy-Weinberg equilibrium
with P < 2⇥ 10 7(0.05/250, 000 markers) in both cases and controls (an stringent
criterion to avoid the exclusion of any causal variant of major effect), (ii) a minimum
genotype call rate of 90%, (iii) the presence of one or more than two alleles, and (iv)
a MAF < 1%.
4.2.3.2 Filtering and Classification of Functional Variants
Exonic variants with potential functional effect were determined using the func-
tional prediction information available in the dbNSFP NS Functional Predictions
GRCh 37 annotation track, previously described in Chapter 2.
4.2.3.3 Genetic Analysis of CEFVs
Single- and multi-locus additive linear-mixed effect models (LMEMs) [17, 18, 19]
were fitted to test the association of these variants to AOO of AD. CEFVs signifi-
cantly associated with the AOO of AD were determined after correction by multiple
testing using the false discovery rate (FDR) [20] and an alternative method based
on extreme-values theory [21]. A detailed explanation of the LMEM models is pre-
sented in Chapter 2.
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Figure 4.1: (a) Box- and violin-plots for the AOO of AD by gender (top), early-onset (middle), and
level of education (bottom) in 60 patients carrying the PSEN1 E280A mutation. The associated
P-value after testing for differences in the average AOO is shown. (b) Filtering workflow of exonic
variants leading to the selection of 71 variants harboured in genes previously associated as modifiers
of the AOO of AD in carriers of the PSEN1 E280A mutation [16]. (c) Partition of phenotypic variance
for each forward inclusion (steps 1 to 10) and backward elimination (10 steps after the dotted line).
The yellow vertical line marks the model selected based on the lowest Bayesian Information Criterion
(BIC).
4.3 Results
4.3.1 Quality Control
A total of 247,874 variants in the Illumina’s HumanExome 12v1 A BeadChip were
submitted to quality control. In the first filter, 50,814 variants with call rate > 70%,
in Hardy-Weinberg equilibrium in both cases and controls, and located on auto-
somal chromosomes were kept. This number was reduced to 71 common variants
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with potential functional effects at the end of the filtering process (Figure 4.1b).
These resulting common variants are harboured in chromosomal regions previously
reported as AOO modifiers in PSEN1 p.Glu280Ala E280A AD [16].
4.3.2 Associated exonic variants
Multi-locus additive LMEMs including all 71 common variants located in genes
previously reported as ADAOO modifiers in patients with PSEN1 p.Glu280Ala
E280A AD were fitted. Based on the Bayesian Information Criterion (BIC), a multi-
locus additive LMEM with three steps in the forward/backward selection algo-
rithm [19] was selected (BIC =  50.8). In this model, the proportion of genetic
variance explained was ⇠ 20% (Figure 4.1c, yellow vertical line). It was found
that variant rs2391191 (UCSC GRCh37/hg19 coordinates) is significantly associated
with AOO in our sample of patients with AD carrying the Paisa mutation (P =
1.94⇥ 10 4, PFDR = 9.34⇥ 10 3). Located in position 106,119,446 of chromosome 13,
this is a missense variant (R [AGG] ! K [AAG]) in the DAOA gene (NM 172370).
Two more exonic variants were found to be nominally associated with the AOO
in patients with PSEN1 E280A AD: rs9790 (P = 7.63⇥ 10 3, PFDR = 0.1832) map-
ping to chr 16: 3,586,230 (UCSC GRCh37/hg19 coordinates) and corresponding
to a missense variant (R [CGG] ! W [TGG]) in the CLUAP1 gene (NM 015041);
and rs17136239 (P = 0.0325, PFDR = 0.391) which maps to chr6: 656,343 (UCSC
GRCh37/hg19 coordinates) and corresponds to a missense variant (Q [CAA]!R
[CGA]) in EXOC2 (NM 018303).
4.4 Discussion
Variants within or close to the DAOA, CLUAP1 and EXOC2 genes were previously
identified as AOO modifiers of AD in carriers of the PSEN1 p.Glu280Ala E280A
mutation [16]. Here, a CEFV inDAOA is reported to modify AOO in AD. This result
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suggests a potential genetic interaction [22] between PSEN1 and DAOA, similar to
what it has been shown in genes involved in cholesterol, amyloid, inflammation
and oxidative stress in sporadic [23], late-onset [24] and familial AD [25].
The DAOA gene, also known as G72, is located in the 13q33.2 chromosomal
region, expands 25,168 bp (UCSC GRCh37/hg19 coordinates) and its expression is
enriched in the brain, spinal cord, and testis. In mice, G72 has been found to be over-
expressed in testis and cerebral cortex, with low to no expression in other tissues
[26]. DAOA, which has typically been associated with bipolar disorder (BD) and
schizophrenia (SZ), encodes a protein that may act as an activator of the DOA (D-
amino acid oxidase) enzyme, which degrades the gliotransmitter D-serine, a potent
activator of N-methyl-D-aspartate (NMDA) type glutamate receptors [27]. Poly-
morphisms in DAOA have been associated with the occurrence of neuropsychiatric
symptoms such as depression, apathy, aggression, delusions, hallucinations and
psychosis in AD [28, 29]. In particular, the development of psychotic symptoms
has been attributed to a similar psychosis-modifier gene mechanism to that of SZ
because of the cytokine pathway disruption in both diseases [30, 31].
NMDA receptors (NMDARs) are glutamate-gated cation channels with high cal-
cium permeability, critical for the development of the central nervous system (CNS),
generation of rhythms for breathing and locomotion, and the processes underlying
learning, memory, and neuroplasticity [32, 33, 34, 35]. NMDARs regulate the func-
tional and structural plasticity of individual synapses, dendrites, and neurons by
activating specific calcium-dependent signaling cascades [35, 36, 37]. Specifically,
both synaptic strengthening and weakening processes are mediated by Ca2+ influx
through NMDARs [35]. Evidence in mouse models suggest that adult mice benefit
from the genetic enhancement of the NMDAR function as it improves memory, but
that blocking the NMDAR in the brain compromises learning and spatial memory
as a consequence of the impairment of synaptic plasticity [32, 34, 37, 38, 39, 40].
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Furthermore, abnormal expression levels and altered NMDAR function have been
implicated in numerous neurological disorders, including AD [35, 36], and there-
fore considered an important therapeutic target in this neurodegenerative disease
[34, 35, 36]. In fact, a partial NMDAR antagonist, memantine, was approved to
treat moderate to severe AD in the US and Europe [41, 42]. However, the success of
memantine and other NMDARs has been limited in the clinical setting due to their
low efficacy and side effects [35, 43, 44].
Two more exonic variants, one in CLUAP1 and one in EXOC2, were found to be
nominally associated with the AOO in patients with the PSEN1 E280A AD.
The CLUAP1 gene spans 38,125 bp in the 16p13.3 chromosomal region, and inter-
acts with APP, CLU and theMelanoma associated antigen 11 (MAGEA11) gene, located
in locus Xq28. Gene ontology analyses suggest an important role of CLUAP1 in
synaptic growth at neuromuscular junction, neuron remodelling, exocytosis, axon
midline and smooth endoplasmic reticulum calcium ion homeostasis. Mouse mod-
els support the role of Cluap1 in ciliogenesis due to the concentration of p75 neu-
rotrophin receptors in the primary cilia membranes [45]. In humans, cilia are in-
volved in numerous cellular activities [45], and have been suggested to impact cog-
nitive deterioration in AD as a consequence of the neurogenesis process occurring
in the hippocampus (which is necessary for new memory encoding) [46]. Subse-
quently, novel therapeutic approaches to AD, especially at the early stage of its
development, have been outlined [46].
The EXOC2 gene encodes a protein member of the exocyst complex. This com-
plex, triggered in many ways by Ca2+ [47], is essential for tying exocytic vesicles
to the plasma membrane [48]. In mice, higher total presynaptic mitochondrial vol-
umes are associated with higher levels of exocytosis in stimulated hippocampal
synaptosomes. [38] Furthermore, weighted gene co-expression analysis of poste-
rior cyngulate (PC) astrocytes in AD showed that EXOC2 was part of the largest
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co-expressed modules, providing evidence that brain immunity and mitochondrial
function in PC astrocytes are perturbed in AD [49]. These findings correlate with
other studies suggesting an important role of astrocytes in AD, particularly in the
earliest neuronal deficits [50], and their contribution to the neuroinflammatory com-
ponent of neurodegeneration during latter stages of the disease [51].
In this chapter, a follow up of a GWAS study associating several loci with the
AOO of AD in the world largest genealogy segregating a form of EOAD [16] was
presented. Overall, the analysis presented here confirmed a potential role of the
DAOA gene, a usual suspect associated with shaping the natural history of AD, as
a AOO modifier gene in the E280A pedigree. Furthermore, this result reinforces the
feasibility of the pooling/bootstrap-based GWAS strategy proposed by Ve´lez et al.
[16] and validated in silico in Chapter 6.
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Chapter5
Age of onset modifier genes in
Sporadic Alzheimer’s disease
Abstract
In this chapter, pathogenic genetic variants modifying the age of onset
(AOO) in sporadic Alzheimer’s disease (sAD) are identified using a com-
prehensive approach involving the selection of patients sAD exhibiting an
extreme phenotype (defined based on the AOO) from a genetic isolate,
whole-exome genotyping of functional variants and statistical, computa-
tional and bioinformatic tools. Single- and multi-locus linear mixed-effects
models were used to test the association between filtered functional vari-
ants and Alzheimer’s disease AOO (ADAOO). A posteriori enrichment
and bioinformatic analyses were applied to evaluate the non-random clus-
tering of these associate variants to physiopathological pathways involved
in Alzheimer’s disease (AD). More than 20 risk variants were identified,
some of them harboured in conspicuous genes implicated in the phys-
iopathology of AD (MAGI3, rs61742849, bˆ =  14.3, PFDR = 4.38⇥ 10 34;
OPRM1, rs675026, bˆ = 5.424, PFDR = 1.15 ⇥ 10 33; TTBK2, rs6493068,
bˆ =  0.48, PFDR = 4.27 ⇥ 10 2; FPR1, rs867228, bˆ =  0.94, PFDR =
1.34 ⇥ 10 6; NFATC1, rs6493068, bˆ =  0.94, PFDR = 1.34 ⇥ 10 8). The
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enrichment analysis revealed that MAGI3 is involved in neuron apoptosis
(P = 2.24⇥ 10 4) and apoptotic processes (P = 1.67⇥ 10 4); OPRM1 has
an important role in neurogenesis (P = 7.73⇥ 10 7), dopamine receptor
signalling (P = 7.73⇥ 10 7) and Wnt protein secretion (P = 1.67⇥ 10 7)
through the transcriptional regulation of G protein-coupled receptors (en-
coded by OPRM1 and FPR1); TTBK2 acts as a key regulator of ciliogenesis,
and putatively phosphorylates tau and tubulin proteins (the TTBK family
of genes is involved in neuronal and cognitive dysfunction in mammalian
models of AD); FPR1 is involved in the inflammatory processes linked to
AD (P = 4.84⇥ 10 20), the negative regulation of glutamergic synaptic
transmission (P = 5.86⇥ 10 3) and the positive regulation of apoptosis
(P = 4.01 ⇥ 10 5) through the canonical Wnt signalling pathway; and
NFATC1 is implied in memory (P = 4.22⇥ 10 4), oligodendrocyte differ-
entiation (P = 1.69 ⇥ 10 2), AD (P = 4.51 ⇥ 10 23) and late-onset AD
(P = 8.37 ⇥ 10 19). This set of new genes harbouring these mutations
could be of importance for prediction, follow-up and eventually as thera-
peutical targets of AD.
As discussed in Chapter 3, new genomic approaches are needed in complex genetic
disorders to identify genetic variants either conferring susceptibility to disease or
modifying the expression of a particular phenotype (i.e., age of onset in Alzheimer’s
disease). It is now well-accepted that the common disease-common allele hypothe-
sis [1] gives modest results in complex human disorders and that new alternatives
are needed.
In Chapter 2, a framework for detecting modifier genes in complex human dis-
ease that combines genetic, statistic and bioinformatic tools was presented. The
validity of this framework relies on recent advances in the detection of genetic
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variants arguing that their effect can be better assessed based on oligogenic mod-
els involving rare and common genetic variants of major effect (i.e., exonic muta-
tions) [2, 3, 4, 5, 6, 7] when individuals with extreme phenotypes are ascertained
[8, 9, 10, 11]. In this study, the extreme phenotype is defined as having an age
of onset (AOO) that is much earlier or much later than that observed in the Paisa
genetic isolate, with some individuals having an AOO that overlaps the AOO of
individuals with late-onset familial Alzheimer’s disease in the E280A pedigree (see
Subsection 1.2.2 for more details).
5.1 Introduction
Alzheimer’s disease (AD) (OMIM 104300) is a neurodegenerative disorder that ac-
counts for ⇠ 60  80% of dementia cases, especially on people over 65 [12]. Preva-
lence estimates indicate that ⇠ 27 million people are affected with AD, and 1 in 85
individuals will be affected by 2050 worldwide [13]. Clinical manifestations of the
disease include learning disabilities, cognitive decline and memory loss [14, 15, 16].
In contrast with familial AD ( fAD), sporadic AD (sAD) represents vastly most of
AD cases and defines a subtype of AD where explicit affected relatives are either
absent or cryptic to the clinical anamnesis.
Although Mendelian inheritance and major mutant causal genes are present in
fAD [17, 18, 19, 20, 21, 22], only susceptibility loci of minor effect (those with a
relative risk of 1.1   1.3) have been identified in sAD [12, 23, 24] with variants
in the Apolipoprotein E (APOE) gene being the major genetic risk factor in late-
onset cases [12]. Recent genome-wide association studies (GWAS) have successfully
identified common genetic variations at over 20 loci associated with late-onset AD
(LOAD) outside of the APOE locus [25]. These loci are of minor effect are harbored
in or near novel AD genes including BIN1, CR1, CLU, PICALM, CD33, EPHA1,
MS4A4/MS4A6, ABCA7, CD2AP, SORL1, HLA-DRB5/DRB1, PTK2B, SLC24A4-RIN3,
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INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, CASS4, AKAP9 and TRIP4
[25, 26].
Genetic isolates have shown to be a powerful tool for the genetic mapping
of inherited diseases [11]. During the last 30 years, our group has studied the
‘Paisa’ community from Antioquia, Colombia. This community is genetically ho-
mogeneous, exhibits high degrees of endogamy, and the number of sibs is tra-
ditionally larger compared to that of families from other areas of the country
[27]. The study and recruitment of thousands of members from multigenerational
and extended families in the Paisa community have allowed the discovery of new
gene associations that predispose to complex genetic conditions including AD and
other dementias [9, 28, 29, 30], attention deficit/hyperactivity disorder (ADHD)
[10, 31, 32, 33, 34], rheumatologic and autoimmune conditions [35, 36, 37, 38, 39]
and non-syndrome facial clefting [38, 40, 41, 42, 43, 44, 45].
Within the Paisa community, our group has studied the world’s largest multi-
generational pedigree in which the E280A mutation in the PSEN1 (often referred to
as the Paisa mutation) co-segregates with early-onset AD (EOAD) [46]. Along with
the presence of exhaustive and detailed medical records of several hundred of indi-
viduals, the fact that this pedigree originated as a consequence of a founder effect
makes it a valuable resource for genetic research [11, 29], and the development of
biomarkers for predicting and following-up AD [28].
One of the most intriguing aspects of the clinical phenotypes in this pedigree
is the broad spectrum of the ADAOO that ranges from the earliest thirties to the
eighties [47]. In a previous manuscript, Ve´lez et al. [9] identidied genome-wide
previously reported and novel loci significantly associated as ADAOO modifiers
in this mentioned pedigree, including the DAOA (rs778296, P = 1.58 ⇥ 10 12),
CD44 (rs187116, P = 1.29⇥ 10 12), GREM2 (rs12129547, P = 1.69⇥ 10 13), NPHP1
(rs10173717, P = 1.74⇥ 10 12), CADPS2 (rs3757536, P = 1.54⇥ 10 10), and ADAMTS17
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(rs4965279, P = 1.69⇥ 10 7) genes . These ADAOO modifier genes are potential
therapeutical targets in AD given their role in biological, molecular and signalling
processes.
Following this approach, in this study the whole-exome screening of functional
variants in patients with sAD ascertained from the Paisa genetic isolate who had ei-
ther early or late ADAOO (i.e., had an extreme phenotype) was performed. Several
pathogenic exonic variants of major effect harboured in both previously reported
and novel ADAOOmodifier genes with remarkable genome-wide significance were
found. Pathway, network and process enrichment analyses converge to support the
involvement of these risk variants in the physiopathology of sAD, opening new
roads towards the understanding of the genetic basis of this complex form of AD.
5.2 Patients and Methods
5.2.1 Subjects
Fifty-four individuals with sAD were included in this study. These patients inhabit
in the Metropolitan Area of Medellin in Antioquia, Colombia. Genetic studies have
shown that this community shares the same genetic background with the E280A
pedigree (see Subsection 1.2.2 for more details)[47] and has not been subject to
microdifferentiation [11, 27].
5.2.2 Clinical assessment
Clinical, neurological and neuropsychological assessments of these patients were
performed at the Group of Neurosciences AD Clinic, University of Antioquia in
Medellin, Colombia, using a Spanish version of The Consortium to Establish a Reg-
istry for Alzheimer’s Disease (CERAD) evaluation battery [48] fully described in
Chapter 2, and adapted for the cultural and linguistic characteristics specific to this
99
CHAPTER 5. AOO MODIFIER GENES IN SPORADIC AD
population [47, 49, 50, 51]. The Ethics Committee of the University of Antioquia,
and ANU approved this study. Written informed consent was obtained from all
participants.
5.2.3 Whole-exome genotyping
Genomic DNA was whole-exome genotyped by the Australian Genome Facility
(Melbourne, VIC, Australia). DNA was whole-genome amplified, fragmented, hy-
bridized, fluorescently tagged, and scanned using the Infinium assay [52]. Whole-
exome genotyping was conducted using Illumina’s HumanExome 12v1 A Bead-
Chip (see Chapter 2 for more information).
5.2.4 Genetic/statistical Analysis
5.2.4.1 Quality control, filtering and classification of exonic variants
Genotypes were extracted using the Genotyping module of Illumina’s GenomeS-
tudio v2010.3 (with the default settings) and the Illumina HumanExome 12v1 A
manifest cluster file. Samples with calls below Illumina’s expected 99% single nu-
cleotide polymorphisms (SNPs) call rates were excluded. Genotype files were pro-
cessed in Golden Helix SVS 8.3.0 (Golden Helix, Inc. Bozeman, MT, USA) using the
GenomeStudio DSF Plugin. Marker exclusion criteria included (i) deviations from
Hardy-Weinberg equilibrium with P < 2 ⇥ 10 7 (0.05/250,000 markers) in both
cases and controls, (ii) a minimum genotype call rate of 90% and (iii) the presence
of one or more than two alleles. Rare variants (those with a minor allele frequency
[MAF] < 1%) were also excluded.
Exonic variants with potential functional effect were determined using the func-
tional prediction information available in the dbNSFP NS Functional Predictions
GRCh 37 annotation track described in Chapter 2. This filter uses SIFT [53], PolyPhen-
2 [54], MutationTaster [55], Gerp++ and PhyloP [56], and is implemented in SVS.
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5.2.4.2 GWAS of CEFVs
Single- and multi-locus additive, dominant and recessive linear mixed-effect mod-
els (LMEMs) with up to 20 steps in the backward/forward optimization algorithm
were fitted to study the association of exonic variants to ADAOO [4, 57, 58]. Single-
locus LMEM assumes that all loci have a small effect on the trait, whilst multi-locus
LMEM assume that several loci have a large effect on the trait. Both types of models
are implemented in Golden Helix 8.3.0. Sex and years of education were included
as fixed effects and the IBD matrix as random effects to account for potential in-
breeding. The optimal model was selected using a comprehensive exploration of
multiple criteria (discussed in subsubsection 2.2.5.1), which includes the Bayesian
Information Criterion (BIC), the extended BIC (eBIC), the modified BIC (mBIC), the
Multiple Posterior Probability of Association (mPPA), the log-likelihood and the
minimum pseudo-heritability (defined as the proportion of inheritance explained
by the random effects, and ideally close to zero). A method based on extreme-value
theory [59] and the false discovery rate (FDR) [60] were used to correct for multiple
testing.
5.2.4.3 Network enrichment analysis
Network and pathway analyses were performed in order to identify key physiolog-
ical pathways and networks harbouring the candidate genes considered as ADAOO
modifiers. Genes with potential functional effect were examined with the ‘Analyse
Network’, ‘Process Networks’, ‘Shortest Paths’ and ‘Direct Interactions’ algorithms
implemented in MetaCore version 6.20 build 66481 (Thomson Reuters, New York,
USA). To minimise artefacts in the statistical analysis (which can arise from genes
in the database that may be in the same network but have no functional connection
or interaction with any gene from our filtered list) only nodes with direct physical
interactions between the encoded proteins in the database were included.
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5.2.4.4 Biological relatedness between candidate and core genes
The Human Gene Connectome (HGC) database [61] was used to quantify the bi-
ological relatedness between ADAOO modifier genes in our patients with sAD,
and genes previously reported in AD. The list of genes with known functional
and/or physiological relevance and/or association to AD was obtained from the
Gene Prospector database [62]. Genes within the top 10 percentile were selected for
the HGC analysis of candidate genes. To evaluate the significance of these distances,
P-values were estimated via random permutation of pairwise gene interactions in
the HGC database, and subsequently corrected using FDR.
5.3 Results
5.3.1 Patients
Out of the 54 individuals included in this study, 43 (80%) were women and 11
(20%) men. The average ADAOO in all samples was 63.26± 6.94 years. Analysis
of the ADAOO distribution suggests that patients may be clustered in two different
groups; the first group consists of 30 (57%) individuals with an average ADAOO
of 57.86± 5.13 years (Figure 5.1a, orange line), whilst 24 (43%) individuals belong
to the second group and have an average ADAOO of 69.08±2.41 years (Figure 6.1a,
pink line). Statistically significant differences in ADAOO were found between these
groups (P = 2.92⇥ 10 10) but not by gender (Females: 63.95± 6.44; Males: 60.54±
8.42, P = 0.232)(Figure 5.1b). The number of years of education ranged from 0-18:
one patient had no information; one (2%, n = 53) never attended school; 22 (42%)
completed primary school (grades 1-5); 23 (43%) completed high school (grades
6- 11, inclusive); and seven (13%) attended tertiary education. No difference was
found in ADAOO across the four education groups when including individuals
with at least one year of education (F2,49 = 1.362, P = 0.265) (Figure 5.1c). Although
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Figure 5.1: (a) Histogram and probability density plots for the ADAOO in 54 patients with sAD.
Analysis of the ADAOO distribution disclosed the presence of two hidden groups with an average
ADAOO of ⇠ 57 and ⇠ 69 years old, respectively. Box- and violin-plots for the ADAOO by (b)
gender and (c) education group. No difference in the average ADAOO was found in either case. (d)
ADAOO as a function of the years of education. Individuals with < 3 or > 13 years of education
seem to have an earlier ADAOO.
not statistically significant, ADAOO seems to increase for individuals with < 3 and
> 13 years of education (Figure 5.1d).
5.3.2 Quality control and filtering of exonic Variants
A total of 247,874 variants in the Illumina’s HumanExome 12v1 A BeadChip were
submitted to quality control. In the first filter, variants with a call rate of > 90% and
in Hardy-Weinberg equilibrium were kept. The second filter excluded rare variants.
A total of 36,085 variants were submitted to the third filter (functional evaluation) in
Golden Helix SVS 8.3.0. At the end of the filtering process, 11,544 common exonic
functional variants (CEFVs) remained for analysis (Figure 5.2a).
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Figure 5.2: (a) Filtering process applied to exonic variants. Filter 1 excludes variants with a genotype
call rate < 90%, in Hardy-Weinberg disequilibrium and with one or more than two alleles. Filters
2 excludes variants with MAF < 1% and Filter 3 those not functional. A total of 11,544 common
functional variants remained for analysis at the end of this process. (b) Manhattan plot for the
11,544 common functional variants included for analysis. Markers with   log10(P) > 3.98 were
significant after FDR correction. The pink horizontal line corresponds to Bonferroni’s significance
threshold. Beanplots [63] for the ADAOO in the top six significant variants are also shown. Pink,
blue and dotted horizontal lines respectively correspond to the within genotype average ADAOO,
the individuals’ ADAOO and the global average ADAOO in 54 patients with sAD. (c) Dendrogram
showing the biological relatedness between ADAOO modifier genes (Table 5.1, shown in red) and
the top 10 percentile genes with functional relevance in AD. Genes with statistically significant
biological relatedness are presented at the bottom.
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5.3.3 CEFVs modifying ADAOO
A recessive multi-locus LMEM with 17 steps in the forward selection algorithm was
chosen based on the lowest eBIC, the highest mPPA, and the lowest log-likelihood
and pseudo-heritability criteria (93.45, 0.998,  5.03 and 4.54⇥ 10 5, respectively).
After FDR correction, a total of 25 variants were significantly associated as ADAOO
modifiers in our patients with sAD (Table 5.1 and Figure 5.2b). The call rate for
these variants was > 0.95, and the corresponding raw and FDR-corrected P-values
were exceptionally small (Table 5.1). These two properties strongly indicate the
nonrandomness of these findings.
Based on the estimated regression coefficient bˆ of the multi-locus LMEM, the
CEFVs reported herein can be classified in two groups: those variants ‘accelerat-
ing’ ADAOO (group 1, bˆ < 0, n = 14, Table 5.1), and those ‘delaying’ ADAOO
(group 2, bˆ > 0, n = 11, Table 5.1). Variants rs35946826 (GPR45, bˆ =  12.7,
PFDR = 3.08⇥ 10 36), rs61742849 (MAGI3, bˆ =  14.3, PFDR = 4.38⇥ 10 34) and
rs61749930 (MYCBPAP, bˆ =  12.1, PFDR = 6.06⇥ 10 27) in the first group, and vari-
ants rs675026 (OPRM1, bˆ = 5.4, PFDR = 1.15⇥ 10 33), rs7677237 (HERC6, bˆ = 2.1,
PFDR = 3.58⇥ 10 15) and rs34230332 (C3orf20, bˆ = 1.6, PFDR = 4.81⇥ 10 7) in the
second group are of particular interest because of their effect on the ADAOO. Put
in context, having two copies of the A allele in rs35946826 accelerates ADAOO by
⇠ 13 years compared to having zero or one copies of the allele. Conversely, having
two copies of the A allele in rs675026 delays ADAOO by ⇠ 5.5 years compared to
having zero or one copies of it (Table 5.1 and Figure 5.2b).
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5.3.4 HGC-based biological distance
Eighteen of the 24 genes exhibiting exceptional statistical levels (Table 5.1) are repre-
sented in the HGC database and hence their biological relatedness to core AD genes
could be established (Figure 5.2c, in red). The absence EBLN1, C3orf20, FAM47E,
C16orf96, TTC18 and AGBL3 in the dendrogram is due to the lack of annotation
information in the HGC database. Consequently, the biological distance could not
be calculated.
Statistically significant biological relatedness was successfully identified between
TTBK2, which causes spinocerebellar ataxia type 11, and APOC1, ABCA7 and TF
(three of the core AD genes), whilst both MAGI3 and IDE, and MAGI3 and BIN1
were nominally significant (Figure 5.2c, bottom). Of particular importance is the
pairwise comparison between TTBK2 and TF as these pair of genes had the most
significant biological relatedness (Figure 5.2c). Additionally, TTBK2 is biologically
related to APOC1 and ABCA7 (Figure 5.2c).
These results also indicate that WDR46 is closely biologically related to ICAM1,
GAB2 and TREM2, whilst FPR1 is closely related to APP, andMAGI3 to IDE, all bio-
logically related to APOE (Figure 5.2c). GPR45 and NFATC1 share similar biological
relevance with CHAT and CD2AP, whilst OR52E4, RGS11 and OPRM1 belong to
the same node of CR1. ZNF646, CENPJ and FRAS1, three of our genes modifying
ADAOO, belong to the same cluster of TNF and PTGS2, two prominent proinflam-
matory genes that are functionally implicated in AD. Despite not being as closely
related than other previously described genes, GAL3ST4 (highly expressed in spinal
cord and with low expression in the brain) shares similar biological features with
CLU. Interestingly, CHGB, HERC6 and KLHDC4 belong to the cluster compassed by
PSEN1 and PSEN2, which have long been described to cause AD (Figure 5.2c). The
relevance of KLHDC4 is also highlighted by two CEFVs (rs34779002 and rs2303772)
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delaying ADAOO in our patients (Table 5.1). Finally, ATP8B3 is closely related to
ACE, whilst MYCBPAP clusters with CD33 (Figure 5.2c).
5.3.5 Pathway enrichment analysis
In what follows the results of the pathway and enrichment analysis on the genes
harbouring specific single-nucleotide changes modifying AOO in individuals with
sAD. As described in detail further below, these genes were found to be mainly
in apoptosis, neurological signalling and Wnt signalling GO processes, and in AD
itself.
5.3.5.1 Apoptosis- and neurological signalling-related processes
Key physiological processes concerning the genes with significant bˆ coefficients
(Table 5.1) were also identified using network and pathway enrichment analysis
in MetaCore. In particular, MAGI3, FPR1, OPRM1 and NFATC1 were found to be
involved in physiological processes such as neuron apoptosis, neurogenesis and
memory, all containing statistically significant ontological process (P < 0.05, Tables
5.2 and 5.3). For instance, the network node showing the interaction of the b-
adrenergic receptor with MAGI3 (Figure 5.3a) suggests that this gene is involved
in neuron apoptosis (P = 2.24⇥ 10 4), apoptotic processes (P = 1.67⇥ 10 4) and
regulation of the MAP kinase activity (P = 1.31⇥ 10 6).
NFATC1, OPRM1 and FPR1 are involved in oligodendrocyte differentiation (P =
1.69⇥ 10 2), positive regulation of neurogenesis (P = 1.34⇥ 10 3) and negative
regulation of synaptic transmission (P = 2.04⇥ 10 7), respectively, and have im-
portant implications in AD, EOAD, LOAD and memory. FPR1 and NFATC1 are
involved in immune related processes, which could also have implications for AD,
whilst FPR1 is involved in the release of IL1b, which is thought to contribute to neu-
roinflammation and neurodegeneration (P = 6.23⇥ 10 3; Table 5.2) and NFATC1
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is a necessary activator of TLR3 signalling (P = 2.74⇥ 10 2)(Figure 5.3b). This later
process is seemingly facilitated by dephosphorylation of NFATC1 by calcineurin
(Table 5.2 and Figure 5.3b). It was also found that OPRM1 is implicated in the
regulation of NF-kB activity (P = 5.78⇥ 10 3), neurogenesis (P = 7.73⇥ 10 7) and
dopamine receptor signalling (P = 7.73⇥ 10 7) through the binding of G protein
a-q/11 to FPR1 (Figure 5.3c).
These findings also indicate that the ACE1 enzyme cleaves amyloid b, which
results in an inhibitory effect on the amyloid b activity and accumulation (Figure
5.3d). The cleaved protein then binds to and subsequently activates G protein-
coupled receptors (GPCRs), which are important molecules involved in neuron
recognition (P = 6.38 ⇥ 10 3), development (P = 1.22 ⇥ 10 4), differentiation
(P = 4.48⇥ 10 2) and generation (P = 1.87⇥ 10 6), as well as in apoptotic signal-
ing (P = 4.68⇥ 10 4) and calcium transport (P = 5.40⇥ 10 3)(Table 5.3). Hence, a
mutation in the GPCR encoding genes (FPR1 andOPRM1) might change the regula-
tion of these functions, which in turn could affect neurological function, potentially
leading to symptoms in AD (P = 2.76⇥ 10 14) and LOAD (P = 7.14⇥ 10 11). This
mechanism coincides with other previous findings showing that amyloid b accu-
mulation can disrupt GPCR function and therefore the aforementioned processes
[64].
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5.3.5.2 Wnt signalling-related processes
FRP1 andOPRM1, reported in Table 5.1, were also identified to have key roles of po-
tential relevance in Wnt signaling via various mechanisms (Tables 5.4 and 5.5, and
Figure 5.4). For instance, Figure 5.4a suggests the initiation of Wnt signaling pro-
cess through the transcriptional regulation of GPCRs (encoded by the OPRM and
FPR1 genes) by the c-myc transcription factor and/or the binding to and activation
of Phospholipase C (PLC) g. Gene ontology analysis shows that this mechanism
might be important in positive regulation of apoptosis (P = 4.01⇥ 10 5, Table 5.5).
GPCRs can also impact Wnt signaling via alternate pathways and processes by
binding and subsequently activating G Protein a I family members (Figure 5.4b),
which might result in the negative regulation of Wnt protein secretion (P = 1.28⇥
10 2, Table 5.5). The NPFF receptor 2 and the Nociceptin receptor bind the µ-
type opioid receptor encoded by the OPRM1 gene (Figure 5.4c). This binding has
an inhibitory antagonistic effect on OPRM1 and thereby restricts the regulatory
capabilities of this protein in important processes such as calcium ion transport and
homeostasis (P = 1.39⇥ 10 5, Table 5.4), and PLC signaling (P = 4.29⇥ 10 3, Table
5.5).
The network and enrichment analysis also indicated that Wnt signaling is not
only influenced by activation effects through proteins binding to receptors, but
could also be regulated by antagonistic effects such as the binding of Nociceptin
receptors, SSTR2, Substance P Receptor and NPFF Receptor 2 to the µ-type opioid
receptor (encoded by the OPRM1 gene)(Figure 5.4c and Figure 5.4d). Both net-
works suggest that this mechanism inhibits the activity of the µ-type opioid recep-
tor, which consequently results in the negative regulation of Wnt protein secretion.
This regulatory cascade seems to continue as a consequence of the µ-type opioid
receptor binding to and activating the d-type opioid receptor. Furthermore, this
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process is also facilitated by the activation of G Protein b/g after it binds to GPCRs
(P = 1.66⇥ 10 7 and P = 4.98⇥ 10 6 for Figure 5.4c and Figure 5.4d, respectively).
5.4 Discussion
Despite the clinical, neuropsychological and neuropathological proven similarities
between fAD and sAD [65, 66, 67, 68, 69], the identification of causative genetic
variants has only been successful in the former [12, 23]. Here it is reported that
25 CEFVs modify ADAOO in patients with sAD ascertained from a genetic isolate.
In addition to their genomic functional implications, the effect size of these mu-
tations is genome-wide significant and stands after correction for multiple testing.
Furthermore, some of these pathogenic mutations point toward conspicuous genes
that have been either previously implicated in the physiopathology of AD, or sig-
nificantly linked to pathways, networks, or processes related to AD as shown by
the pathway and enrichment analysis.
Some genes harbouring these mutations deserve a more detailed report. For in-
stance, the network and pathway enrichment analysis showed that MAGI3 interacts
with the b-adrenergic receptor playing a role in neuron apoptosis. Furthermore,
MAGI3 interacts with PTPRB [70] and PTEN [71], modulators of the AKT1 gene, a
critical mediator of growth factor-induced neuronal survival, reported as disturbed
in AD [71, 72, 73, 74].
GPCRs mediate most cellular responses to hormones and neurotransmitters and
play important role in the physiopathology of AD (see Tables 5.2 and 5.3) [64, 75,
76]. Our pathway and enrichment analysis (Tables 5.4 and 5.5, Figure 5.4) showed
that GPCRs, encoded by FPR1 and OPRM1, might also have a key role in apoptotic
processes. Thus, a mutation in either or both of these genes encoding GPCRs may
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disturb the apoptotic regulation process. Excessively high levels of apoptosis, may
lead to destruction of cells key to neurological processes. Conversely, if the muta-
tion(s) lead(s) to a reduction in apoptotic activity, this may lead to the accumula-
tion of cell contents and or proteins with potential neurotoxic effects. To find that
an exonic mutation in GPR45 (rs35946826, L [CTC]!I [ATC], bˆ =  12.7, PFDR =
3.08⇥ 10 36) accelerates AOO in individuals with sAD, strongly highlights the po-
tential of GPCRs as a therapeutic target in sAD. This gene is expressed in the central
nervous system, the periphery and neural cells [77, 78].
Gene ontology annotations relate FPR1 with FPRL1, a variant of the formyl pep-
tide receptor (FPR). FPRL1 is activated by amyloid b42 and participates in its inter-
nalization in macrophages and subsequently in the cytotoxicity for neuronal cells,
which suggests that is involved in inflammatory aspects of AD [79, 80]. Further-
more, FPR1 was found to be linked with the release of IL1b (Table 5.2), which is
thought to contribute to neuroinflammation and the neurodegeneration that follows
[81].
OPRM1 belongs to the family of µ-Opioid receptors that have been implicated in
learning and memory, as well as in locomotor activity, thermoregulation, hormone
secretion and immune functions. The network and pathway enrichment analyses
implicated OPRM1 in the regulation of NFkB activity, neurogenesis, and dopamine
receptor signalling, through the binding of G protein a-q/11 to FPR1 (Figure 5.3c),
all fundamental mechanisms linked to the genesis of AD.
Wnt signaling regulates the structure and function of the nervous system in
adults [82]. Recent studies suggest that perturbations of Wnt signaling may pro-
mote human neorodegenerative diseases [83]. Because the loss of Wnt/b-catenin
signaling function underlies the Ab-dependent neurodegeneration observed in AD,
the Wnt signaling pathway has been proposed as a therapeutic treatment for AD
[84, 85]. Furthermore, pathway and enrichment analyses showed that OPRM1 and
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FPR1 play a key role in the negative regulation of Wnt protein secretion (P =
1.28⇥ 10 2) and the positive regulation of apoptosis via the canonical Wnt signal-
ing pathway (P = 4.09⇥ 10 5)(Table 5.4). A mutation in either one of them can
restrict or modify these biological processes aforementioned in addition to severally
disturb the regulation of Ca2+ transport, and PLC activity [86].
NFATC1 encodes a protein that is a necessary activator of the TLR3 signaling,
which is facilitated by the dephosphorylation of NFATC1 by calcineurin [87]. The
TLR3 neuroinflammatory response and overexpression in the nervous system leads
to the inhibition of neuronal growth cones, and overall neuron development in
mice. Conversely, mice with defects in TLR3 are less susceptible to neurodegener-
ative disorders [88]. Recently, a mouse model of AD showed that inhibition of the
NFAT pathway alleviates amyloid b neurotoxicity of AD [89], which confirms the
previously reported association between NFAT/calcineurin signaling with both AD
[90] and cognitive decline [91]. The discovery of this mutation harbored in NFATC1
would be crucial to better understand the implications of this pathway in causing
AD.
TTBK2 is mildly expressed in the prefrontal cortex, encodes a serine-threonine
kinase that acts as a key regulator of ciliogenesis, and putatively phosphorylates
tau and tubulin proteins. The HGC-based analysis showed that TTBK2 is closely
biologically related with APOC1, ABCA7 and TF, all of them important AD genes
(Figure 5.2c, bottom). Mutations in TTBK2 cause spinocerebellar ataxia type 11, a
neurodegenerative disease characterized by progressive ataxia and atrophy of the
cerebellum and brainstem
As a whole, in this chapter the existence of common pathogenic genetic variants
significantly associated to ADAOO with remarkable accelerating or delaying effects
is reported. These variants were detected after applying a comprehensive approach
involving the whole-exome genotyping of functional variants in a group of patients
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ascertained from a genetic isolate exhibiting an extreme AOO phenotype, and in
silico approaches to assess the functional effect of these single-nucleotide changes
in the absence of functional experiments. Genes harbouring these variants were
shown to be involved in crucial pathways that might largely contribute with the
pathophysiology of sAD and provides an initial explanation for the wide range of
AOO found in AD. Even though common mechanisms are involved resulting in
known AD pathological pathways such as Ab or hyperphosphorylated tau depo-
sition, the modulation or fine-tuning of this or other relevant pathways are deter-
mining of AD pathology onset. In future studies the interest could be to model
their functionality in mouse models of AD as a first step to evaluate their role as
ADAOO modifier genes and their potential as therapeutical targets.
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Chapter6
Validation of Pooling/bootstrap-based
GWAS
Abstract
A new method of pooling/resampling genome-wide association study
(prGWAS) was presented by Ve´lez et al. [1]. When applied to patients
with Alzheimer’s disease (AD), prGWAS uncovered both new and known
loci associated to this condition. In this chapter, the prGWAS method
is compared in silico with the traditional GWAS approach using the Well-
come Trust Case Control Consortium (WTCCC) data, a well-known GWAS
on seven human complex diseases. It is found that prGWAS identifies up
to 98% of the previously reported signals showing strong or moderate as-
sociation at a fraction of the genotyping costs, suggesting that prGWAS
can be considered an efficient, specific, and accurate alternative to GWAS.
These findings also provide insights into other potential applications such
as next generation sequencing.
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6.1 Introduction
In a recent manuscript, Ve´lez et al. [1] presented a new strategy for genome wide as-
sociation studies (GWAS), denominated pooling/bootstrap-based GWAS (prGWAS).
This methodology is well suited to identify disease-associated genetic variants us-
ing limited and relatively small samples at a fraction of the individual genotyping
cost [1]. prGWAS was applied to a unique cohort of patients with an autosomal-
dominant form of Alzheimer’s disease (AD) segregating a fully-penetrant mutation
in the Presenilin-1 (PSEN1) gene [1, 2, 3, 4]. The method identified new and pre-
viously reported loci underpinning the susceptibility to AD and/or modifying the
age of onset of this dementia [1].
Here, the cross-validation of prGWAS methodology using the Wellcome Trust
Case Control Consortium (WTCCC) data, a collection of publically available genetic
information obtained by a network of ⇠ 50 research groups across the United King-
dom (http://www.wtccc.org.uk/), is presented. Based on performance measures
[5], it is found that prGWAS provides efficient, specific and accurate parameters
comparable to those obtained from the application of traditional GWAS. Further-
more, prGWAS detects 98% of all regions of the genome showing strongest or mod-
erate evidence of association [6] whilst using a reasonably number of DNA pools.
Overall, these findings demonstrate that prGWAS might be considered as a feasi-
ble alternative to individual genotyping, and provide insights of its use into other
potential whole genome designs.
6.2 Methods
In what follows, the WTCCC data and the prGWAS methodology are described
in detail. First, the WTCCC sample collections, the genotype data and the genetic
analyses performed are elaborated. Further, based on [1], the prGWAS methodol-
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ogy and the steps involved to construct DNA pools, estimate the allele frequencies,
perform the genetic association analysis, detect SNPs associated with disease and
combine the association results using meta-analytical methods are described. Fi-
nally, the strategy to contrast the results from the GWAS performed using all data
and those obtained using prGWAS is presented later in the chapter.
6.2.1 WTCCC data
6.2.1.1 Sample description
The WTCCC aimed to understand patterns of human genome sequence variation,
and to explore their utility for the design and analyses of GWAS. The WTCCC
analysed n ⇠ 2, 000 cases of each of seven complex human diseases and n ⇠ 3, 000
control individuals, all of them from England, Scotland and Wales. Genotyping of
⇠ 1.8 million single nucleotide polymorphism (SNPs) in the n ⇠ 17, 000 samples
was performed using high-throughput technologies [6].
Approximately 14,000 individuals were phenotyped for seven complex human
diseases (bipolar disorder [BD], Crohn’s disease [CD], coronary artery disease [CAD],
hypertension [HT], rheumatoid arthritis [RA], type 1 diabetes [T1D] and type 2 di-
abetes [T2D]) and comprised the case cohorts, each of which includes n ⇠ 2000
samples [6].
The two control collections, assumed to be samples from the general population
are n ⇠ 3, 000 individuals from the 1958 British Birth Cohort (58C, n ⇠ 1, 500) and
from blood donors recruited as part of this project (NBS cohort, n ⇠ 1, 500). Both
cohorts have approximately the same number of males and females. Individuals in
the 58C cohort, aged 44-45 years, were born in the same week in 1958; NBS samples
are from blood donors with 18-69 years of age. Previous comparison of SNP allele
frequencies between the 58C and NBS cohorts showed few significant differences
[6] and are therefore treated as a unique cohort in this study.
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6.2.1.2 Genotype data
Control cohorts were genotyped using the lllumina 1.2M and Affymetrix V6.0 plat-
forms, and cases were genotyped using the Affymetrix 500K SNP-chip. Complete
information for the genotyped SNPs was obtained from Illumina (www.illumina.com)
and Affymetrix (www.affymetrix.com). Non-autosomal SNPs and those with no
available coordinate information were excluded. Genotypes for all samples were
obtained after application to the WTCCC, and processed in R [7] and Python
(www.python.org).
6.2.1.3 Genetic association analyses
Genetic association analyses were performed in PLINK [8] version 1.07. SNPs with
a minor allele frequency (MAF) of at least 1%, a p-value greater than 10 5 for
the Hardy-Weinberg equilibrium test, and a genotype frequency of at least 95%
across all samples were included for analysis. To some extent, these parameters
mimic those previously used by the WTCCC [6]. After completion, results of the
association analyses for all chromosomes in a specific case cohort were combined
in a single file.
6.2.2 prGWAS method
By combining DNA pooling [9] and bootstrap [10], prGWAS significantly increases
the statistical power and exponentially reduce expenses compared to traditional
GWAS. This allows the identification of disease-associated SNPs using DNA from
small samples of cases and controls [1]. Here the steps to construct DNA pools,
estimate the allele frequencies, detect disease-associated SNPs and combine the
statistical evidence using meta-analytical methods are described in detail.
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6.2.2.1 Construction of DNA pools
Let N1 and N2 be the total number of controls and cases, respectively, n1 and n2 the
total number of DNA samples in the master plate (for cases and controls, respec-
tively), and n0i = [ni/2], with [x] the integer part of x. Note that, by design, n1 < N1
and n2 < N2 and that N1 ⇠ 3, 000 and N2 ⇠ 2, 000 for each disease in the WTCCC
data under this notation.
DNA pools were constructed following Ve´lez et al. [1]. First, a random sample
of size ni is drawn from Ni to form the master plates; and secondly, k samples of
size n0i are randomly selected without replacement from the master plate (Figure
1). During the random selection process within master plates, it is unlikely that
an individual’s DNA sample would be selected more than once. However, it is
possible that some individuals belong to several of the k DNA pools but not to the
same DNA pool. In the context of prGWAS, k represents the number of DNA pool
pairs to be generated from the master plates [1].
In silico experiments were performed to study the effect of n1, n2 and k. In these
experiments, master plates of size n1 = n2 = n = {250, 500, 1000} were generated;
these sample sizes correspond to selecting, respectively, 8%, 16% and 33% of the
total number of controls, and 12.5%, 25% and 50% of the total number of cases for
each disease. Further, for n1 and n2 given, k = {1, 2, 3, 4, . . . , 10} pairs of DNA pools
were constructed using the individuals’ identifiers (Figure 6.1). Based on the values
of n1, n2 and k, a total of 30 in silico scenarios were evaluated for each disease.
6.2.2.2 Allele frequency estimation
After constructing the pairs of DNA pools, the genotypes for all m genotyped SNPs
were retrieved from the pedigree files previously constructed (see Supplementary
Material of Ve´lez et al. [11] for more information) by matching the IDs of the indi-
viduals in the DNA pools with those of the WTCCC samples. The allele frequency
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Figure 6.1: In silico experimental strategy to construct and analyze DNA pools using prGWAS on
the WTCCC data. In the Collection stage, the 58C and NBS case cohorts are combined into a single
case cohort comprising n ⇠ 3000 individuals. Further, in the Master plates stage, the DNA master
plates for the control and case cohorts are constructed by randomly sampling without replacement
ni individuals from each cohort (i = 1, 2). Likewise, up to k random samples of size n0i = [ni/2] are
subsequently draw from each master plates in the Subsampling stage (here, [x] the integer part of x).
Finally, in the Testing stage, the allele frequencies of m SNPs in cases and controls are compared for
each pair of DNA pools, and the p-values combined across all pools using meta-analytical methods.
for the jth SNP in the ith group was estimated as
pˆi,j =
2y2,j + y1,j
2n0i
(6.1)
where y1,j and y2,j are, respectively, the number of individuals with one and two al-
leles in the jth SNP (i = 1, 2; j = 1, 2, . . . ,m). The number of alleles was determined
based on the ordered two-string genotypes for each SNP.
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6.2.2.3 Detecting associated SNPs
As described in Ve´lez et al. [1], for each SNP it is of interest to test
H0,j : p1,j = p2,j j = 1, 2, . . . ,m (6.2)
against a suitable alternative hypothesis, say H1,j. Because a total of k DNA pools
are generated for cases and controls, (6.2) needs to be tested k times for each SNP.
For k fixed, the test statistic for this purpose is given by [1]:
Tj =
2n01n02( pˆ1,j   pˆ2,j)2
n02 pˆ1,j(1  pˆ1,j) + n01 pˆ2,j(1  pˆ2,j)
(6.3)
with n0i and pˆi,j as previously defined (i = 1, 2; j = 1, 2, . . . ,m). Under the null
hypothesis of no difference between the allele frequency of cases and controls for
the jth SNP, Tj follows c2 with one degree of freedom; the p-value for the jth SNP
can be calculated as pj = Pr(Tj > c21), j = 1, 2, . . . ,m.
Let a 2 (0, 1) be the type I error probability of the test. As m > 1 statistical tests
are being performed (and usually m ! •), it is imperative to control by multiple
testing [12]. The main problem of rejecting H0,j when pj < a is that actual type I
error probability of the m tests is am = 1  (1  a)m, leading to an increased number
of false positives as m! •. Although several criteria have been proposed to control
by multiple testing in GWAS [13, 14, 15, 16, 17, 18, 19], the False Discovery Rate
(FDR) [14], a relatively new approach, suitable for exploratory analysis [15], less
stringent and more powerful than Bonferroni’s [14, 15, 16] is preferable in prGWAS
[1]. The jth SNP is said to be disease-associated in the lth pair of DNA pools if
p(l)j < a, with p
(l)
j the FDR-corrected p-value for the jth SNP when the lth pair of
DNA pools is generated (j = 1, 2, . . . ,m; l = 1, 2, . . . , k).
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6.2.2.4 Combination of p-values
Based on the k pairs of DNA pools being generated and subsequently compared
using (6.3), a total of k p-values are calculated for each of m SNPs in the SNP-chip.
Further, p-values for each SNP are combined using the Stouffer’s Z-transformed
method [20, 21] after introducing some degree of dependence [22]. The test statistic
for the jth SNP is given by [22]
Z⇤S =
8>><>>:
{(1  r)A+ rB} 1/2 ·Âkl=1 wlZl if r is known
{A(1  C) + BC} 1/2 ·Âkl=1 wlZl if r is not known
(6.4)
where r is the correlation parameter, wl the weight, Zl the quantile of a N(0, 1)
distribution associated with p-value of the lth study, A = Âkl=1 w
2
l , B =
n
Âkl=1 wl
o2
,
and C = rˆ⇤+
p
2g(1  rˆ⇤)(k+ 1) 1/2. Expressions for g can be foud elsewhere [22].
When combining the k p-values for each SNP, the null hypothesis of interest is
whether the allele frequency between cases and controls is the same across all pairs
of DNA pools, that is
H0 : p1,l = p2,l l = 1, 2, . . . , k, (6.5)
against the alternative H1 : p1,l > p2,l for some l. Under H0 in (6.5), the Z⇤S statistic
follows a N(0, 1) distribution. Hartung [22] showed that rˆ⇤ = max
n
  1k 1 , rˆ
o
with
rˆ = 1   1k 1 Âkl=1
⇣
Zl   1k Âkl=1 Zl
⌘2
. Thus, the calculation of one- and two-tailed
p-values follows [21].
6.2.3 Comparison of prGWAS and GWAS
Let S(l)1,j and S
(l)
2,j be binary variables constructed after applying the prGWAS and
traditional GWAS on the WTCCC data, such that S(l)1,j = 1 if p
(l)
j < a and zero
otherwise, and S(l)2,j = 1 if p
⇤
j < a and equal to zero otherwise. Here, p
⇤
j is the
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Table 6.1: (a) Possible results when the GWAS and prGWAS are compared. Here, a is the number of significant
markers found by both methods, b is the number of positive SNPs according to prGWAS but not positive
according to GWAS, c corresponds to those markers not found to be significant by prGWAS but that are true
positives according to GWAS, and d is the number of SNPs labeled as not significant by both methods; (b)
expressions for calculating the performance measures used to quantitatively compare prGWAS and GWAS.
(a)
prGWAS GWASSignificant Not significant
Significant a b
Not significant c d
(b)
Measure Expression
Sensitivity a/(a+ c)
Specificity d/(c+ d)
Positive predictive value (PPV) a/(a+ b)
Negative predictive value (NPV) d/(c+ d)
False discovery rate (FDR) 1-PPV
False negatives rate (FNR) 1-NPV
Classification rate (CR) (a+ d)/(a+ b+ c+ d)
Lift a(a+ b+ c+ d)/{(a+ b)(a+ c)}
Bonferroni-corrected p-value of the jth SNP.
Results from the prGWAS method were compared to those obtained in GWAS
using several performance measures [5] after constructing 2⇥ 2 contingency tables
(Table 6.1a) for every combination of disease, chromosome, k and sample sizes of
the master plates. Initially, the results from the association analysis using GWAS
and those using prGWAS were merged by SNP after the p-values from the GWAS
analysis were corrected by multiple testing using Bonferroni’s criterion. For the lth
pair of DNA pools and n1 and n2 fixed, the entries of the 2⇥ 2 contingency table
are a(l) = Âmj=1 I{S(l)1,j=1,S(l)2,j=1}
, b(l) = Âmj=1 I{S(l)1,j=1,S(l)2,j=0}
, c(l) = Âmj=1 I{S(l)1,j=0,S(l)2,j=1}
and d(l) = Âmj=1 I{S(l)1,j=0,S(l)2,j=0}
, where I{·} is an indicator variable. For l fixed, a
corresponds to the number of statistically significant SNPs (i.e., positive markers)
found by both methods, b is the number of positive SNPs according to prGWAS but
not positive in GWAS, c is the number of not significant markers using prGWAS
but positive using GWAS, and d is the number of SNPs not statistically significant
by neither method. In this context, markers found to be positive using the complete
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data set are said to be true positives (Table 6.1a).
In addition to the classical measures, we also calculated the lift, a performance
measure initially introduced as ‘interest’ by Brin et al. [23] and recently used in
data mining and marketing [24] to evaluate the relative performance of alternative
classification models (Table 6.1b) [25]. If A is the event ‘detecting a marker as being
statistically significant using prGWAS’ and B the event ‘detecting a marker as being
statistically significant using GWAS’, lift measures how many times more often A
and B occur together than expected if they were statistically independent [25]. In
other words, this is equivalent to quantify how much more successful the prGWAS
method is likely to be than if no predictive model (i.e., random selection) was used
to detect statistically significant markers.
6.3 Results
6.3.1 Previously reported SNPs
Table 6.2 presents the association signals at previously replicated loci. Using prGWAS,
we were able to detect 11 of the 13 associations previously reported [6]; marker
rs4420638 in CAD did not pass quality control (see Methods) and marker rs3087243
in T1D was not prGWAS significant at 5%. As a function of the sample size of the
master plates, no difference was found in the number of detected markers (trend
p-value= 0.2421, Figure 6.2a).
In Table 6.3 regions of the genome with the strongest association signals are
presented. Twenty of the 21 signals previously reported in a standard analysis
[6] were detected by prGWAS, with 43% (9/21) of these signals being statistically
significant for at least one value of n. From the 63 signals/sample size combinations,
11% (7/63) were not significant at 5% (BD: rs420259 for n = 500; CD: rs10761659
and rs2542151 for n = 250; T1D: rs11171739 for n = 250; T2D: rs9465871 regardless
136
CHAPTER 6. VALIDATION OF POOLING/BOOTSTRAP-BASED GWAS
Table 6.2: Comparison between prGWAS and GWAS to detect previously replicated loci.
Collection SNP prGWAS p-value (k) Genotypic p-value1n = 250 n = 500 n = 1000
CAD rs4420638 ND ND ND 1.7⇥ 10 3
CD rs17221417 1.33⇥ 10 15(3) 9.46⇥ 10 9(2) 1.49⇥ 10 13(3) 4.0⇥ 10 11
rs11805303 1.66⇥ 10 10(9) 1.77⇥ 10 10(6) 6.38⇥ 10 13(5) 5.9⇥ 10 12
RA rs615672 3.99⇥ 10 20(7) 7.24⇥ 10 15(9) 6.97⇥ 10 34(3) 7.5⇥ 10 27
rs6679677 1.09⇥ 10 4(9) 2.38⇥ 10 25(8) 2.09⇥ 10 26(2) 5.6⇥ 10 25
T1D rs3087243 a a a 1.8⇥ 10 5
rs2104286 2.25⇥ 10 2(8) 8.43⇥ 10 7(2) 6.26⇥ 10 10(2) 4.3⇥ 10 5
rs3788964 a a 1.75⇥ 10 3(2) 7.6⇥ 10 3
rs6679677 1.09⇥ 10 8(9) 7.33⇥ 10 23(9) 2.04⇥ 10 30(5) 5.4⇥ 10 26
rs9270986 3.74⇥ 10 136(4) 6.31⇥ 10 148(2) 3.18⇥ 10 301(2) 2.3⇥ 10 122
T2D rs1801282 a 3.88⇥ 10 3(3) 8.07⇥ 10 4(2) 5.4⇥ 10 3
rs4506565 1.41⇥ 10 5(9) 7.32⇥ 10 4(9) 3.24⇥ 10 14(3) 5.1⇥ 10 12
rs5215 a 4.67⇥ 10 3(2) 6.86⇥ 10 3(4) 5.6⇥ 10 3
a Not statistically significant. ND = Not determined as a consequence of not passing quality control (see Methods). 1 As in
Table 2 of [6]. SNP = Single nucleotide polymorphism; Chr = chromosome; n = sample size of the master plate (see
Methods); k = number of DNA pools being combined. BD = bipolar disorder; CAD = coronary artery disease; CD = conduct
disorder; RA = rheumatoid arthritis; HT = hypertension; T1D = type 1 diabetes; T2D = type 2 diabetes.
of n). Furthermore, the number of detected markers increases with n (trend p-
value= 0.0283, Figure 6.2b).
A total of 58 markers were reported as showing moderate evidence of association
(6th column, Table 6.4): 13 in BD, nine in RA and T2D, eight in CD, seven in T1D,
and six in CAD and HT. Of those, six (10.3%) did not pass prGWAS quality control.
Despite detecting all signals using prGWAS, 38 of the 174 (22.4%) signals/sample
size combinations were not significant for at least one value of n. Overall, the
number of markers detected increases with n (trend p-value= 0.00343, Figure 6.2c).
6.3.2 Number of DNA pools
Figure 6.2 depicts the number of DNA pools to be generated k as a function of the
sample size of the master plates n to obtain, using prGWAS, similar p-values to
those reported previously when the full genotype data is used.
Panel (a) depicts the results to detect markers is previously replicated loci (Table
2a). As a function of n, regression analysis shows that k decreases as a function of n
(trend p-value= 7.88⇥ 10 4). Furthermore, analysis of variance (ANOVA) discloses
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Table 6.3: Comparison between prGWAS and GWAS to detect previously replicated loci with the strongest
association signals.
Collection SNP prGWAS p-value (k) Genotypic p-value1n = 250 n = 500 n = 1000
BD rs420259 ⇤ a 3.82⇥ 10 8(10) 6.29⇥ 10 8
CAD rs1333049 8.39⇥ 10 15(3) 1.58⇥ 10 12(4) 1.51⇥ 10 13(3) 1.16⇥ 10 13
CD rs11805303 1.66⇥ 10 10(9) 3.19⇥ 10 12(7) 6.38⇥ 10 13(5) 5.85⇥ 10 12
rs10210302 3.76⇥ 10 14(10) 3.17⇥ 10 15(4) 6.50⇥ 10 17(3) 5.26⇥ 10 14
rs9858542 2.53⇥ 10 6(9) 1.02⇥ 10 7(10) 1.94⇥ 10 8(7) 3.58⇥ 10 8
rs17234657 1.34⇥ 10 28(3) 8.01⇥ 10 13(4) 3.73⇥ 10 13(2) 1.99⇥ 10 12
rs1000113 ⇤ ⇤ 2.03⇥ 10 7(7) 3.15⇥ 10 7
rs10761659 a 9.93⇥ 10 5(9) 5.60⇥ 10 5(8) 1.75⇥ 10 6
rs10883365 ⇤ ⇤ ⇤ 5.82⇥ 10 8
rs17221417 ⇤ 1.33⇥ 10 15(3) 1.49⇥ 10 13(3) 3.98⇥ 10 11
rs2542151 a 4.17⇥ 10 5(4) 5.48⇥ 10 9(4) 2.03⇥ 10 7
RA rs6679677 ⇤ 2.38⇥ 10 25(8) 2.09⇥ 10 26(4) 5.55⇥ 10 25
rs6457617 3.46⇥ 10 64(10) 3.21⇥ 10 78(5) 1.21⇥ 10 96(3) 5.18⇥ 10 75
T1D rs6679677 ⇤ 7.33⇥ 10 23(10) 2.04⇥ 10 30(5) 5.43⇥ 10 26
rs9272346 1.30⇥ 10 132(8) 3.92⇥ 10 162(4) 1.19⇥ 10 128(2) 5.47⇥ 10 134
rs11171739 a 4.71⇥ 10 8(9) 2.45⇥ 10 11(5) 9.71⇥ 10 11
rs17696736 ⇤ 6.07⇥ 10 14(4) 5.33⇥ 10 24(2) 1.51⇥ 10 14
rs12708716 4.90⇥ 10 7(8) ⇤ 4.26⇥ 10 7(10) 4.92⇥ 10 7
T2D rs9465871 a a a 3.34⇥ 10 7
rs4506565 ⇤ ⇤ 3.24⇥ 10 14(3) 5.05⇥ 10 12
rs9939609 1.14⇥ 10 9(4) 1.23⇥ 10 6(4) 3.40⇥ 10 11(3) 1.91⇥ 10 7
a Not statistically significant. ⇤ Statistically significant in prGWAS but the resulting combined p-value was higher than that
obtained using the full data set. 1 As in Table 3 of [6]. Abbreviations as in Table 6.2.
a statistically significance difference in the average value of k as a function of n
(F2,26 = 7.197, p-value= 0.00325). The highest Tukey’s honest significance difference
was obtained after comparing k for n = 1000 and n = 250 (d =  4.25, padjusted =
0.0237). These results suggests that, in prGWAS, the larger the value of n the lower
the number of DNA pools to be generated in order to obtain comparable p-values
to those obtained at previous robustly replicated loci.
The number of DNA pools to be generated in prGWAS decreases as a function
of n (trend p-value= 0.0252) for detecting regions with the strongest association
signals (Table 6.3). However, no statistically significance difference was found be-
tween the average value of k across sample sizes (kall = 5.63, k250 = 7.11, k500 =
5.93, k1000 = 4.68; F2,40 = 2.723, p = 0.0778).
Furthermore, no linear relationship between n and k (trend p-value= 0.189)
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Figure 6.2: Number of pairs of DNA pools to be randomly generated in prGWAS to obtain com-
parable p-values to those (a) previously replicated loci (Table 6.2); (b) regions with the strongest
association signals (Table 6.3), and (c) regions of the genome showing moderate association when
the full genotype data is used (Table 6.4). Here, n is the sample size of the master plates across all
seven diseases. Number of markers with similar p-values to those previously reported are presented
in parentheses. Individual data points were jittered to facilitate interpretation.
nor in the average value of k for all sample sizes (kall = 5.29, k250 = 5.85, k500 =
5.76, k1000 = 4.92; F2,61 = 0.898, p = 0.413) was found when detecting regions of the
genome with moderate evidence of association (Table 6.4). Altogether, these results
indicate that prGWAS detects those regions of the genome showing the strongest
or moderate evidence of association previously reported by randomly generating a
reasonably small number of DNA pools regardless of the sample size of the master
plates.
6.3.3 Performance measures
A total of 4,158 (7 diseases ⇥ 22 chromosomes ⇥ 3 master plates’ sample sizes
⇥ 9 combined p-values) 2⇥ 2 contingency tables were constructed in all in silico
experiments. The main results are presented in Figure 6.3.
Across all seven diseases, the sensitivity ranges from 0.15% to 1.4%. Regardless
of k, the lowest sensitivity values are obtained when the sample size of the master
plate is n1 = n2 = n = 250 and the highest, except for CAD, RA and T1D, when
n1 = n2 = n = 1000 (see Figure 6.3a across all diseases).
Figure 6.3b shows the specificity results. It can be seen that specificity increases
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Table 6.4: Comparison between prGWAS and GWAS to detect signals with moderate association.
Collection SNP prGWAS p-value (k) Genotypic p-value1n = 250 n = 500 n = 1000
BD rs4027132 8.33⇥ 10 6(8) a 9.88⇥ 10 8(4) 9.68⇥ 10 6
rs7570682 a a 7.58⇥ 10 4(9) 1.64⇥ 10 5
rs1375144 7.7⇥ 10 6(4) 5.93⇥ 10 5(5) 9.64⇥ 10 5(7) 1.31⇥ 10 5
rs2953145 a ⇤ 3.91⇥ 10 5(3) 6.57⇥ 10 6
rs4276227 a 5.61⇥ 10 9(2) ⇤ 2.62⇥ 10 5
rs683395 ND ND ND 5.11⇥ 10 6
rs6458307 ND ND ND 4.35⇥ 10 6
rs2609653 ND ND ND b
rs10982256 4.57⇥ 10 6(4) ⇤ ⇤ 4.41⇥ 10 5
rs10134944 a ⇤ 1.68⇥ 10 5(10) 6.89⇥ 10 6
rs11622475 a a 7.58⇥ 10 7(8) 8.14⇥ 10 6
rs1344484 a ⇤ 9.99⇥ 10 5(5) 1.03⇥ 10 5
rs3761218 ND ND ND 6.71⇥ 10 6
CAD rs17672135 ⇤ 6.07⇥ 10 10(9) 2.51⇥ 10 4(5) 2.35⇥ 10 6
rs383830 ⇤ ⇤ 7.92⇥ 10 5(4) 1.34⇥ 10 5
rs6922269 a ⇤ 1.91⇥ 10 4(6) 1.50⇥ 10 5
rs8055236 a 2.09⇥ 10 5(8) 1.26⇥ 10 6(2) 5.60⇥ 10 6
rs7250581 a a 2.48⇥ 10 6(3) 2.50⇥ 10 5
rs688034 a ⇤ 3.77⇥ 10 6(5) 3.75⇥ 10 6
CD rs12037606 1.08⇥ 10 5(6) 9.54⇥ 10 5(5) ⇤ 1.09⇥ 10 5
rs6596075   1.04⇥ 10 6(3) ⇤ 3.19⇥ 10 6
rs6908425 ⇤ a a 1.10⇥ 10 5
rs9469220 ⇤ 2.99⇥ 10 6(3) 1.82⇥ 10 8(2) 2.28⇥ 10 6
rs7753394 a 4.34⇥ 10 5(2) 6.06⇥ 10 5(2) 2.59⇥ 10 5
rs7807268 a 1.60⇥ 10 5(7) 2.36⇥ 10 7(2) 4.42⇥ 10 6
rs6601764 ⇤ 9.84⇥ 10 7(8) 4.64⇥ 10 6(8) 8.95⇥ 10 6
rs8111071 a 4.88⇥ 10 5(10) 1.45⇥ 10 5(6) 1.75⇥ 10 5
HT rs2820037 a ⇤ ⇤ 7.66⇥ 10 7
rs6997709 a 3.58⇥ 10 5(5) 5.70⇥ 10 5(4) 4.36⇥ 10 5
rs7961152 a ⇤ 3.65⇥ 10 4(9) 3.03⇥ 10 5
rs11110912 a a 1.45⇥ 10 5(6) 1.94⇥ 10 5
rs1937506 a a ⇤ 4.53⇥ 10 5
rs2398162 a 7.89⇥ 10 4(10) 9.06⇥ 10 4(8) 5.67⇥ 10 5
RA rs6684865 a   9.87⇥ 10 5(6) 3.14⇥ 10 5
rs11162922 a 9.50⇥ 10 6(5) 2.13⇥ 10 6(4) a
rs3816587 a ⇤ a 9.25⇥ 10 6
rs6920220 a a 6.44⇥ 10 5(5) 1.58⇥ 10 5
rs11761231 a ⇤ 4.33⇥ 10 6(3) 2.65⇥ 10 6
rs2104286 ⇤ 2.44⇥ 10 5(5) 2.85⇥ 10 11(2) 2.52⇥ 10 5
rs9550642 3.24⇥ 10 116(2) 5.19⇥ 10 79(2) 2.31⇥ 10 101(3) 3.90⇥ 10 5
rs2837960 ⇤ ⇤   1.68⇥ 10 6
rs743777 ⇤   2.67⇥ 10 3(8) 1.15⇥ 10 6
T1D rs2639703 a 3.11⇥ 10 4(8) ⇤ 1.74⇥ 10 5
rs17388568 a a 3.68⇥ 10 9(4) 3.27⇥ 10 6
rs2544677 a a a 4.43⇥ 10 5
rs17166496 ⇤ a a 5.20⇥ 10 6
rs2104286 a 8.43⇥ 10 7(2) 6.26⇥ 10 10(2) 4.32⇥ 10 5
rs11052552 1.80⇥ 10 7(10) 1.40⇥ 10 3(9) a 7.24⇥ 10 7
rs2542151 ⇤ ⇤ 2.47⇥ 10 6(4) 1.16⇥ 10 5
T2D rs4655595 a 1.49⇥ 10 6(5) 5.24⇥ 10 9(2) 1.33⇥ 10 5
rs6718526 1.39⇥ 10 5(7) 2.31⇥ 10 7(6) 1.79⇥ 10 9(2) 1.16⇥ 10 5
rs358806 ND ND ND 3.05⇥ 10 6
rs7659604 a a ⇤ 9.42⇥ 10 6
rs9326506 a ⇤ ⇤ 2.99⇥ 10 5
rs12304921 ND ND ND 7.07⇥ 10 6
rs1495377 a ⇤ 2.51⇥ 10 7(5) 6.52⇥ 10 6
rs2930291 ⇤ 7.15⇥ 10 6(7) ⇤ 4.40⇥ 10 5
rs2903265 ⇤ ⇤ 1.89⇥ 10 5(9) 4.98⇥ 10 5
a Not statistically significant. b Not reported. ⇤ Statistically significant in prGWAS but the resulting combined p-value was
higher than that obtained using the full data set. 1 As in Table 4 of [6]. ND = Not determined as a consequence of not
passing quality control (see Methods). Abbreviations as in Table 6.2.
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slightly as a function of k when n is fixed, and is slightly higher for k fixed when n is
large. In practical terms this implies that applying prGWAS using master plates of
relatively large size would result in higher specificity values (i.e., 99%) regardless
of k. However, as per the results when the GWAS approach is used, it also seems
that the change in specificity is not particularly high for large n.
Figure 6.3c presents the results for the classification rate (CR). Obtained values
range between 80% and > 90%, with master plates of larger size and higher values
k producing lower CRs. Conversely, when n is small (i.e., n = 250), prGWAS
produces the higher CRs for k > 2. Furthermore, the CR tends to increase slightly
when k > 5 for this sample size.
Results for the Positive Predictive Value (PPV) and Negative Predictive Value
(NPV) are presented in Figure 6.3d and Figure 6.3e, respectively. In the former,
master plates of size n = 1000 provide PPV of > 70% regardless of k, with PPVs
stabilizing when k > 3. Despite not being the highest, master plates of ⇠ 16% of
controls and ⇠ 50% of cases (i.e., n = 500) produce PPVs between 50% and 80%.
On the other hand, the NPVs range from 80% to 90%, with the highest values found
when n = 250 regardless of k, followed by n = 500 and n = 1000. As a function of
k, the NPV decreases for n = 1000 and n = 500, and slightly increases when k > 3
for n = 250 (panel (e), blue line).
Figure 6.3f depicts the FDR. The results indicate that the FDR decreases as k in-
creases, and that, in contrast with n = 1000 which produces FDR values close to the
nominal type I error probability a, n = 250 produces higher FDR values. When the
master plate is of size n = 1000 (i.e., randomly selecting ⇠ 33% of the total number
of controls and ⇠ 50% of the total number of cases) the FDR is close to the nominal
level after k > 4 for most diseases, except T1D. This value of k translates in hav-
ing at least 4,000 cases and equal number of controls in the equivalent association
analysis [1].
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Figure 6.3g depicts the results of lift for predicting statistically significant mark-
ers using prGWAS as a function of n and k. Across all diseases, lift values are higher
as the sample size of the master plates increases, suggesting that the prGWAS
method performs better at predicting statistically significant markers than a ran-
dom choice targeting model. Lift values range between 2.5 and 7.5, with the highest
values being recorded when for 2 < k < 4 when n = 1000 and n = 500 regardless
of the disease, and the lowest values when n = 250 regardless of k. On the other
hand, the lift for predicting negative markers is slightly greater than one for all dis-
eases (data not shown). Altogether, these results suggest that the prGWAS method
is potentially useful for predicting positive markers in future data sets.
6.4 Discussion
By varying the number of pairs of DNA pools and the sample size of the master
plates, it was possible to demonstrate that prGWAS is efficient, specific and accurate
compared to conventional GWAS [1].
In the GWAS approach, a total of ⇠ 17, 000 DNA samples were genotyped,
whereas using prGWAS this number would have been considerably reduced to
at least 80 DNA pools (up to 10 DNA pools per disease + 10 DNA pool from the
controls) regardless of how many individuals’ DNA samples are present in the mas-
ter plates. As in DNA pooling genotyping every pool is treated as a single DNA
sample, the reduction in genotyping costs by using prGWAS is substantial.
Despite the encouraging results of the prGWAS method when compared to
GWAS using the WTCCC data, some limitations need to be acknowledged. First,
in contrast with the reported GWAS results [6], in the analyses reported here indi-
vidual genotypes from all cases and controls were used for the genetic association
analysis; secondly, no control by population structure was performed, and thirdly,
no SNPs were removed after visual inspection. However, the fact that by apply-
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ing prGWAS to this well-known genetic data it was possible to reproduce ⇠ 98%
of the SNPs showing moderate and strong association [6] at a minimal fraction of
the genotyping costs, positions prGWAS as a feasible and important alternative to
GWAS.
Potential applications of prGWAS include whole-exome and whole-genome se-
quencing for cases and controls, and GWAS when families of (not necessarily) iden-
tical structure with affected and unaffected siblings are recruited [26].
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Chapter7
Discussion
Modifier genes (MGs) may be responsible for the changes and wide-spread of the
age of onset (AOO), and for how the disease progresses overtime (see Slavotinek
and Biesecker [1] and Chapter 1). The identification of MGs in human complex
diseases in general, and in Alzheimer’s disease (AD) in particular, has been of par-
ticular interest since their introduction 75 years ago [1, 2, 3, 4, 5]. This search has
been boosted over the last few years by new high-throughput genotyping technolo-
gies, study designs and analytical tools to assess their contribution to disease.
In AD, the identification of AOO MGs is of special relevance as they may impact
diagnosis, treatment, prevention and genetic counselling, and lead to the discovery
and development of new therapeutic targets [1, 3, 4, 5, 6, 7]. Depending on the
effect of MGs on the AOO, these therapeutic targets can accelerate or decelerate the
AOO. That is, signs and symptoms of AD can appear much earlier or much later
than in the population under study, respectively. Identifying these MGs and fully
understanding their role in the pathophysiology and natural history of AD could
greatly benefit not only the population being studied, but also other populations
around the world. Indeed, blocking MGs accelerating AOO and activating those
that delay it could offer a better quality of life to those individuals in the initial
stages of the condition, or to those individuals at risk that will develop AD in the
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future but have not yet shown any signs or symptoms. From the clinical point
of view, demographic information and the genetic profile for modifier genes in
individuals without an AD diagnosis, combined with proper predictive modelling
tools, could greatly inform AD diagnosis and long-term follow-up. In Chapter 3
I have presented and discussed precisely this in the context of familial AD ( fAD).
Other authors have performed similar work in fAD for predicting mild cognitive
impairment (MCI) status and presence of the E280A mutation in the PSEN1 gene
using non-invasive biomarkers of AD [8].
7.1 From AD to other complex human diseases
Following previous work of our group that identified MGs governing the appear-
ance of AD at an early- (before 48 years) or late-onset (after 50 years) [9], in Chap-
ter 6 of this thesis I have shown that the pooling/bootstrap-based genome-wide
association study (prGWAS) method proposed by Ve´lez et al. [9] is feasible and
produces results that are comparable with those by the traditional GWAS. In partic-
ular, I have found that prGWAS detects, at a fraction of the recruitment and geno-
typing costs, up to 98% the previously reported signals showing strong or moderate
association overall [10] in the seven human complex diseases studied by the Well-
come Trust Case Control Consortium (WTCCC) [11]. These findings highlight the
ability of the prGWAS method to detect association signals in other diseases other
than AD when a case/control design is used, but also opens new venues for the
development of a similar framework for GWAS that include related individuals or
whole-exome and whole-genome sequencing for cases and controls.
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7.2 AOO modifier genes in fAD
Several studies have been aimed at identifying AOO MGs in fAD. The first study,
performed by Lendon et al. [12] in individuals with the E280A mutation in the
PSEN1 gene from the Paisa genetic isolate, found no difference in the AOO between
APOE e4 carriers and non-carriers. A follow-up study showed that carriers of the
APOE e4 allele were more likely to develop AD earlier than those not carrying the
allele [13], to develop AD at an earlier age than those without the allele. Together,
these two studies suggest an epistatic interaction between PSEN1 and APOE to
modify the AOO in individuals with familial AD ( fAD) from this population.
Marchani et al. [14] studied individuals from Germany suffering from early-
onset fAD caused by the N141I mutation in the PSEN2 gene. The authors estab-
lished new several candidate regions, and identified one strong signal of linkage
of AOO at chromosome 1q23.3 (P < 0.001) when all three families were included
(n = 265). Linkage signals were also detected to chromosomes 1q23.3 (P < 0.001),
17p13.2 (P = 0.0002), 7q33 (P = 0.017), and 11p14.2 (P = 0.017) when a sin-
gle family (n = 65) was included. These linkage signals encompass several genes
either previously associated with AD or late-onset AD (LOAD). The signal in chro-
mosome 1 encompasses genetic variants in the Cholinergic receptor, nicotinic, beta 2
(CHRNB2); that on chromosome 17 includes Netrin-1 (NTN1) and the Tyrosine kinase,
non-receptor, 1 (TNK1) genes; and the signal in chromosome 11 includes the Brain-
derived neurotrophic factor (BDNF) gene, which has been previously reported to be
associated with LOAD [15] and cognitive decline in preclinical AD [16]. Further-
more, mRNA levels in these genes have shown to be decreased in the hippocampus
of individuals with AD [17].
In the prGWAS method, cases and controls are defined based on a dichotomous
phenotype, or as the result of a continuous phenotype that has been categorised
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in two mutually-exclusive classes [9]. The authors applied prGWAS and identified
previously reported and new loci associated as AOO modifiers in AD in individu-
als with fAD from the Paisa genetic isolate [18, 19]. Some of these genes include
DAOA (rs778296, P = 1.58⇥ 10 12), CD44 (rs187116, P = 1.29⇥ 10 12), GREM2
(rs12129547, P = 1.69 ⇥ 10 13), NPHP1 (rs10173717, P = 1.74 ⇥ 10 12), CADPS2
(rs3757536, P = 1.54⇥ 10 10), ADAMTS17 (rs4965279, P = 1.69⇥ 10 7), CLUAP1
(rs1134597, P = 1.12⇥ 10 8) and EXOC2 (rs2804737, P = 3.28⇥ 10 6). Interestingly,
an independent study in a Caribbean population with G206A PSEN1 fAD found
that homozygous individuals for the rare allele in rs906815 single nucleotide poly-
morphism (SNP), located in the Nephronophthisis 1 (juvenile) (NPHP1) gene, had an
AOO that is ⇠ 21 years earlier than that of individuals carrying the common allele
in this SNP. This result confirms the AOO modifying effect of the NPHP1 gene in
PSEN1 fAD, and that this effect is independent of the genetic background and the
mutation type exhibited by individuals affected with fAD.
Although applying prGWAS results in detecting previously reported and new
susceptibility loci in AD [9], the fact that individuals suffering from AD were
grouped as early-onset and late-onset based on the AOO and a cutoff value cal-
culated as the average AOO of AD in the Paisa genetic isolate (i.e., early-onset:
AOO < 48 and late-onset: AOO > 50), limits its application to diseases in which
such a cutoff value is non existent. Another potential but not less important aspect
to improve in the method is that individuals for who the signs and symptoms of AD
began at 30 years of age, are grouped in the same class of an individual for whom
the condition began at age 45. Though the AD status of these two ‘hypothetical’ in-
dividuals is early-onset, grouping them as a ‘unique’ individual with an AOO < 48
may result, compared to using the AOO as it is, in a less powerful procedure from
the statistical point of view [20].
To tackle the aforementioned disadvantages of the prGWAS method and ame-
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liorate the impact of categorisation when defining cases and controls, in Chapter 2
I proposed and described in detail a general framework to identify MGs in hu-
man complex diseases when, instead of using a cutoff value to define when the
symptoms begin, a continuous phenotype (i.e., AOO) is used. This framework,
involves genetic, statistical, bioinformatic and data mining tools. Genetic isolates
[18, 19], extreme phenotypes [9, 21, 22, 23, 24, 25, 26] and whole-exome genotyping
comprised the genetic component of the framework proposed in this thesis, whilst
linear mixed-effect models [27] (to assess the association of genetic variants to AOO
whilst controlling for population structure) and predictive modelling constitute the
statistical component. Lastly, functional prediction [28, 29, 30, 31, 32] and pathway
analysis are the corresponding bioinformatics components. Though each of these
components itself plays an important role in genetic research, the main contribution
of this framework is the integration of these components to build a tool that is more
powerful than its components alone for the identification of MGs.
I applied the above framework to a cohort of n = 72 individuals with PSEN1
E280A fAD from the Paisa genetic isolate and identified genetic variants of major
effect modifying the AOO in these individuals (see Table 3.2).
7.3 AOO modifier genes in sporadic AD
In sporadic AD (sAD), the second clinical form of AD, various studies have iden-
tified AOO modifier genes. Compared to the studies identifying AOO moodier
genes in fAD, those in sAD required a larger sample size and resulted in modifier
genes of small effect (that is, the presence of specific genetic variants change the
AOO slightly). A meta-analysis of 7,873 individuals with sAD and 13,274 controls
of Caucasian origin found that the P86L polymorphism in the Calcium homeostasis
modulator 1 (CALHM1) gene interacts with the APOE e4 allele to modify the AOO in
AD [33]. Leduc et al. [34] studied the association between the rs3846662 polymor-
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phism in the Homo sapiens 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene
and both AD and mild cognitive impairment (MCI) conversion, and found that this
genetic variant has a protective effect on AD risk, delays AOO and reduces the
conversion from MCI to AD. Interestingly, the individuals included in this study
(n = 250 age-matched controls and n = 324 autopsy-confirmed AD cases) were
descendants from several founders who migrated from France, which makes them
a valuable resource for genetic studies [18, 34]. More recently, Naj et al. [35] studied
the contribution and effect of genetic variants to AOO in 9,162 participants who de-
veloped AD after 60 years of age using linear models. The authors reported several
genetic variants of small effect (between 3 to 6 months) modifying AOO in these
individuals, with none of them exceeding the effect conferred by the APOE gene.
Two important aspects are worth highlighting in the aforementioned studies as-
sessing the AOO modifier effect of genetic variants in sAD. First, the resulting
effect size of the identified genetic variants on the AOO is small; and secondly, the
recruited cohorts are of large size, generally of the order of hundreds or thousands
of individuals. Because of the effect size of these genetic variants is small, they are
more likely common variants (i.e., with a minor allele frequency [MAF] < 1%) to
be intronic and less likely to be non-synonymous changes at the protein level (i.e.,
mutations). This aspect, discussed in Chapter 5, is related to the modest success of
the common disease-common allele hypothesis [36] to identify genetic variants of
major effect (i.e., mutations) in complex genetic disorders.
As presented in Chapter 5, the newly developed framework presented in this
thesis (see Chapter 2 for more details) was used to identify AOOmodifier mutations
in n = 54 individuals with sAD from the Paisa genetic isolate. Although some
of the resulting genes harbouring these AOO modifier mutations (see Table 5.1)
have been previously described as having either a biological or functional role in
animal models of AD, this study is the first to report that genetic mutations in these
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genes modify AOO in sAD. In addition to having major accelerator (or decelerator)
effects on the AOO, these genes have important implications in apoptosis- and
neurological signalling- and Wnt signalling-related processes (see Tables 5.2 to 5.5).
7.4 Main findings in the Paisa genetic isolate
In what follows, I present the main findings of this thesis after applying the pro-
posed framework in this thesis for the identification of MGs in individuals suffering
from fAD and sAD from the Paisa genetic isolate in Antioquia, Colombia. The im-
plications of these findings are highlighted in different context including the patho-
physiology, aetiology, natural history of AD, and as potential therapeutic targets in
this neurodegenerative condition.
7.4.1 Findings in PSEN1 E280A fAD
I first applied the framework proposed in this thesis (see Chapter 2) to determine
whether previously reported AOO MGs in PSEN1 E280A fAD [9] also harboured
genetic variants of major effect (i.e., mutations) modifying the AOO. As shown
in Chapter 4, a mutation harboured in the DAOA gene modifies AOO in n = 57
individuals with PSEN1 E280A fAD from the Paisa genetic isolate. Furthermore,
two additional mutations in the CLUAP1 and EXOC2 were nominally associated
as AOO modifiers. These findings, in addition to a recent study reporting that
the NPHP1 gene accelerates the AOO in ⇠ 21 years in individuals with a similar
form of PSEN1 fAD [37], indicate that mutations in these genes are likely to exist
and interact with PSEN1 to modify the AOO. Altogether, these findings not only
highlight the importance of these genes in the natural history of AD (see Section 4.4
for more details), but also open new research avenues for better undestanding of
the aetiology, pathogenesis and neuropathology of the disease.
In a slightly larger sample of 72 individuals with PSEN1 E280A fAD, I success-
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fully identified common (i.e., with a MAF > 1%) AOO modifier mutations har-
boured in the APOE, GPR20, TRIM22, FCRL5, AOAH, PINLYP, IFI16, RC3H1 and
DFNA5 genes (see Table 3.1). The AOO modifier effect of these common mutations,
measured as the bˆ coefficient in the linear mixed-effects model [27], shows that
those harboured in the TRIM22, AOAH, PINLYP, IFI16, and DFNA5 genes acceler-
ate the presence of AD signs and symptoms in these individuals, whilst those in
harboured in the APOE, GPR20, FCRL5, and RC3H1 genes delay the AOO (i.e., have
a protective effect). In context, this indicates that a higher order interaction between
PSEN1 and these genes occurs to drastically modify the AOO in these individuals
with fAD from the Paisa genetic isolate. In particular, the fact that the APOE e2
allele is delaying the AOO in fAD by 8.85 years (Figure 3.4c). In the clinical setting,
this implies that the APOE e2 allele has a protecting effect in PSEN1 E280A fAD,
which is consistent with recent evidence and molecular mechanisms [38, 39].
After identifying AOO modifier mutations in fAD, I used the ARPA-based pre-
dicting model (see subsubsection 3.2.3.3) to construct a diagnostic tool with poten-
tial applications in the clinical setting. This easy-to-use diagnostic tool integrates
demographic information (i.e., years of education) and the genotypes in identified
AOO modifier mutations to predict whether an individual will develop early- or
late-onset fAD. Indeed, an individual with A/A in rs2682585 (PINLYP) and more
than six years of education will be classified as LOAD with a probability of 76.5%
(95%CI = 0.734-0.792) (see Subsection 3.3.4 and Figure 3.3a).
7.4.2 Findings in sAD
A total of 25 AOO modifier mutations were identified in sAD. Based on their effect,
these modifier mutations accelerate (bˆ < 0, n = 14) or decelerate (bˆ > 0, n =
11) the AOO in sAD (see Table 5.1). In addition to their effect on the AOO, the
implication of the GPR45, MAGI3, OPRM1, FPR1, OPRM1, TTBK2 and NFATC1
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genes, which harbour some of the identified AOO modifier mutations, represent
the most significant finding of this study.
In particular, the GPR45 gene has been proposed as a therapeutical target in AD
and other complex human diseases [40]; MAGI3 is involved in neuron apoptosis,
apoptotic processes, neurogenesis, and Wnt protein secretion; OPRM1 and FPR1)
encode G protein-coupled receptors (GPCRs); TTBK2 is a key regulator of ciliogene-
sis, and putatively phosphorylates tau and tubulin proteins; FPR1 is involved in the
inflammatory processes linked to AD as well as the the synaptic transmission and
apoptosis; and NFATC1 is implied in memory, oligodendrocyte differentiation, AD
and LOAD (see Tables 5.2 to 5.5). These implications, along with their AOO modi-
fier effect, which by all means are highest reported in sAD, highlight the importance
of these MGs in prediction, follow-up and eventually as therapeutical targets of AD.
7.4.3 From fAD to sAD, back and beyond
In Chapter 3, along with the MGs harbouring them, nine AOO modifier mutations
were reported in PSEN1 E280A fAD. Among those AOO MGs, G protein-coupled
receptor 20 (GPR20) gene, initially identified in fAD, was further replicated in an
independent sample of n = 54 individuals from the Paisa genetic isolate suffering
from sAD (see Table 5.1b). The GPR20 gene belongs to the GPCR gene family, to
which the GPR45 gene also belongs to (and which was identified as an AOO MG in
sAD, see Table 5.1). Interestingly, the GPR20 gene has a delaying effect on the AOO
(bˆ = 12.12, PFDR = 6.58⇥ 10 22, Table 3.1a) in fAD and an accelerator effect in sAD
(bˆ =  22.05, PFDR = 4.44⇥ 10 2, Table 3.1b), suggesting a protective interaction
effect between PSEN1 and GPR20 in the Paisa genetic isolate (i.e., a much later
AOO in fAD than in sAD).
As previously discussed in Chapter 5, GPCRs are important in the physiopathol-
ogy of AD [41, 42, 43] and might also be key roles in the in apoptotic processes
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(see Tables 5.2 to 5.5). Both GPR20 GPR45 are expressed in the central nervous
system, the periphery and neural cells [44, 45, 46]. Finding that exonic mutations
in GPCR genes accelerate or decelerate the AOO in individuals with fAD and sAD
emphasises the potential of GPCRs as a therapeutic target for AD [40, 47], and
opens new windows of research towards a better understanding of the aetiology,
physiopathology, and natural history of AD.
7.5 Further directions
In this thesis I have successfully identified AOO MGs in the world’s largest multi-
generational pedigree segregating AD (see Subsection 1.2.2 for more details about
this pedigree) using the general framework described in Chapter 2. In what follows,
I describe five future research directions that could further expand the acquired
knowledge on AD gained as a result of this research, and offer new perspectives
into how AD diagnosis and follow-up should be done.
1. Replication on a larger sample from the Paisa genetic isolate.
Although a one-direction replication strategy was performed to determine whether
genetic variants modifying AOO in individuals suffering from fAD also modify
AOO in individuals with sAD (see Tables 3.1 and 5.1, respectively), further research
is needed to study and potentially replicate the AOO modifier effects of these ge-
netic variants in a larger sample of individuals from the general population (not
necessarily from the Paisa genetic isolate), and groups of individuals exhibiting
fAD or sAD. These studies will also allow to better understand how these AOO
modifier genetic variants shape the natural history of AD, conversion from MCI
to AD and vice-versa, and possibly how these genetic variants change the rate of
cognitive decline.
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2. Study the frequency of genetic variants modifying AOO in other populations.
As shown in Tables 3.1 and 5.1, common genetic variants of major effect (i.e., mu-
tations with a MAF > 1% in the Paisa genetic isolate) modify AOO in individuals
with fAD and sAD from Antioquia, Colombia. Among these, the allele frequency
of the APOE alleles are, by far, the most studied in different populations around
the world [48, 49, 50], including the Paisa community [51]. However, little is known
about the allele frequency of the remaining AOO MGs. Further study of these fre-
quencies could shed some light into the understanding of how these AOO modifier
genes impact number of cases and the prevalence of AD in these populations. Ul-
timately, quantifying this genetic diversity may contribute to the development of
therapeutic targets for AD that are more effective in some, but not all populations
around the world.
3. Functional studies in animal models expressing (or lacking) AOO modifier variants.
One of the components of the framework proposed and applied in this thesis to
identify MGs is the in silico prediction of potential functional implications of single-
nucleotide changes at the protein level using a collection of several algorithms (see
Chapter 2 for more details). Although in silico experiments can be considered a
good approximation to what may actually occur without performing in vivo func-
tional studies, they do not fully replace them. Mouse models of AD expressing or
lacking some of the AOO MGs are needed to elucidate their potential as therapeu-
tical targets in AD.
4. Validation of the ARPA-based predictive model in the clinical setting.
I have shown in Section 3.3 that a predicting model constructed using an Advanced
Recursive Partitioning Approach (ARPA) produces exceptional results in predict-
ing AD status (early- vs. late-onset) in individuals from the E280A pedigree. This
157
CHAPTER 7. DISCUSSION
model, which involves a combination of demographic and genomic information,
correctly classifies individuals as EOAD or LOAD (call rate: 84.5%, 95%CI = 76.1%–
91.5%, Figure 3.3c). As a diagnostic tool in the clinical setting, individuals with the
A/A genotype in rs2682585 (PINLYP), six or less years of education and the C/T
genotype in rs62621173 (IFI16) are likely to develop LOAD according to this ARPA-
based predictive model (Figure 3.3a). Despite how straightforward it is to apply
this model to assess whether individuals with a particular demographic and genetic
profile will develop EOAD or LOAD, further research is needed to validate these
predictions in the clinical setting. Indeed, stress testing the ARPA-based model and
validating the results with clinical-based diagnostic of AD using a similar approach
to that sketched in Table 3.3, may help to elucidate the predictive power of this
model in a real-world scenario. This ARPA-based model could also be used in the
ongoing clinical trial of AD [52] to determine whether an individual should be in-
cluded or not depending on his/her predicted AD status.
5. Construction of an ARPA-based predictive model for AOO instead of AD status.
An additional improvement to the ARPA-based predictive model previously dis-
cussed is the use of the AOO itself rather than AD status. The use of continuous
variables instead of categorical ones results in a loss of power [20], so an ARPA-
based for predicting AOO is likely to perform better. Another benefit of using
AOO instead of AD status in the clinical setting is the possibility to inform individ-
uals when, including a time frame, the AD sings and symptoms will begin. This
information will ultimately empower clinicians, genetic counsellors and individuals
to work together in the laborious endeavour against this devastating neurodegener-
ative condition. Further extension of this new model include the prediction of AOO
in individuals from the general population.
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7.6 Conclusions
In this thesis I have proposed and described in detail a general framework for iden-
tifying MGs in human complex diseases. As a test case, I applied this framework
and identified AOO MGs in individuals suffering from either familial or sporadic
AD from the world’s largest multigenerational pedigree located in the Paisa genetic
isolate in Antioquia, Colombia. In addition to remarkable accelerating/delaying
effects on the AOO, these MGs provide an initial explanation for the wide range
of AOO in individuals with AD from the Paisa community [53]. Also, they are
involved in crucial pathways that might largely contribute to the pathophysiology
of AD, and may serve as potential therapeutical targets for early intervention.
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